<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:dikbD2R="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03632379-0F9B-40E6-AD20-A96CD8B23F77">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 12:59:04 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:753A757B-7698-40A8-ACE1-691D171C6802"/>
    <pav:lastSavedOn>2015-11-27 13:05:05 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:9307016F-E9AA-444E-96AE-3BC78A43A1D9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:840B134E-12B7-48C4-B190-BDB422C243C5">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:454F492B-D0E0-4A76-BDD3-E5E5352E985A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-27 15:26:53 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-27 15:27:03 -0700</pav:lastSavedOn>
    <ao:body rdf:nodeID="N71267490521a4f4c9703b13b39d9218d"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:D1DF16F7-536B-439E-9F08-06244C127A27</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AF4DEBC5-9BB5-4E67-9233-EA6CF63CDDD1">
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:auc>17</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1721C320-9792-47DC-A899-FDA7D84185FD"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9F3F11D3-C7A1-420F-B53D-7DDD99F26149"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29F80390-619A-4D4E-85DF-9F91BBC93E1F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>ncreases in plasma concentrations</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:26F01BEB-8A13-499D-9D40-12847573EFA3"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D065F2DD-5CFB-4FD7-8670-C2609A7AF841">
    <dikbD2R:preciptDuration>5</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CC9400B2-6234-42D1-BF9A-62833F467AAE"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/47B72996-9818-4E71-8012-F051F26EC31B"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>5</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E0970196-D134-4422-8BAE-D3CCBD91749F">
    <dikbD2R:dose>150</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>aspirin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1191</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8F65635-1B59-4D68-831D-98C51B2BA1F6">
    <ao:exact>nefazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with </ao:prefix>
    <pav:createdOn>2015-11-27 13:52:45 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B8F65635-1B59-4D68-831D-98C51B2BA1F6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A09359D-D57C-4AE2-ACF4-939491BA5632">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-11-29 16:14:23 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>In a clinical study, subjects on stable doses of</ao:suffix>
    <domeo:uuid>1A09359D-D57C-4AE2-ACF4-939491BA5632</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a drug interaction study, co-administration of INVEGA® (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC24h and Cmax,ss) of valproate in 13 patients stabilized on valproate. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A09359D-D57C-4AE2-ACF4-939491BA5632"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A7D93C5A-A4E1-49B2-BD29-0CA6AD59BAC0">
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>5 to 8</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9815A9B0-2D1B-42F7-83FF-5F58C2163BA9"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmax>1.6</dikbD2R:cmax>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/65A57778-0E8A-47BB-84C8-FDB9009067B0"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38693F8A-D66B-4B52-9D07-71D27A0A8BA2">
    <pav:createdOn>2015-11-29 15:26:27 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>P95 </ao:exact>
    <ao:prefix>and </ao:prefix>
    <ao:suffix>in CYP2D6 extensive metabolizers (EM) are 18, 26, and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37, and 31 hours, respectively. Steady-state concentrations are attained within 3 to 4 days of dosing. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38693F8A-D66B-4B52-9D07-71D27A0A8BA2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E63A937A-F4BB-4F74-B9C7-A8C474F685BF">
    <pav:previousVersion>urn:domeoserver:annotationset:11AC153B-8927-4712-917D-E80A1F5EE0EA</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 14:10:53 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 14:11:00 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC2DEF4C-2C5E-44A2-8CA9-E27CD02591A7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nd7b0fbaabcff402cbed4814e2b94ea76"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E35AAEB3-1DB8-4484-8966-FB2967A8421B">
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F95A7906-77D9-4142-B5EF-248A36946CAE"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C9EDA675-ED26-43E4-8061-1C047319A799"/>
    <dikbD2R:objectDuration>5.5</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>5.5</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B">
    <ao:item rdf:resource="urn:domeoclient:uuid:735172DD-19A0-47A3-B634-A0814A8FF8C1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:22D3DA0E-4B6B-4D98-A518-21851A279008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F19827BB-074B-4991-95E0-9AF9140F3884"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1B3462E-12D2-4EEF-92D6-0B320A83DD37"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF74822F-037C-4E79-A820-BA3EE59DDDDD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23513472-8961-48CA-B8A4-C77322C0E2CF"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:04C214D6-1185-484E-885F-A1AFEF1A016C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD1F9484-6EB3-4E52-B92F-043B329FF4F0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D2E2348-A23F-4EA3-A871-CE3E46E25FA6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:811832DC-AE50-48B1-B204-28227F31662A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59F42EBC-9CD0-480C-A4B3-55B676C7CB69"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF3B6D5A-0359-4442-8B25-793A6BB3A014"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C04EE2A-2410-449A-B9D9-C4AA64768FBA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:478CF235-C243-45F5-9098-9713BA1DA1E0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CD6637B7-C3FE-45D0-8475-210B47AB50E8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EA8B8EC6-D2B5-43CD-B2EF-AF7F7D53D5D0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EBDFC926-7101-458A-8B2A-609DCFE3A51B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC89070F-CF31-45D5-85E7-2C081A994BC8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1A910D8-A39E-4044-8FF4-DFBD6BEE3166"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8EA98525-F448-4B95-B267-77726F4431F5</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:9ACFE793-29DF-4CA6-9709-3C3107DBE6CD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0DE2E7A8-3EA3-4894-BD98-3884D1EA2A77"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:344272B9-FC48-4C52-9382-8CB229B86151"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2214DB9E-4F05-43E2-B4B9-0AE1AE0EF56A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2B88C45E-AB6A-4FBC-8B81-2D42817789EC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1D14FA0-ADB1-4837-9BDE-10248FE7F7B3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5234AC97-29F8-4BF6-94F3-1D0DAB147BDB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8F1C6E19-795C-4671-BA7E-EF58AAAB0B42"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6D628FD1-D1C1-4432-A9FF-4420281EF24F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D17A5693-99EE-4628-B181-EAE5F470886C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E9B9271-8DC8-4D37-99B4-BE38177BEAF3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:997A051C-D98A-46D5-BA19-A2359C7A14A1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D139E916-C0D1-4F43-8AE9-51520F45601D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C33A5FA2-1852-423F-B545-5E62A72CA176"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AFD1C577-0D19-4C26-A5F2-6ADEB361378F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B18D5F8C-E9C7-4711-BC17-EC18D647DC8A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8405CE11-632E-4607-A4FA-9E95883B310E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DEDC9ADC-0466-4920-BCC2-4ED079CDC661"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4ACCD478-5329-40B1-B5E2-2C12525A80F7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2BC4CA28-7B1F-4474-954A-91FC480F5503"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7E1E78E9-8B95-45D3-AF61-010956EF204D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:071B4042-31BD-4DB6-84DD-13AB240BDF31"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3EF7B3A7-CFBC-4CBD-B6B4-20EB848BFDE4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DCCF87D1-9FD6-46CA-B89D-DFDB28C4131E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4ACA52ED-6885-4EB8-AC37-D77339B859E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C6CBF886-EB77-4871-9B92-E89575CC5C61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A58ACB44-BB3F-439A-955D-3A07B3CAAF91"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:68C0A9F3-C764-45AC-B50A-0EEE75F16C59"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BCB3B2E1-8478-425A-94F8-03758A62DB50"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E9725E4A-EB71-4392-8E5F-AA1AC2898F91"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DD628499-7A48-45E7-A5AD-9747726585FE"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A47E5FC5-B36A-472F-9111-0543B5A932EE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:977C7C15-6219-4D2B-A620-98EA85E22F8C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:03632379-0F9B-40E6-AD20-A96CD8B23F77"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:80E1AEE9-40DF-434F-81D4-046998DE0B9D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:65AC8562-41F8-43FD-BD3F-A68C5954BF1E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F487F5E1-C8E4-483F-97F9-488259318B02"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:41125D0B-B211-4273-8318-2FBC61E9AAE0"/>
    <permissions:permissions rdf:nodeID="Ndbf6fe0552424d979ec1b5125b51a7ed"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6AA7E7BB-591C-444B-8624-E3164CD7E995"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:66BB73BD-A6E6-46F1-B487-603EC76686DD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:09FB62C3-9235-4DAA-8A6C-92276BCB7074"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:58D99026-B745-4FF7-A3A0-B2FACBA08309"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14305115b858015115cd5b5c0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0FE2E97A-E5A9-4650-95C4-7A69F34113EA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:07F498A9-34E6-4620-9A6A-A2886D6E9236"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E4764B3-9044-4FE4-90DE-1D6487B76F5C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE914B7B-F5CD-4D40-BE6B-2B95AA95022D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C44D80F8-627B-4C0A-8EC0-3E4A5A88236A"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/abde6cc1-3f20-4db6-bfd3-7b337ada4a65"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08135AC9-72C6-4D42-90A8-CF119829E056"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4C8EAD2D-AAFB-4337-8707-BCEDEA93ED13"/>
    <pav:createdOn>2015-11-17 07:06:31 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:4577F1B0-D5DD-4C41-A711-54E310F40FFC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AF5319C-A6B1-42BE-BCD4-1717198C1679"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C0C8CDB5-88C4-48D8-AA9A-519896EE0B7B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B47B0B5-D658-4672-99AA-89C615EC69A8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:32E72936-6FF3-42B7-93C4-E8C2145690E7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:074B9E92-F154-4ADC-860B-D18D27A7DA40"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59CF9A2D-CDE1-4B21-811F-F66588AAB846"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7FC54327-CC52-44BC-9FDC-2621E712C6B1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C181F797-C31B-483D-AFFA-8497935BDB0C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:33F19646-4AFA-4867-A605-C09A6DD95562"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5703BD03-8DCC-4337-A01D-50171BFCC1AB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1EB49031-0A78-4B54-A475-B946A3CBE64F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:215AF6A5-CB4C-4FEE-A51F-2340EA5280D3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E8EA8011-55E0-4390-BAA5-C227224B9F56"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0213ACE5-8FCA-45C5-B5C4-34F7274E2F8A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:82CDE090-E6D4-4A1D-A232-DCE85D9B61A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB1811DA-9D96-4E85-BECE-8D3BC88346FF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CEE6D02F-9B57-4DAE-8FF5-528B2E070606"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9DE601BF-5AD9-4D33-AB58-050BE48C2BAD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3E6D417-CA94-49FA-B4CC-0C3A2ECA1C40"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD852660-47E6-415B-9C3F-EAE3985ADB2C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:27B9BFEB-2AC6-4DA7-8252-5BB47EFF7664"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E55E5C30-F484-4AC6-8BEC-AEFBB5F6DB49"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF183E4F-C2ED-4B99-9E19-7BAA7B8DB17B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E48F8C47-78CE-4D89-9516-5A857CD88BFE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D7C58694-BCBC-4F91-84BF-4F421D25C3B9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23D4BC95-7FE0-447D-9A6F-3297089E13F6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7238090B-8742-4BD6-AD6B-032836EC742C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D28A995A-00DD-4EFB-9632-5FC9943CEC61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6E7A70E-1E5A-4F2E-B5DC-2E630D29C99B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA8C33F0-184B-4FE7-B56A-EB4C2B4E0EB2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6205F210-9F39-42CE-9730-C83F86093133"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:72B6878C-1764-43E9-B083-CDE8EC9DEC4B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D8A16754-DDD5-46F9-A2DC-E9BAE8826046"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:26750B95-67E1-45B3-930F-B0BEF0F748A0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A85B5FBC-459D-4CB8-9662-B23479A06E4D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:51F73025-EEE1-48D5-878D-17C8557651E5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C56BD4CD-B397-4DC5-9704-9DF95C092691"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F84C2E30-58FA-40DA-956B-0EA7D04827C3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:475F7B77-E061-4A6F-95B7-C36897DF559F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:36342C92-85CE-4C41-921A-E7DD3B99659B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:81E7F1BA-1EF8-46DF-BB55-6BB90E0AD851"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5610B93D-317A-46EE-8194-447329366CB5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:83D6CEA6-6E31-4CB7-AC57-0377FA37BDF1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13241C85-CB03-45BE-BB6E-F5F23CAEF107"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AEE6D10-6A4D-463D-8065-D90E56D5D8A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7BFFC0AC-72FC-4E80-85FF-37492628DB14"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2E6FC1A6-A6D3-46C4-9994-4F63BED57AE0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F9737EE-2E26-497A-A104-45CCDED3729E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2F166181-1DD8-4C61-A8DF-E6C4777F2F95"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16B4A019-2B1B-477D-BB67-2A6837108B71"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6AFD35D6-426E-411A-980B-61F7308B57FB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:96372F84-7A06-4AE7-8D78-4CDA367FF6DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E320105-D57B-40A4-8945-49913004210C"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">53</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 15:22:19 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:84A05B74-066D-4648-87E1-73D6B43E3B58"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:76ABB379-BDD6-4FC7-B180-50102BD590C0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23E0AC7B-2AD6-4FC6-90D5-219E46CEF416"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E63A937A-F4BB-4F74-B9C7-A8C474F685BF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7621502D-D15B-4D51-8697-29BB5AC29CB9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:54B8C0D1-B5E4-40A2-8AAA-72247E9E6B09"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4C99FE09-36BF-46D9-8079-6D36F38882B8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2507ACFD-B2EA-4A26-A36A-ED36ED90FFD1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E0DEF03E-6F27-4EC3-AE06-F11EF6CCCD59"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7993BEB-BF6E-42B2-A965-AA85C25A9843"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:BFF7A9C6-AFAA-4CEF-BF33-A451C97F3ECD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7A8BCFB-75F1-4C7C-A4E9-25570054D6B2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:67DF62D5-C811-414F-98EE-B90C1A865DD7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6D9B0838-E163-4F3C-9EE0-11BA444876EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C0A2E871-78A7-4456-92EB-52F21BA18ED0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C98E3AD-5EBA-40B2-A31A-F464C6918864"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D70D5A4-70CD-48E9-B948-E08F0AEF8D76"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:840B134E-12B7-48C4-B190-BDB422C243C5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:087D3863-00C4-4371-9026-7D30ABE4A0AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC1092C9-5217-4C0E-BFC9-4FFAD5C9B30B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB17E6F4-D252-45F1-99C2-453CD278FBEE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D9F9167-BB9F-4316-89B9-E6836B470F29"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBDD2F62-38ED-408D-BC5D-77DD22BFAEE8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB6BE9C9-6B1C-4A42-A0C7-E4294DC4A8C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90C83758-E752-494B-815B-B550B4B2D07E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA557A92-DB78-431C-8AD4-DFA60B10001F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F940E99-1158-4E67-A47A-33E3C0052768"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9C17DF2-D0B4-4BEB-8DF8-016CCA8462C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:63383907-5872-498C-8D64-787EDCABF2DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:372D521B-0AF3-4D63-B84E-890BACC672E6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EF7B3A7-CFBC-4CBD-B6B4-20EB848BFDE4">
    <ao:body rdf:nodeID="N825c86de9e1c46dfa95b22bb8666f74d"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8D2C279-998D-4042-8423-B8D42628E79D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 12:37:36 -0700</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:04E00EBB-DAB5-4802-A8BB-7E38AE95CA57</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-29 12:26:10 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C8C76935-577F-4009-8DB8-74EE9B2D11C9">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A8A292EA-FED9-44CC-9255-2525F7C85520">
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CC40722A-E2AC-4241-962B-D8CBA4DFAB09"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B77EB882-0666-4767-B8F7-9B5793668868"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>QID</dikbD2R:preciptRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14305115b858015115cd5b5c0000">
    <foafx:email>grizzle@pharmacy.arizona.edu</foafx:email>
    <foafx:title></foafx:title>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:homepage></foafx:homepage>
    <foafx:middlename></foafx:middlename>
    <rdfs:label>Amy</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:lastname>Grizzle</foafx:lastname>
    <foafx:firstname>Amy</foafx:firstname>
    <foafx:name>Amy</foafx:name>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B77EB882-0666-4767-B8F7-9B5793668868">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB1811DA-9D96-4E85-BECE-8D3BC88346FF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 13:52:04 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0ADA95F0-9E4F-48C0-AECF-8A3311B99135"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FE8D2E0E-C1A2-4877-B915-E558A22472FE">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B616B77C-A5A5-48F2-B302-1188603C0515"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F6D4C5D0-9A4A-44F7-86D3-FD38804A56A1"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>less than 50</dikbD2R:auc>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>no effect</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0CF9D40-E7F9-4C45-8F9C-EBCD9B164AAC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4ED59BB5-AFB9-4A56-B36A-96423643B327"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-29 16:18:01 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f4bcdebf-db7b-4c95-b1b2-8bc46c7992e0</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E8FE416-EFE8-4F72-9F7D-D213DCF09D38</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="N0aa7035b2b3c49689cf061333bf8ae08"/>
    <pav:lastSavedOn>2015-11-29 16:18:02 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:58722CD2-6315-44BB-ABAA-6C71A1CC40AF</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9725E4A-EB71-4392-8E5F-AA1AC2898F91">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 13:52:46 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A83638F6-F9F8-4ED0-95A7-9FB860F8D0DB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A85B5FBC-459D-4CB8-9662-B23479A06E4D">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:CCF8D4C0-ED71-48BF-90B5-05A837923C9D</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-29 11:51:35 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 11:51:40 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DD1A843-1C70-4B7A-8D88-C88ACBFD7200"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">35</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="N7d0efe0871974046a0fc4cce68de5f35"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C1AD50A-355C-4CC2-92F4-ABDAC41316D9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Lithium </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C1AD50A-355C-4CC2-92F4-ABDAC41316D9"/>
    <pav:createdOn>2015-11-29 11:47:38 -0700</pav:createdOn>
    <ao:suffix>– In 13 healthy subjects the coadministration of </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/19B786F4-620E-4D91-8ED8-60C04B53FE55">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>risperidone</rdfs:label>
    <dikbD2R:dose>3</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410">
    <permissions:permissions rdf:nodeID="N04e98ca531a14745a4bb6fb7f48e541e"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE93AD63-AECF-4FE6-8BB6-D094B1FF138C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED0BFDD6-2CF9-47A8-89E7-25E157AF657D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90FC8745-2407-404E-BD4B-99FB2452C0F7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3B7EBBC-118C-4A78-931A-EC3760A0E444"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:727A8BA0-3F81-4AB3-BC6C-D96DB9FEF1AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:86888333-61F0-4045-9D83-5BD06A5658EC"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-17 07:06:30 -0700</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:86A1A8FE-C01D-4C84-839E-7CF9C2E972D5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C16A4386-E817-47EE-BB17-CFB546704691"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/1486cffc-9ce6-46d9-9ef5-55c95411a730"/>
    <pav:previousVersion>urn:domeoserver:annotationset:60ED4CA9-15F0-4119-B723-F7EC799E74C0</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED246471-796A-4AD9-882B-FAE6B2D5191A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C160B72-BFFB-4671-9BC5-F4C1E31C62C0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:87824097-8AE4-4BE2-B08E-EE8B1E80C84C"/>
    <pav:lastSavedOn>2015-11-29 15:59:31 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <rdfs:label>NER Sets</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e14305115b858015115cd5b5c0000"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFD1C577-0D19-4C26-A5F2-6ADEB361378F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-27 14:51:24 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:B2F0EB05-E0EB-4922-AA0F-0CEC355CD052</pav:previousVersion>
    <ao:body rdf:nodeID="N77be304281174bb1a15a7a687b7d9e25"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:003D4AC4-0165-4256-B259-5CCB82BFE98F"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-27 14:51:32 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:811832DC-AE50-48B1-B204-28227F31662A">
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F96677C6-1C74-4FF9-A213-2E4759B0106A"/>
    <pav:createdOn>2015-11-27 14:13:25 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5c536dcc-38f9-4944-92b7-e840f72ecd24">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>        Vortioxetine binds with high affinity to the human </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5c536dcc-38f9-4944-92b7-e840f72ecd24"/>
    <pav:createdOn>2015-11-17 07:06:30 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <ao:exact>serotonin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> transporter </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D111515-2645-486C-8F68-140D66A05386">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-29 16:20:57 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E8FE416-EFE8-4F72-9F7D-D213DCF09D38</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 18:21:18 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N14831740d60b45699222461d20275537"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:4FB596C9-CF1F-44D5-B230-3E900F98BC7A"/>
    <pav:lineageUri>urn:domeoserver:annotation:C78650B4-F46D-407B-9B6C-2D2A0BD96C70</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9D98A93-52E8-4E62-A985-E597FDF227C1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:88D9DD30-BE39-40B1-BC54-8CC2CF73B39A</pav:lineageUri>
    <pav:createdOn>2015-11-29 15:32:10 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:32ED9CF2-3B2D-49DE-A5FB-3BF6BBE03DF3"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-29 17:32:26 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FC54327-CC52-44BC-9FDC-2621E712C6B1">
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 13:51:59 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A0DF2F4-47BC-466E-B9FF-1B8DB8E12EF7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:95870830-AF59-4DFB-971A-73777FABF0DC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CE94D821-2A6F-4B47-8C5D-A21979EE8BDC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEDC9ADC-0466-4920-BCC2-4ED079CDC661">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:28744B2C-4D66-48C7-A127-44A7969798E7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 13:52:42 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E2DEC3D4-2592-4FA7-92C1-9771F986D7B6">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1D72C992-8920-4AA8-989B-6DF9186C967E"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E4764B3-9044-4FE4-90DE-1D6487B76F5C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1760788-5433-46AC-BD9D-E7C6CAFBA554"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-11-27 14:14:41 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA8B8EC6-D2B5-43CD-B2EF-AF7F7D53D5D0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 13:51:49 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6B688F9E-D542-479F-8A91-8A8FD6A4F743"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7A604DEB-DC58-476F-8875-3A615029CA81">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>P88</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>3</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A58ACB44-BB3F-439A-955D-3A07B3CAAF91">
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 13:52:10 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:867FA548-AB1D-4E98-A667-D66F5E87B146"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BEE9FE1D-A7A2-4ABA-845A-2729B07DC6FA">
    <rdfs:label>mCPP</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10673974-435F-4B70-9255-F2BE9DA4F9AA">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4857CA94-1937-42E7-88E8-813E99F04FC8"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>entered plasma concentration as AUC</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/283AE4E1-E0D3-4AA7-84D0-D3866A8BCE17">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Lithium</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>500</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD5D04A6-F170-4510-A3B2-0A99375EF646">
    <ao:exact>Multiple doses of BRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam.</ao:exact>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 13:37:59 -0700</pav:createdOn>
    <ao:suffix> A clinical study has shown that</ao:suffix>
    <domeo:uuid>AD5D04A6-F170-4510-A3B2-0A99375EF646</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD5D04A6-F170-4510-A3B2-0A99375EF646"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5AD91245-37B0-422A-A863-C949FC69D024">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>increased by approximately 2 fold. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5AD91245-37B0-422A-A863-C949FC69D024"/>
    <ao:exact>Nefazodone </ao:exact>
    <pav:createdOn>2015-11-27 13:52:41 -0700</pav:createdOn>
    <ao:suffix>plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefazodone</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:215AF6A5-CB4C-4FEE-A51F-2340EA5280D3">
    <pav:lastSavedOn>2015-11-29 12:41:53 -0700</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">44</pav:versionNumber>
    <ao:body rdf:nodeID="N8009a3549d324212add59536328733a8"/>
    <pav:createdOn>2015-11-29 12:41:51 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE2CE7EA-E303-4246-B06F-5986E6406A5E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:1800C86D-5686-46A8-8D40-7CA692A12B0A</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A434153-A2A6-4FC6-9D66-CB5ACB2E58C1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent</ao:exact>
    <ao:prefix>were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 13:08:09 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A434153-A2A6-4FC6-9D66-CB5ACB2E58C1"/>
    <domeo:uuid>5A434153-A2A6-4FC6-9D66-CB5ACB2E58C1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26750B95-67E1-45B3-930F-B0BEF0F748A0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 13:52:13 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:67481C74-371C-4862-A91B-2EF001CD2459"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:216DABAE-4E29-4BD7-87F5-731C1468F641">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>When</ao:suffix>
    <pav:createdOn>2015-11-29 14:41:32 -0700</pav:createdOn>
    <ao:exact>Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:216DABAE-4E29-4BD7-87F5-731C1468F641"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BC65EE1C-3EDA-4DA8-B82D-D39939681594">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BEE9FE1D-A7A2-4ABA-845A-2729B07DC6FA"/>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:auc>3 to 6</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C8C76935-577F-4009-8DB8-74EE9B2D11C9"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E48F8C47-78CE-4D89-9516-5A857CD88BFE">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E8DA484-C2D9-420A-AED5-3F50F80F061E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N5d9213528b5341f5b63e872e6df9a648"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">21</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C402D82A-75F4-460E-BD6C-A243C3EB79B7</pav:previousVersion>
    <pav:createdOn>2015-11-27 15:04:22 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-27 15:04:35 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C56BD4CD-B397-4DC5-9704-9DF95C092691">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-27 14:13:31 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:33EA5337-D252-4182-9DB8-587566E439DA"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B616B77C-A5A5-48F2-B302-1188603C0515">
    <rdfs:label>midazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9F69369B-851D-46BA-9757-58771CAC6045">
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D4D6DE49-6A19-44C3-AE29-4B5A7819802A"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E1A61B2C-DD79-4787-A231-F8ADF9A5D1A2"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76ABB379-BDD6-4FC7-B180-50102BD590C0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <pav:createdOn>2015-11-27 15:24:42 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2372A928-BD15-42B9-8687-3034567BE4FB"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 15:27:03 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:D1DF16F7-536B-439E-9F08-06244C127A27</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E56E467-D2E9-4FD0-906F-904EC26C2808">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-29 16:36:18 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <ao:body rdf:nodeID="Na26011b93ebf4cfcaf067b9bf24a5ccf"/>
    <pav:previousVersion>urn:domeoclient:uuid:7685bcaf-274a-44c1-9eb7-34cf3ee40830</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2C3C70A-31A7-4682-8C0A-C17879CE7EE9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 16:36:20 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD852660-47E6-415B-9C3F-EAE3985ADB2C">
    <pav:createdOn>2015-11-27 13:04:48 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 13:05:05 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FCD0E530-8F8E-4DC2-8259-E34AFEDB4AF9"/>
    <ao:body rdf:nodeID="Ne743ee0d2e8343f58c4d64e212adb3e0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:C9A7329F-7A17-45E8-898A-8894CBF786E9</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72B6878C-1764-43E9-B083-CDE8EC9DEC4B">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4C0B0F5-8154-4C4B-AB5D-E0020CB44B39"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:A9194EB4-4229-45D9-A89D-128E5602CCC2</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N2717e2ed8ba742e384f2fffa7354a237"/>
    <pav:createdOn>2015-11-27 14:24:05 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:24:14 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9A16457C-AEBA-43B6-A5BD-6453D06F3550">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69194F70-ED82-4288-827E-EFFB9FC5D936">
    <ao:prefix>, or its metabolite </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 11:47:49 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HO-NEF</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>; however, there were small decreases in the steady-state plasma concentrations of two </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69194F70-ED82-4288-827E-EFFB9FC5D936"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4BF2DDA9-5301-4F65-A3A3-46F56FCF2E06">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>6</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/170BED1E-0308-4D70-A22C-296D933E6822"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:auc>20</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/93C01C02-AC29-476C-9710-886515E4BB20"/>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23AD2102-1B2F-4F6A-951C-406C5C47FE42">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <pav:createdOn>2015-11-29 13:44:16 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>23AD2102-1B2F-4F6A-951C-406C5C47FE42</domeo:uuid>
    <ao:exact>Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].</ao:exact>
    <ao:suffix> Patients receiving other drugs that interfere with hemostasis should be carefully monitored when</ao:suffix>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23AD2102-1B2F-4F6A-951C-406C5C47FE42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A632357-E3AB-47BD-BF8C-4D53021229A9">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>and HO-NEF were increased by approximately 25%.</ao:suffix>
    <ao:prefix>In patients with cirrhosis of the liver, AUC values of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 14:16:05 -0700</pav:createdOn>
    <ao:exact>nefazodone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A632357-E3AB-47BD-BF8C-4D53021229A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D28A995A-00DD-4EFB-9632-5FC9943CEC61">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4E4A228-1A8D-40AC-87D1-97D386D8645A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 14:15:18 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:66A72D72-C10C-4A3D-B807-16C7C3FF656E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/890DD709-3F19-4308-AA4E-80BBF686213E"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1BFD0E33-C60D-4F25-AB63-31D35DC0B3BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82A92D72-95AD-427B-9591-98F0E4D35ECB">
    <pav:createdOn>2015-11-27 14:13:37 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsade de pointes type. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Nefazodone </ao:exact>
    <ao:suffix>has been shown </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82A92D72-95AD-427B-9591-98F0E4D35ECB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:238B9075-B421-489D-A010-A8EF3556636C">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/94B3F018-11E2-4832-8B5E-0A7A8E4C14A4"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:auc>17</dikbD2R:auc>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E189DA94-A439-4E3C-98B6-7652BB56AA09"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/890DD709-3F19-4308-AA4E-80BBF686213E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>150</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F522A0D3-2136-4518-AF51-C0C7ECF2404A">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0E24E1CD-CB5A-4E16-B21E-4F4B8E9BCBB2"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7DD8DFBE-5804-4005-9029-C9EE5BA5083F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FB596C9-CF1F-44D5-B230-3E900F98BC7A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Co-administration of a single dose of INVEGA® 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone. Dosage reduction for INVEGA® should be considered when INVEGA® is co-administered with valproate after clinical assessment.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4FB596C9-CF1F-44D5-B230-3E900F98BC7A"/>
    <domeo:uuid>4FB596C9-CF1F-44D5-B230-3E900F98BC7A</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>have not been studied. The clinical relevance is unknown.  </ao:prefix>
    <pav:createdOn>2015-11-29 16:20:57 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EB9494E7-E621-4E75-B99C-C3D024ED571A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>atorvastatin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83367</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E655280-5EED-43B7-AA88-6CF39DA84943">
    <pav:createdOn>2015-11-29 14:33:09 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E655280-5EED-43B7-AA88-6CF39DA84943"/>
    <ao:exact>Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:prefix>elimination and cause increased blood levels.   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16B4A019-2B1B-477D-BB67-2A6837108B71">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:8860D4F1-061C-4487-846C-3A90F231BB2F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">51</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 13:14:12 -0700</pav:lastSavedOn>
    <ao:body rdf:nodeID="Neca71e7e24584a75863c94e3ccef07ae"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-29 13:14:10 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:7D1FD71C-9A3B-43AC-9FA2-1A3EE43785C2</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2606DE11-2CCD-4846-8F6B-E0862411E5F2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:268B86ED-00B7-4A33-9D2E-6D537E9DBD1A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/24489CCC-A5C7-44A7-8C17-85AB593AE745"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B1D81255-D16D-419E-BE81-0B4750F62110"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F23FD930-9B00-45B9-BCB8-4727885A2F3A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/09B73A09-125E-448D-992D-C17E9E5803FC"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>4</dikbD2R:preciptDuration>
    <dikbD2R:auc>57</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>19</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5C52525A-B363-4F1D-8624-921F4140235B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:464BCBC3-CECA-4BBE-A5E8-BF79FC6A24FF">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9CCBD3B5-32AE-4E6E-A41D-4FB5762A9341"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59F42EBC-9CD0-480C-A4B3-55B676C7CB69">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 11:45:58 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:1F47D1EC-6C75-4D09-A9C2-B20AA86B8661</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 11:46:00 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">32</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A92CBBE-B7B0-497D-B206-F8C4234E12EC"/>
    <ao:body rdf:nodeID="N632063493ca04019a30267209db39a4e"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FDD85673-4F67-4207-9753-84465C464858">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:28A9AFF4-7A6A-40C0-9722-0F14D3F85551">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E0970196-D134-4422-8BAE-D3CCBD91749F"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FDD85673-4F67-4207-9753-84465C464858"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB531E09-9659-4FEE-B29F-84A4A6A8C4DA">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>. The </ao:suffix>
    <ao:exact>P88</ao:exact>
    <pav:createdOn>2015-11-29 15:26:48 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>-demethylation (mediated by CYP3A4). There are 2 predominant iloperidone metabolites, P95 and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB531E09-9659-4FEE-B29F-84A4A6A8C4DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:256318B4-8529-49FF-8231-F70ED9111A64">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:28A9AFF4-7A6A-40C0-9722-0F14D3F85551"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3E6D417-CA94-49FA-B4CC-0C3A2ECA1C40">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 13:52:30 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:763B87D5-0B58-40F4-9392-1361B52B0945"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/620832B6-79D4-43B8-AB09-2652A2795BBD">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>triazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>.25</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFF7A9C6-AFAA-4CEF-BF33-A451C97F3ECD">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-27 13:52:26 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:64226B39-C96C-4FAB-87D6-62CE1560628B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF7E327F-13CE-4D87-98D5-B8F880D008EF">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 11:47:16 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF7E327F-13CE-4D87-98D5-B8F880D008EF"/>
    <ao:prefix>or its metabolite, 2-hydroxy desipramine .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:480F8392-D266-442E-A27E-89378F9ADE68">
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EB95F59C-3400-49D0-BFB5-01B1FE8D88DA"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EB9494E7-E621-4E75-B99C-C3D024ED571A"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>6</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:auc>3 to 4</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B88C45E-AB6A-4FBC-8B81-2D42817789EC">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:body rdf:nodeID="Ne8d158f41d1c48fabba9d45b9183b042"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 15:24:30 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 15:24:14 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:8A7E09B5-7C04-47CC-9ABE-F84454602776</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD30BB22-1CA0-48D7-A3E3-CAA83997648E"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C160B72-BFFB-4671-9BC5-F4C1E31C62C0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:72AD937E-2BC8-4149-AD5B-32EE67899FC9</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Ne1eca61a60be4c78b490a250513af48e"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 13:38:00 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 13:37:59 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD5D04A6-F170-4510-A3B2-0A99375EF646"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D139E916-C0D1-4F43-8AE9-51520F45601D">
    <pav:lastSavedOn>2015-11-27 13:58:57 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:21056399-99EE-473A-8CFE-7154EB23C815</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Ndde46d6c9edb4e6a969529714d2dee1b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:ACD60A5C-AAC2-45EB-B79C-40CB7139B22B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-11-27 13:58:50 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5CEDFFC9-712F-4814-B6B2-CBE93DBB409C">
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/57C27E72-C145-4435-B98C-35FCEEBD420B"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/437442C7-5AC6-4F5F-A72A-054FD0209487"/>
    <dikbD2R:auc>9</dikbD2R:auc>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AEE6D10-6A4D-463D-8065-D90E56D5D8A7">
    <ao:body rdf:nodeID="Naebc4acaafd542228a5ea16cbeed86f5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-29 11:40:44 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:429BA634-0508-4EF4-B2CA-4E573CFD7834"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FCE35EA5-872E-4883-ADC4-0E05965DE708</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-29 11:40:46 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/19488034-D21B-4580-9746-89F7955C04ED">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>8 or 12</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>P95</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A241933B-4573-4A12-A430-14E450C510E4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>nefazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. Consequently, it is recommended that nefazodone not be used in combination with </ao:suffix>
    <ao:prefix>concentrations for achieving an antidepressant effect for </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A241933B-4573-4A12-A430-14E450C510E4"/>
    <pav:createdOn>2015-11-27 14:14:12 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC89070F-CF31-45D5-85E7-2C081A994BC8">
    <pav:createdOn>2015-11-27 14:16:06 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:588B27DA-246B-4806-9C1C-F6C04D43E761"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B792182-9A40-4CC8-AE59-7F2FE0559A85">
    <ao:suffix>(see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 12:58:54 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>triazolam </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B792182-9A40-4CC8-AE59-7F2FE0559A85"/>
    <ao:prefix> causes a significant increase in the plasma level of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9F2E7FA-A105-41F1-9E70-964C5CD89D19">
    <pav:lineageUri>urn:domeoserver:annotation:FA148E0E-9617-40AB-94D9-DD6573C0A7AA</pav:lineageUri>
    <pav:createdOn>2015-11-29 15:26:24 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:75EB1BA8-B7AD-4FB9-8C24-8B944CCAC185"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6CC24C09-171B-4BD4-B94A-C325790CA1C2">
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>23</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>Percent</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F8B34BDD-A209-463A-B8B6-624FEB4FD223"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>5.5</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4A3AD5DC-4E4F-47B2-A087-ED9D9B3B78F2"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>5.5</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>54</dikbD2R:cmin>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>28</dikbD2R:auc>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminDirection>Increase</dikbD2R:cminDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41241210-B2F3-4462-A957-B7BFD185ABAD">
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:auc>2 to 3</dikbD2R:auc>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>23</dikbD2R:numOfParticipants>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7DC522EA-0A81-4830-B0EF-09FF5FAA9C04"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30F89F72-D818-4D92-8E13-B51DAEC88BA1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE93AD63-AECF-4FE6-8BB6-D094B1FF138C">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N950c3d1b466e4a179c65a222ea2e3202"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:23AD2102-1B2F-4F6A-951C-406C5C47FE42"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C2441E8C-5B5C-4F55-8CBF-27503BDC9E07</pav:previousVersion>
    <pav:createdOn>2015-11-29 13:44:16 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 13:44:17 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FB0E10E8-73E3-46E8-96FC-06F9CF61641C">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>up to 20</dikbD2R:cmax>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7C7584DA-CC8A-4325-BC44-F99B15A42393"/>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7463F20A-89CE-4113-BB70-6AEAF246299D"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>up to 50</dikbD2R:auc>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A47B065-DF4E-4861-A520-A5389C57DB72">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 12:28:45 -0700</pav:createdOn>
    <ao:exact>4-hydroxypropranolol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> for the metabolite, </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. The kinetics of </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A47B065-DF4E-4861-A520-A5389C57DB72"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6F3917C-0C4F-4A59-A88E-BE65DF876BE3">
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/056F529F-1EAD-4CB5-BFBA-FF503870B2B7"/>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1E71250A-6C1B-4FC9-9A01-1B01CA877F6F"/>
    <dikbD2R:auc>about 50</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF2386BF-98B0-45F8-9D72-B8D67AF3FA04">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/65094F27-7584-4279-88E4-44C277B96B36"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5A4BDF91-021A-4D7D-B7E5-68DE542CE18C"/>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7993BEB-BF6E-42B2-A965-AA85C25A9843">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 14:14:31 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1B40DED-8AE7-4C9D-B933-1BB559EF43AE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/36F7D2FF-16D3-4242-93BC-BA6D9F141B02">
    <rdfs:label>hydroxynefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2EEB6CB-CD25-4E3A-B21D-714A82928509">
    <domeo:uuid>E2EEB6CB-CD25-4E3A-B21D-714A82928509</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 13:10:40 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2EEB6CB-CD25-4E3A-B21D-714A82928509"/>
    <ao:exact>Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43F463C7-C891-4889-BC65-A3073882E738">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1B29B32D-3228-4AD9-9172-39BA9035C5D8"/>
    <dikbD2R:comment>entered plasma concentration increase as AUC</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED246471-796A-4AD9-882B-FAE6B2D5191A">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:D95636C5-92C5-433A-B843-910BEDF57D99</pav:previousVersion>
    <pav:lastSavedOn>2015-11-29 13:52:49 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <ao:body rdf:nodeID="N2e638e00fd5f454f9305682697464f75"/>
    <pav:createdOn>2015-11-29 13:49:35 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7606AAF1-3E92-4498-ABAA-E0839B0414D4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0605D5E7-E502-448C-8979-745E84FA3019">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:nodeID="N864f94d73a2b48fd989b4f3e23c6e899"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:CF39FF1A-0D28-452C-94C1-1126A4EBB6A4</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF6FC2F3-8A44-4BD0-B1FE-A7B1A6AFE872"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-29 15:23:58 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-29 15:23:59 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D3707F84-929A-45B8-B833-790099CE9F32">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/88EF6876-2009-4582-A53A-62889E0A1A28"/>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>QID</dikbD2R:objectRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EC37481F-0E3F-4A67-8255-9B40021D038C"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1EB49031-0A78-4B54-A475-B946A3CBE64F">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C20ABBAE-EBDE-4BE2-A566-D21AAFF83B55</pav:previousVersion>
    <pav:lastSavedOn>2015-11-29 11:47:19 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">33</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-29 11:47:16 -0700</pav:createdOn>
    <ao:body rdf:nodeID="N9fcded797db74a46bcd83be0fe909743"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF7E327F-13CE-4D87-98D5-B8F880D008EF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D9573E7-C378-4BFE-BD2A-139CA7BE06A7">
    <ao:exact> Pharmacodynamic effects of haloperidol were generally not altered significantly. There were no changes in the pharmacokinetic parameters for nefazodone</ao:exact>
    <ao:suffix>. Dosage adjustment of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> This change is of unknown clinical significance.</ao:prefix>
    <pav:createdOn>2015-11-27 14:26:42 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6D9573E7-C378-4BFE-BD2A-139CA7BE06A7"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BAD4753-CA92-4B4C-81EF-2B15350B64E1">
    <ao:exact>Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 14:36:35 -0700</pav:createdOn>
    <ao:prefix>elimination and cause increased blood levels.   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BAD4753-CA92-4B4C-81EF-2B15350B64E1"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0E0AB83A-A859-4776-8F09-9D2BA268E2E0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>P95</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>3</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BB2A5668-ED51-4F1C-8504-94D32FB63543">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:797F33E1-4895-461A-9544-FAA771762563"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>increases in plasma concentrations</dikbD2R:comment>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0FE3AFEE-397E-4C79-87D5-6E537C6CFB8D">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EE564225-35EE-4C35-A17D-535418DE34AD"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9DEDFAAA-B84C-40A9-8F2A-A516FC06325C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9C17DF2-D0B4-4BEB-8DF8-016CCA8462C6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 14:01:39 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N56b312e5e84f474aa1e3cfa5af7e18ad"/>
    <pav:previousVersion>urn:domeoserver:annotationset:138FFC6D-AECA-43BB-98D8-8D81B58EFF1A</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:4B9F853C-4776-489E-8666-77F967CF04F1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:01:33 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E1E78E9-8B95-45D3-AF61-010956EF204D">
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 14:15:37 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1DCC66E0-33AF-4335-B6DC-30738D4A7C1A"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD1F9484-6EB3-4E52-B92F-043B329FF4F0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">31</pav:versionNumber>
    <pav:createdOn>2015-11-29 11:44:01 -0700</pav:createdOn>
    <ao:body rdf:nodeID="N684948a7d5e74782989590c90de07c15"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:995D2E1E-C7D0-4226-B448-CFE5BF4D7A33</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8E0F4F1-725B-440C-8516-2454A2FD8082"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 11:44:04 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC49D92D-1F3B-44DB-A883-1E15A72D5D87">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 15:26:33 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9F19DFC1-B956-47A6-9A81-88B272B4A446</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB2BC77B-643D-416D-A2D9-DE5D07159D6E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A8E22455-896F-4D87-A8C3-0FB8329B5D18">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2CAB70DC-64E8-4857-85DC-D99B49CF5BFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D17A5693-99EE-4628-B181-EAE5F470886C">
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:79A3606D-77B0-40B6-885E-538884F96BD3"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 13:51:46 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:739BD25D-E4E1-4CCD-BE8D-4356360E904D">
    <ao:exact> When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.</ao:exact>
    <ao:suffix> Similarly, there were no changes in the pharmacokinetic parameters of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 15:22:40 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> –</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:739BD25D-E4E1-4CCD-BE8D-4356360E904D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6A91F928-56CF-47B5-BF20-792888E25196">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/23005184-A113-4DFD-BCFC-E9BEBEB8682F"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D9EC5242-3B85-4C10-B091-55CD228BA988"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D95B1124-4116-4693-BC27-750D9B3C32EB">
    <ao:prefix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine , astemi</ao:prefix>
    <ao:exact>z</ao:exact>
    <pav:createdOn>2015-11-27 14:45:40 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>ole, cisapride, and </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D95B1124-4116-4693-BC27-750D9B3C32EB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/302AE5BE-1AE3-4522-ABED-56E03190B4E8">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA557A92-DB78-431C-8AD4-DFA60B10001F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 15:22:19 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N922c1f28b08e4e2bb190039bc837bcc5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:66474FA6-ACAD-4813-8312-71501069CDDB</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:96FDB1C0-D695-47D2-A45F-9D3FB620E026"/>
    <pav:createdOn>2015-11-29 13:21:18 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1D14FA0-ADB1-4837-9BDE-10248FE7F7B3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-27 14:13:37 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:82A92D72-95AD-427B-9591-98F0E4D35ECB"/>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7606AAF1-3E92-4498-ABAA-E0839B0414D4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7606AAF1-3E92-4498-ABAA-E0839B0414D4"/>
    <ao:exact>Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>7606AAF1-3E92-4498-ABAA-E0839B0414D4</domeo:uuid>
    <pav:createdOn>2015-11-29 13:49:35 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B99A2A53-02F3-4314-8A45-29FE68EECEDB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <domeo:uuid>B99A2A53-02F3-4314-8A45-29FE68EECEDB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of BRINTELLIX, no significant effects were observed in INR, prothrombin values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin [see Drug Interactions (7.4)].</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Coadministration of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B99A2A53-02F3-4314-8A45-29FE68EECEDB"/>
    <pav:createdOn>2015-11-29 13:42:03 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFECA5A9-DBC3-4CA2-8043-D4ECB305BB03">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>triazole-dione</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-29 12:28:55 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFECA5A9-DBC3-4CA2-8043-D4ECB305BB03"/>
    <ao:suffix> were not affected by coadministration of </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FCD0E530-8F8E-4DC2-8259-E34AFEDB4AF9">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Because not all commercially available dosage forms of triazolam permit a sufficient dosage reduction, the coadministration of</ao:suffix>
    <ao:exact>The coadministration of triazolam and nefazodone causes a significant increase in the plasma level of triazolam (see WARNINGS and PRECAUTIONS), and a 75% reduction in the initial triazolam dosage is recommended if the two drugs are to be given together. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FCD0E530-8F8E-4DC2-8259-E34AFEDB4AF9"/>
    <pav:createdOn>2015-11-27 13:04:48 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:068E23A7-91BA-46F8-8AA8-0BC4338961A3">
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5087328A-6B7E-45AB-AA35-A9864D92E659"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F2980295-2A51-40F5-AA37-45335104B965"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7A392041-33EF-4D12-8BF4-62EB95C30DEF">
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/96AB3BB2-36D3-45A3-9110-1ACDA1EB8D0E"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9BC74DC8-C226-42EA-A40B-BB9E9B5840C5"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:172456A8-6419-405D-BEE0-97CBA06A001E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A8FA6342-AE30-4A60-9DF2-2D38331CB23A"/>
    <dikbD2R:cl>UNKUNK</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DC198BE2-4718-485E-B220-0325F0207DBE"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D8ACAFB7-FEA4-485B-BAE1-FA78D203E02D">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4AAD4CA7-7462-46F4-9045-95F2DCA449F7"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>19</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4A8D7449-0CF6-4125-9DAB-EEC4C0334A69"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4CF4B4CA-5B4A-4563-9BA2-BAD879EE65DB">
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/40254</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>valproate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:67E962B2-BA92-4A9D-8B3F-ED7E10330F77">
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C142D5C3-CBF1-4AED-B5BB-C6FE136BD4CC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EC1A312F-DD46-4067-81E4-131CC559171D"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2E6FC1A6-A6D3-46C4-9994-4F63BED57AE0">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:957CB6EB-1223-4840-B725-8918855B9F6A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-27 14:12:40 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 14:12:47 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:066DDCD3-9F5E-4295-BE85-94C84C710B8E</pav:previousVersion>
    <ao:body rdf:nodeID="N25a38dd81ac44ac4af75ab450445e725"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:59184FDB-08F9-4704-B62C-A542084105F2">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>1.6</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0576B398-81B8-4A8F-9F54-F85CFC881F7C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/273D8417-392D-492E-97C8-B512585685DA"/>
    <dikbD2R:preciptDuration>5 to 8</dikbD2R:preciptDuration>
    <dikbD2R:t12>UNK</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D8A16754-DDD5-46F9-A2DC-E9BAE8826046">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-29 11:47:46 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E08E393A-F69F-4986-9750-C4292A3A1CAB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EE564225-35EE-4C35-A17D-535418DE34AD">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/568FFDF3-669F-43DF-8577-91E1FE29F73A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0695463B-FC87-4370-88DA-456E999EA88E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32E72936-6FF3-42B7-93C4-E8C2145690E7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:45:51 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB848352-7DA0-4562-978F-4DC3B5FAE1BA"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:96B7DE32-6FEA-4443-8BCF-EF92853D8652">
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3AD95BDA-9AB8-4242-867A-D6901708F40D"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cl>35</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cmax>37</dikbD2R:cmax>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clDirection>Increase</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:auc>37</dikbD2R:auc>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9DEDFAAA-B84C-40A9-8F2A-A516FC06325C"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7621502D-D15B-4D51-8697-29BB5AC29CB9">
    <ao:body rdf:nodeID="N179fef97738f431892eb0503cc85fa5b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 15:07:38 -0700</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E67ED01D-77C2-4699-8D18-C97D690C4E83"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 15:07:30 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:CE625B91-EC0A-4F9F-96E4-D74D69E9BB15</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29F288B3-A31F-4DEB-8BDB-5FE8B771E151">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:614F6CA5-F0D8-4ABA-B1D3-B5C35B90A8B6"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/443FABCB-38AC-4A89-A55C-8D5BD76BE7FF">
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC2DEF4C-2C5E-44A2-8CA9-E27CD02591A7">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Alprazolam   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 14:10:53 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC2DEF4C-2C5E-44A2-8CA9-E27CD02591A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:679B03FE-2E5B-4DEB-BC09-297F13FAE5CE">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>alprazolam </ao:exact>
    <pav:createdOn>2015-11-27 13:52:39 -0700</pav:createdOn>
    <ao:prefix>(200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefa</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:679B03FE-2E5B-4DEB-BC09-297F13FAE5CE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9fcded797db74a46bcd83be0fe909743">
    <domeo:sets rdf:resource="urn:pddi:uuid:A34E444D-9FFD-4D2B-B51C-143C85D22CAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F1C6E19-795C-4671-BA7E-EF58AAAB0B42">
    <ao:context rdf:resource="urn:domeoclient:uuid:04C6CCB6-558D-4AB6-91B6-02DAB5A75576"/>
    <ao:body rdf:nodeID="N5ea60460902a406e89d16c5b3dad3b65"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-27 14:31:22 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 14:33:28 -0700</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:3105DFB4-65B7-4CAD-9B56-60E875724E1D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1B29B32D-3228-4AD9-9172-39BA9035C5D8">
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6D6115CF-616C-4D9D-96F2-D0737F234FD0"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D2DFAF53-20A2-4BFF-B083-E22F1F812283"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>20</dikbD2R:auc>
    <dikbD2R:preciptDuration>6</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:763B87D5-0B58-40F4-9392-1361B52B0945">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:763B87D5-0B58-40F4-9392-1361B52B0945"/>
    <ao:suffix>should be used (see </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:52:30 -0700</pav:createdOn>
    <ao:exact>triazolam </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>may be considered appropriate, only the lowest possible dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D336AA33-2F87-448E-8CC3-5BE5D6212680">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42463</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>pravastatin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3FD2065B-F0FB-4033-8DD9-432A069E81E1">
    <pav:createdOn>2015-11-29 16:49:19 -0700</pav:createdOn>
    <domeo:uuid>3FD2065B-F0FB-4033-8DD9-432A069E81E1</domeo:uuid>
    <ao:prefix>is not recommended.   Digoxin   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3FD2065B-F0FB-4033-8DD9-432A069E81E1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Dose adjustment for digoxin is not recommended.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8D2C279-998D-4042-8423-B8D42628E79D">
    <pav:createdOn>2015-11-29 12:26:10 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics of nefazodone and its active metabolites. Because of the narrow therapeutic index of digoxin, caution should be exercised when nefazodone and digoxin are coadministered; plasma level monitoring for digoxin is recommended.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8D2C279-998D-4042-8423-B8D42628E79D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> Cardiovascular-Active Drugs   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B7E0E7C-F4ED-4E26-8500-017A82645502">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Because vortioxetine is highly bound to plasma protein, coadministration of BRINTELLIX with another drug that is highly protein bound may increase free concentrations of the other drug. However, in a clinical study with coadministration of BRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein-bound drug, no significant change in INR was observed [see Drug Interactions (7.2)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B7E0E7C-F4ED-4E26-8500-017A82645502"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0B7E0E7C-F4ED-4E26-8500-017A82645502</domeo:uuid>
    <pav:createdOn>2015-11-29 13:59:30 -0700</pav:createdOn>
    <ao:prefix>), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2) .   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N00680abb963a4e72943ccc82ade74512">
    <permissions:accessType>urn:person:uuid:080e14305115b858015115cd5b5c0000</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1486cffc-9ce6-46d9-9ef5-55c95411a730">
    <pav:createdOn>2015-11-17 07:06:30 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-17 07:06:30 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5c536dcc-38f9-4944-92b7-e840f72ecd24"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:614F6CA5-F0D8-4ABA-B1D3-B5C35B90A8B6">
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:auc>23</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A060D451-18E0-40D1-8530-AC514DC29D11"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/36303156-C3AD-4C1D-887C-EF3E3BE504D1"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:34F1F10A-984B-413E-86E0-20388197DE2F">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CBA39573-1C14-4F68-A99F-C2DFE3C435F5"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:auc>17</dikbD2R:auc>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmax>26</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/77B2E7AD-59B1-4E2E-A0C9-38E25FC48AA0"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4E8FE416-EFE8-4F72-9F7D-D213DCF09D38">
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D111515-2645-486C-8F68-140D66A05386"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:19896962-B0C0-490F-BA67-FC1BBD764812</pav:previousVersion>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/f22dfcdf-2ba2-4ede-a1cc-3c8c9bdddc05"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4717B176-0577-45BD-B116-830BC1523DE6"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N00680abb963a4e72943ccc82ade74512"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:A0CF9D40-E7F9-4C45-8F9C-EBCD9B164AAC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6EB8F485-7B2D-4E91-8290-E04362E785A0"/>
    <pav:lastSavedOn>2015-11-29 18:21:18 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f4bcdebf-db7b-4c95-b1b2-8bc46c7992e0</pav:lineageUri>
    <pav:createdOn>2015-11-17 07:08:08 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e14305115b858015115cd5b5c0000"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F940E99-1158-4E67-A47A-33E3C0052768">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-29 12:09:52 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">40</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:A4B29803-5EFE-4BA1-A7DD-B9BFFCE9F426</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E38DC63F-30D7-4127-BC4B-E2CBBC433FEB"/>
    <ao:body rdf:nodeID="N25f45236cd7d42fcad34217c08ee9c6d"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 12:09:54 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BF11ABBB-9E83-4224-86FD-EC3D62309994">
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/302AE5BE-1AE3-4522-ABED-56E03190B4E8"/>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D5222288-15F4-495D-88A8-9021F107F313"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1c89215a-b43a-4651-8ab2-713205a2c758">
    <pav:createdOn>2015-11-17 07:06:31 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:suffix>. Thus, an interaction between iloperidone and other CYP2D6 </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1c89215a-b43a-4651-8ab2-713205a2c758"/>
    <ao:exact>dextromethorphan</ao:exact>
    <ao:prefix>of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B5942F8-1972-4832-85F4-F99B8770541F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-29 15:26:46 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:894E7A4C-55AE-4305-8DE0-838A0AD5F1C6</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2260640B-B516-4CFE-B20A-E869B24B0887"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7DD8DFBE-5804-4005-9029-C9EE5BA5083F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <rdfs:label>diazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BC4CA28-7B1F-4474-954A-91FC480F5503">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:D7188365-B07E-42D3-A4B1-89DD9808BF1B</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 15:29:38 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:16430840-10CE-4EE0-8A15-4BD5C610B2F7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 15:29:17 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B2AFDFE-F0AC-4165-A5F5-3C333B1497E3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>) it is ~8%.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <pav:createdOn>2015-11-29 15:26:39 -0700</pav:createdOn>
    <ao:prefix>in plasma is ~3% and of each metabolite ( P88 and </ao:prefix>
    <ao:exact>P95</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B2AFDFE-F0AC-4165-A5F5-3C333B1497E3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79A3606D-77B0-40B6-885E-538884F96BD3">
    <pav:createdOn>2015-11-27 13:51:46 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nefazodone </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:79A3606D-77B0-40B6-885E-538884F96BD3"/>
    <ao:prefix>Interaction studies of </ao:prefix>
    <ao:suffix>with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7A8BCFB-75F1-4C7C-A4E9-25570054D6B2">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 13:52:27 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BCD08072-2BA4-4B86-A00D-68E56D8C2980"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E189DA94-A439-4E3C-98B6-7652BB56AA09">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>250</dikbD2R:dose>
    <rdfs:label>hydroxynefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/96AB3BB2-36D3-45A3-9110-1ACDA1EB8D0E">
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:961C7CE6-D7CE-4C28-AD91-DDB7E75792F8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:642DB230-AAAA-4CB7-B2CE-D3AA1F7CFAF7"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>small decreases in the steady-state plasma concentrations which are considered not to be of clinical significance.</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8E0F4F1-725B-440C-8516-2454A2FD8082">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.</ao:exact>
    <pav:createdOn>2015-11-29 11:44:01 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>or its metabolite, 2-hydroxy desipramine .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8E0F4F1-725B-440C-8516-2454A2FD8082"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0D86F770-E184-4156-A0D3-0DF3712BDAE8">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>triazole-dione</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:87509163-41CC-484B-913D-AE9FB357321D">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3F5CE9D1-9BE0-4896-90DD-9982AA914CB7"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0C2DC2BC-E67A-425C-84AB-E10836C88580"/>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5610B93D-317A-46EE-8194-447329366CB5">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 13:52:22 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6152FDD-70FC-4215-9F3E-F24C433EF15D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42AC4CE0-AB6A-4478-A4F8-4C3C2FC6DF78">
    <pav:createdOn>2015-11-29 13:57:35 -0700</pav:createdOn>
    <ao:exact>Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2)</ao:exact>
    <ao:prefix>is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <domeo:uuid>42AC4CE0-AB6A-4478-A4F8-4C3C2FC6DF78</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42AC4CE0-AB6A-4478-A4F8-4C3C2FC6DF78"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BDB3DF29-D871-40F0-9690-C84209F70CF7">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>21</dikbD2R:numOfParticipants>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4CF4B4CA-5B4A-4563-9BA2-BAD879EE65DB"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0B1784C1-B50E-4C0E-861A-7CD9AB89C48A"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C3595456-0C41-4682-BBCB-C8A0ADDEE583">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>23</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/443FABCB-38AC-4A89-A55C-8D5BD76BE7FF"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0D3D83E3-39B9-44A0-8CCF-93E60471D336"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0213ACE5-8FCA-45C5-B5C4-34F7274E2F8A">
    <pav:createdOn>2015-11-29 12:47:03 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0CF0B1F-3057-41D9-821F-12154CF94FE0"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C53022DB-44D7-4605-AFC3-3C5070751F00</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">45</pav:versionNumber>
    <ao:body rdf:nodeID="N756c38cb7d6946b9b277347f0dd52eb2"/>
    <pav:lastSavedOn>2015-11-29 12:47:05 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6205F210-9F39-42CE-9730-C83F86093133">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:B2F0EB05-E0EB-4922-AA0F-0CEC355CD052</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 14:46:35 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8CAED791-8BC7-4077-B358-AD64646EAB59"/>
    <pav:lastSavedOn>2015-11-27 14:51:32 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7C58694-BCBC-4F91-84BF-4F421D25C3B9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:15A6E2E2-6EAE-4F64-8DB7-E43182ED5B8F</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-29 13:20:52 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">52</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:97DFBEEE-14F3-4028-B3E6-F6071E43FE3F"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-29 13:20:54 -0700</pav:lastSavedOn>
    <ao:body rdf:nodeID="N805d473eb3e54362a0ec00c8bfad6bd8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F4E8CAF6-6B7D-41AE-893B-AB50CD112F4B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/19B786F4-620E-4D91-8ED8-60C04B53FE55"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9FAFA165-1231-44D3-B913-4A4F118D53A9"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6AE9622-F852-4F0E-8192-892DC06D71D3">
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6D25492B-0310-45B3-B821-455ED079704E"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>21</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>20</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4479E5E3-3FE8-44E9-8B48-B203349BAC6A"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF183E4F-C2ED-4B99-9E19-7BAA7B8DB17B">
    <ao:context rdf:resource="urn:domeoclient:uuid:BD3EFC85-5FA0-4DAE-BD52-248DCE9DAEC7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C7C9A709-D49A-49F1-827C-A0D756FBAF9D</pav:previousVersion>
    <ao:body rdf:nodeID="N0792ae05f1e34e97b30569518ac49a12"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">30</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 11:42:44 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-29 11:42:39 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:372D521B-0AF3-4D63-B84E-890BACC672E6">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:638589D5-BADB-4A55-937A-DE53EB69FBCC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:3476269B-9BD1-48F7-AF3D-4E5F488D761B"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 12:07:13 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">39</pav:versionNumber>
    <ao:body rdf:nodeID="Ndf95894c96614900841170cbb1d9472e"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 12:07:09 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0888B2A8-E583-46EB-A6E9-E57BAACEAC21">
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>2 to 3</dikbD2R:auc>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>23</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7BF63951-B9D2-4094-B78E-FC18068E068C"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7A604DEB-DC58-476F-8875-3A615029CA81"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F63985B6-6C0C-4191-AF0A-5278649B8768">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:80BF077D-8A32-4E3B-B426-5FC6BA9AF123"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9CCBD3B5-32AE-4E6E-A41D-4FB5762A9341">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>5</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/005E8EC2-F0C0-482F-9B71-4663FC89EDA3"/>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3168CEF7-B7F3-41EE-ACBD-19FB41053065"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>5</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/49D30C46-2051-4B34-BB22-9ED56951BD81">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Lithium</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D72C992-8920-4AA8-989B-6DF9186C967E">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8C03D9A3-3740-4537-A617-9284F9AA7380"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/727D32F2-D4B1-4ED5-A97B-EC20F66BCDDE"/>
    <dikbD2R:cl>UNKUNUNK</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:56FF991F-01CD-4B10-BA03-63EC3C881C68">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1E35A43A-D2D9-46E9-A6D2-E61FD973908F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0D3D83E3-39B9-44A0-8CCF-93E60471D336">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>P95</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>3</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8F1EAF47-5BC2-44C1-A73B-5D8A7B6F27A1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F522A0D3-2136-4518-AF51-C0C7ECF2404A"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1382975-3B93-472D-A431-32125774ED7B">
    <ao:suffix> (9%).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact> mCPP</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 15:02:27 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>(23%) and its metabolites hydroxynefazodone  (17%) and</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A1382975-3B93-472D-A431-32125774ED7B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F166181-1DD8-4C61-A8DF-E6C4777F2F95">
    <pav:createdOn>2015-11-29 11:47:38 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C1AD50A-355C-4CC2-92F4-ABDAC41316D9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBDFC926-7101-458A-8B2A-609DCFE3A51B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:2320B431-C8D9-4C7E-B2E9-2673D235C46E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 13:51:55 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5ECC8EDB-2666-470D-B355-05C9ACBBBDBB">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/19488034-D21B-4580-9746-89F7955C04ED"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>5 to 8</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4FE66256-FA9F-40F0-BBC4-E8AC22487FDA"/>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F64295A6-A78F-4219-80D8-DC2F0C1EEE39">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 14:33:09 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 14:35:23 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:6dd98b92-a077-48a1-b8bc-dadebf926c34</pav:previousVersion>
    <ao:body rdf:nodeID="Nd9c40516134d463aaad39dc42dc86fe2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0E655280-5EED-43B7-AA88-6CF39DA84943"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2B6F79C3-A90B-40B0-A414-E3F11AD062CE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>INVEGA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>12</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEE6D02F-9B57-4DAE-8FF5-528B2E070606">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDDAE5B3-3BF3-4489-9DF6-3DC68C60723E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 14:14:09 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C44D80F8-627B-4C0A-8EC0-3E4A5A88236A">
    <ao:context rdf:resource="urn:domeoclient:uuid:AD512468-772D-4AE1-8975-3FADDF6E2E04"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C53022DB-44D7-4605-AFC3-3C5070751F00</pav:previousVersion>
    <pav:createdOn>2015-11-29 12:45:33 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 12:47:05 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">45</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N5157db18ad0e4f4bb7cce177884332c4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8405CE11-632E-4607-A4FA-9E95883B310E">
    <ao:body rdf:nodeID="Nd5c8428f7c2c4e10ba4e3df40545824b"/>
    <pav:lastSavedOn>2015-11-29 13:04:34 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">48</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:83247853-DEFC-4169-AB84-408FC75747DD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8D8A38D1-48DC-412E-AA3A-06B077AB96A7</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 13:04:31 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01626855-A1AF-44F1-B010-337956469537">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-29 14:36:35 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BAD4753-CA92-4B4C-81EF-2B15350B64E1"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:2E416E6E-3B50-4259-ABDF-A1008E7DD3CF</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-29 14:38:11 -0700</pav:lastSavedOn>
    <ao:body rdf:nodeID="N1043149b1a734d098e35b9cdf88fb831"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:26F01BEB-8A13-499D-9D40-12847573EFA3">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AE2D4040-4391-4FCC-8C6F-0E0963CE0DF0"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BBE38590-3A0A-441D-B75D-368857FED92B"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7238090B-8742-4BD6-AD6B-032836EC742C">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A632357-E3AB-47BD-BF8C-4D53021229A9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 14:16:05 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D3923264-1678-47A4-B00B-87878D6B84EB">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdfs:label>triazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F51E7E06-E0E7-4E54-A47C-30B4702B7021">
    <pav:createdOn>2015-11-27 14:16:08 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>In patients with cirrhosis of the liver, AUC values of nefazodone and HO - NEF w</ao:prefix>
    <ao:suffix>re increased by approximately 25%.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>e</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F51E7E06-E0E7-4E54-A47C-30B4702B7021"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7B5F6CD6-A6B7-475C-82D1-F3BEA147402C">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A615638A-6473-41F4-AEC2-59B4DC7846B8"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4857CA94-1937-42E7-88E8-813E99F04FC8">
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5B669579-A81E-4650-A229-9EBB75064E12"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>3 to 4</dikbD2R:auc>
    <dikbD2R:preciptDuration>6</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/29EC21B1-34CA-45AA-8A52-909FC2BBD0D2"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F95A7906-77D9-4142-B5EF-248A36946CAE">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4E4A228-1A8D-40AC-87D1-97D386D8645A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nefazodone</ao:exact>
    <pav:createdOn>2015-11-27 14:15:18 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>During premarketing testing, hypomania or mania occurred in 0.3% of nefazodone-treated unipolar patients, compared to 0.3% of tricyclic- and 0.4% of placebo-treated patients. In patients classified as bipolar the rate of manic episodes was 1.6% for </ao:prefix>
    <ao:suffix>, 5.1% for the combined tricyclic-treated groups, and 0% for placebo-treated patients. Activation of mania/hypomania is a known risk in a small proportion of patients with major affective disorder treated with other marketed antidepressants. As with all </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4E4A228-1A8D-40AC-87D1-97D386D8645A"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:356A0201-5302-4E1F-BF6B-B3266CAF28E7">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:356A0201-5302-4E1F-BF6B-B3266CAF28E7"/>
    <ao:exact>triazole-dione</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 11:48:00 -0700</pav:createdOn>
    <ao:suffix>, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96D43F2F-23E0-474B-A1EE-2A64683D0859">
    <domeo:uuid></domeo:uuid>
    <ao:exact>1-pyrimidinylpiperazine.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96D43F2F-23E0-474B-A1EE-2A64683D0859"/>
    <pav:createdOn>2015-11-27 14:51:53 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> metabolite </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FAB6572C-8E24-4917-A5F2-30736A0575A0">
    <dikbD2R:auc>15</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>9</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>9</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmax>29</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9381913D-7524-48AF-8838-3B6C1D9FE98E"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cminType>Percent</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/99261751-D59D-463D-908B-2C86EF9FBEA1"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>27</dikbD2R:cmin>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>Increase</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90FC8745-2407-404E-BD4B-99FB2452C0F7">
    <pav:previousVersion>urn:domeoserver:annotationset:D95636C5-92C5-433A-B843-910BEDF57D99</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-29 13:52:44 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:36EA8083-445E-411E-8DBB-002ACED631D4"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Na3d95202e09945e1954fe5850326dbea"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-29 13:52:49 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5784063-1E17-42C8-8F68-C35B051005F0">
    <pav:createdOn>2015-11-27 14:45:42 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine , </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>, cisapride, and</ao:suffix>
    <ao:exact>astemizole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E5784063-1E17-42C8-8F68-C35B051005F0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43CD3C9E-13E0-4527-A496-E582926D0C6C">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E35AAEB3-1DB8-4484-8966-FB2967A8421B"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:094B3B7D-374E-42BA-B86A-4F2D1B7B223E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nb4c017d1815746f6b10561216b467a6a"/>
    <pav:lastSavedOn>2015-11-29 14:35:23 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoclient:uuid:6dd98b92-a077-48a1-b8bc-dadebf926c34</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-11-29 14:35:14 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDAD52D0-9CC6-4371-BACC-491A985D5815"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4A3AD5DC-4E4F-47B2-A087-ED9D9B3B78F2">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>m-chlorophenylpiperazine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1AE747D7-078B-417A-93E9-24BDFCF2213C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1AE747D7-078B-417A-93E9-24BDFCF2213C"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-29 11:39:14 -0700</pav:createdOn>
    <ao:exact>Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>There were also no changes in the pharmacokinetics of</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/056F529F-1EAD-4CB5-BFBA-FF503870B2B7">
    <dikbD2R:dose>250</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58FA4C9E-EFE5-451B-BDB2-2A0E16D15FE7">
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>2</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:auc>2</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/710EDE66-0C1A-45F5-93EC-1FA51222A7E7"/>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/857BBE20-9C66-4C69-99AA-7F6490B9925A"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:087D3863-00C4-4371-9026-7D30ABE4A0AD">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:45:54 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:724B14F4-6D2F-42DF-942A-A6FFC1282B68"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23D4BC95-7FE0-447D-9A6F-3297089E13F6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:FCE35EA5-872E-4883-ADC4-0E05965DE708</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CAFE5868-DB88-40F0-8060-90A49501BE3A"/>
    <pav:lastSavedOn>2015-11-29 11:40:46 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-29 11:39:37 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5FFA28EC-26F7-4105-B4D0-174459E8B00D">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:37611489-A0F7-485B-A33F-CB2770684409"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4">
    <ao:item rdf:resource="urn:domeoclient:uuid:C4B8A774-1126-4D3C-8273-B5F869ED1075"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:71A61532-2D04-4324-8606-18596559220E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F41C1936-689B-4577-B03B-777A68399AC8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B5942F8-1972-4832-85F4-F99B8770541F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D4C682E3-5B29-47A1-B06B-76D809B0F9F9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC49D92D-1F3B-44DB-A883-1E15A72D5D87"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BCE60582-EEF8-4903-A2CF-9A7A71EE4AFA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F9EE1B4-50A2-4FE6-980F-DE908E03BD71"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/8e95d883-bba5-4d9f-860b-5a4f00855ab5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6656620-1F85-48FD-B0C5-BAFBDD4C41DF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N80385adc78eb46e691a76a920169b26b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA4FA05E-AAA7-4B8D-BF3C-30C4573F837C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C50FE61-4F0B-4249-A415-30D4C44EDA08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14288A40-2D34-4A59-A608-C667DF61DAC4"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:E141840D-0B7F-4C50-88A6-A8DB78AC8A14"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-11-17 07:06:31 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BBDD7D3-7944-4527-A230-916714DFC640"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:01626855-A1AF-44F1-B010-337956469537"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:131535CD-04B3-4FFC-8AFA-59E77B73EACA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F64295A6-A78F-4219-80D8-DC2F0C1EEE39"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9D98A93-52E8-4E62-A985-E597FDF227C1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9F2E7FA-A105-41F1-9E70-964C5CD89D19"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0605D5E7-E502-448C-8979-745E84FA3019"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:094B3B7D-374E-42BA-B86A-4F2D1B7B223E"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E153D20-E1F7-4064-AAD5-9707020174CA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE2C8D8A-01BD-4341-A339-CA41B9EB9A46"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:312B5C01-D5D5-41FA-9D7A-314FF7E644F1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:93573759-2565-4DCB-A5AF-E79501572BD5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0344BFF6-39FC-4D2D-9093-E650E5907A2A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8F48AB1-DF57-41AB-AED1-79048FB794E0"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e14305115b858015115cd5b5c0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8F1781DF-F5E2-49EB-94DE-DB4EB7602706"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D40F8BE7-2DB9-434D-8876-564679205191</pav:previousVersion>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC3ACA76-94BC-4A58-9097-A895F29B469B"/>
    <pav:lastSavedOn>2015-11-29 17:32:26 -0500</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:F4D2DAB0-6E6E-4B66-A134-16AF90CB19EA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B227973-2B53-41B9-8774-F63BFDF81B04"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C5BBF77-91DF-409A-AE29-4E9A19C13FDD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A8C8D787-1250-4EED-BAD2-DF784514C725"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB20C2BD-05F3-4D66-B630-D2689F945CEA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:33BA3163-7132-44D6-8621-A686E664FD1F"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b2b22f48-8306-48e1-a4c3-550c7918331f">
    <pav:createdOn>2015-11-17 07:06:28 -0700</pav:createdOn>
    <ao:suffix> and galantamine, which are metabolized by CYP 2D6.         </ao:suffix>
    <ao:exact>donepezil</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>idone did not significantly affect the pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b2b22f48-8306-48e1-a4c3-550c7918331f"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F19827BB-074B-4991-95E0-9AF9140F3884">
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N2cfb4948fd12491d8f48191275338fe6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:87737B8C-62BC-40FB-87DD-A6EA94A5DA88"/>
    <pav:previousVersion>urn:domeoserver:annotationset:28E09469-2198-4974-965A-8D17D98FD040</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-27 14:29:38 -0700</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-27 14:29:31 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBEA875C-AFB9-4EA6-B530-661CD4AF59CF">
    <ao:prefix>ents characterized as ‘postural hypotension’ were as follows: nefazodone (2.8%), tricyclic antidepressants (10.9%), SSRI (1.1%), and placebo (0.8%). Thus, the prescriber should be aware that there is some risk of postural hypotension in association with </ao:prefix>
    <pav:createdOn>2015-11-27 14:14:44 -0700</pav:createdOn>
    <ao:suffix>use. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>nefazodone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CBEA875C-AFB9-4EA6-B530-661CD4AF59CF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4717B176-0577-45BD-B116-830BC1523DE6">
    <ao:body rdf:nodeID="N7d8a126f4902488a82db1b8e5896e119"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-29 16:15:29 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D48B3D20-EBD4-4EF5-9EEF-A1034AB31107"/>
    <pav:createdOn>2015-11-29 16:15:28 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E8FE416-EFE8-4F72-9F7D-D213DCF09D38</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:9285DC9C-C7DC-4115-BB37-13622B5E4488</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f4bcdebf-db7b-4c95-b1b2-8bc46c7992e0</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF74822F-037C-4E79-A820-BA3EE59DDDDD">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 13:06:08 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">49</pav:versionNumber>
    <pav:createdOn>2015-11-29 13:06:04 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:04E60AFE-2853-4C84-9C0F-031D4E56A4B7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:BAC58941-13F6-4650-B6DF-82AF2E15AD38</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="Ne7e6d36b15d546138a25434be95b7135"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C9C65E0-8BB9-4C88-A31B-A636A9CA4F56">
    <pav:createdOn>2015-11-27 14:14:56 -0700</pav:createdOn>
    <ao:suffix>(2.8%), tricyclic antidepressants (10.9%), SSRI (1.1%), and placebo (0.8%). Thus, the prescriber should be aware that there is some risk of postural hypotension in association with </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3C9C65E0-8BB9-4C88-A31B-A636A9CA4F56"/>
    <ao:exact>nefazodone </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>, 0.2%; placebo, 0.3%), the rates for adverse events characterized as ‘postural hypotension’ were as follows: </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:982EBC66-3022-4CEC-AB8F-33FD1D92D401">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-11-29 16:31:24 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <ao:body rdf:nodeID="N4cba0044424f4783a55a841fabaa9238"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 16:36:20 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:7685bcaf-274a-44c1-9eb7-34cf3ee40830</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:312DCDDD-6A8D-4325-A858-41768533FD83"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4598B865-2B5B-4558-A503-0096D7533927">
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   </ao:prefix>
    <pav:createdOn>2015-11-27 14:45:28 -0700</pav:createdOn>
    <ao:exact>Terfenadine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>, astemizole, cisapride, and </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4598B865-2B5B-4558-A503-0096D7533927"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:88AC51BB-6A81-45C3-AFD2-0FD7512E36BE">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FAB6572C-8E24-4917-A5F2-30736A0575A0"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B07978A-8308-4CF0-9A7D-9472FBB3045A">
    <pav:createdOn>2015-11-29 15:31:50 -0700</pav:createdOn>
    <ao:exact>P88 </ao:exact>
    <domeo:uuid>7B07978A-8308-4CF0-9A7D-9472FBB3045A</domeo:uuid>
    <ao:prefix> metabolite </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>is generally equal or less than that of the parent compound. In contrast, the metabolite P95 only shows affinity for 5-HT</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B07978A-8308-4CF0-9A7D-9472FBB3045A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:17D83743-8B5B-46EE-8471-8E7B34339935">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/283AE4E1-E0D3-4AA7-84D0-D3866A8BCE17"/>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>5</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>5</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BF42D0A2-4BC9-4E65-B819-CB0664F47B40"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1E71250A-6C1B-4FC9-9A01-1B01CA877F6F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>1-pyrimidinylpiperazine.</rdfs:label>
    <dikbD2R:dose>2.5 or 5</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80427DD1-9946-4A18-B0CC-52160F5D6046">
    <pav:createdOn>2015-11-29 15:26:54 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>represents 47.9% of the AUC of </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:prefix>metabolites, P95 and P88 . The iloperidone  metabolite </ao:prefix>
    <ao:exact>P95 </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:80427DD1-9946-4A18-B0CC-52160F5D6046"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EC1A312F-DD46-4067-81E4-131CC559171D">
    <dikbD2R:dose>.25</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>triazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB20C2BD-05F3-4D66-B630-D2689F945CEA">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7012A2C1-5FF3-43C6-A36B-14C0FE23B272</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 15:26:48 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB531E09-9659-4FEE-B29F-84A4A6A8C4DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4C682E3-5B29-47A1-B06B-76D809B0F9F9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F40AA5E-949C-4758-8E69-9A203FFBD851"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 15:26:38 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B9AE83FB-E08E-43F6-89F2-2D5482C993CD</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9C0943F7-6177-4002-9661-4C1DDC40D3C3">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7F4E5F05-FC69-4996-B3E6-A6D8BBF5F29A"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:797F33E1-4895-461A-9544-FAA771762563">
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2606DE11-2CCD-4846-8F6B-E0862411E5F2"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D3923264-1678-47A4-B00B-87878D6B84EB"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED0BFDD6-2CF9-47A8-89E7-25E157AF657D">
    <pav:lastSavedOn>2015-11-29 13:36:22 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:15365EF7-6E42-430A-BE5A-2DA60F8E0317"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 13:33:21 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:185ce6a5-62ff-4f7d-9697-a128d9bfc171</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0763E981-403C-4677-A372-37B630B60197">
    <ao:prefix>led trials did not indicate that nefazodone is associated with the development of clinically important ECG abnormalities. However, sinus bradycardia, defined as heart rate ≤ 50 bpm and a decrease of at least 15 bpm from baseline, was observed in 1.5% of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nefazodone</ao:exact>
    <pav:createdOn>2015-11-27 14:15:55 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0763E981-403C-4677-A372-37B630B60197"/>
    <ao:suffix>-treated patients compared to 0.4% of placebo-treated patients (p ≤ 0.05). Because patients with a recent history of myocardial infarction or unstable heart disease were excluded from clinical trials, such patients should be treated with caution.</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4B6EEFF9-747E-492B-9223-624F0F824166">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tacrolimus</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42316</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:84EFB23F-8CEA-4AC6-9E0B-5794B485CFBC">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>5.5</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DF0A528C-40F9-465D-A2D8-6912FF96B34D"/>
    <dikbD2R:objectDuration>5.5</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/36F7D2FF-16D3-4242-93BC-BA6D9F141B02"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C99FE09-36BF-46D9-8079-6D36F38882B8">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 14:16:07 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:20540CD8-D98D-43E5-8821-2996ABBA2593"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDDAE5B3-3BF3-4489-9DF6-3DC68C60723E">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2015-11-27 14:14:09 -0700</pav:createdOn>
    <ao:exact>hydroxynefazodone </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>concentrations for achieving an antidepressant effect for nefazodone. Consequently, it is recommended that nefazodone not be used in combination with </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDDAE5B3-3BF3-4489-9DF6-3DC68C60723E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCCF87D1-9FD6-46CA-B89D-DFDB28C4131E">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 14:26:49 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:40C71DDF-E64D-40BF-B9DF-7B027CF4C07D</pav:previousVersion>
    <ao:body rdf:nodeID="Nfe253546b3704f74be69a602b0524595"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 14:26:42 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:6D9573E7-C378-4BFE-BD2A-139CA7BE06A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:069B52FD-41F4-4B6C-97AF-5E746376D00B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:238B9075-B421-489D-A010-A8EF3556636C"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9BC74DC8-C226-42EA-A40B-BB9E9B5840C5">
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5471D917-9919-482F-909B-0094D0F6BB75">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-29 14:37:53 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5471D917-9919-482F-909B-0094D0F6BB75"/>
    <ao:prefix> and its metabolite </ao:prefix>
    <ao:suffix>, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. </ao:suffix>
    <ao:exact>P88</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0FD397D5-5535-4BD1-8D42-3B654A10CD9D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>digoxin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>.2</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51F73025-EEE1-48D5-878D-17C8557651E5">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A1BD134-4AC0-4444-A720-169B060E6E66"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:13:41 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27B9BFEB-2AC6-4DA7-8252-5BB47EFF7664">
    <pav:createdOn>2015-11-27 15:02:27 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:98707395-C8BF-4473-A76E-5238E96A11F4</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A1382975-3B93-472D-A431-32125774ED7B"/>
    <pav:lastSavedOn>2015-11-27 15:02:35 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AF5319C-A6B1-42BE-BCD4-1717198C1679">
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E28491B-65F8-4B63-9A96-CCE2CFF88C90"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 13:52:40 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B18D5F8C-E9C7-4711-BC17-EC18D647DC8A">
    <pav:createdOn>2015-11-27 14:45:41 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A5E2860B-5E68-4789-B133-52ECBA940C11"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA73ADAA-B396-4AD7-B04A-B5A89DDB2FC5">
    <ao:exact>P95</ao:exact>
    <ao:suffix> by 57%, 55% and 35%, respectively. </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <pav:createdOn>2015-11-29 14:33:28 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>iloperidone and its metabolites P88  and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA73ADAA-B396-4AD7-B04A-B5A89DDB2FC5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F1781DF-F5E2-49EB-94DE-DB4EB7602706">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5471D917-9919-482F-909B-0094D0F6BB75"/>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:createdOn>2015-11-29 14:37:53 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2E416E6E-3B50-4259-ABDF-A1008E7DD3CF</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 14:38:11 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8F48AB1-DF57-41AB-AED1-79048FB794E0">
    <ao:context rdf:resource="urn:domeoclient:uuid:FA73ADAA-B396-4AD7-B04A-B5A89DDB2FC5"/>
    <pav:previousVersion>urn:domeoclient:uuid:6dd98b92-a077-48a1-b8bc-dadebf926c34</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-29 14:35:23 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 14:33:28 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:559472FC-CFF2-4DE2-B68C-00DB95B54C02">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:559472FC-CFF2-4DE2-B68C-00DB95B54C02"/>
    <domeo:uuid>559472FC-CFF2-4DE2-B68C-00DB95B54C02</domeo:uuid>
    <ao:suffix> Multiple doses of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>No clinically relevant effect was observed on steady state lithium exposure following coadministration with multiple daily doses of BRINTELLIX.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 13:36:22 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:096E7687-20C0-4169-98EF-462C12CAE3D3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:096E7687-20C0-4169-98EF-462C12CAE3D3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <pav:createdOn>2015-11-29 14:44:02 -0700</pav:createdOn>
    <ao:exact>Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>When</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:735172DD-19A0-47A3-B634-A0814A8FF8C1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-27 12:58:48 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:445EE9C5-AFB3-417B-B653-381A0F649634</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C41444C-3C96-4FB5-81AF-EBD91491C396"/>
    <pav:lastSavedOn>2015-11-27 13:05:05 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1B40DED-8AE7-4C9D-B933-1BB559EF43AE">
    <ao:suffix>should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotens</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1B40DED-8AE7-4C9D-B933-1BB559EF43AE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:14:31 -0700</pav:createdOn>
    <ao:exact>Nefazodone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ed as ‘postural hypotension’ were as follows: nefazodone (2.8%), tricyclic antidepressants (10.9%), SSRI (1.1%), and placebo (0.8%). Thus, the prescriber should be aware that there is some risk of postural hypotension in association with nefazodone use. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:588B27DA-246B-4806-9C1C-F6C04D43E761">
    <pav:createdOn>2015-11-27 14:16:06 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>In patients with cirrhosis of the liver, AUC values of nefazodone and HO-</ao:prefix>
    <ao:exact>NEF </ao:exact>
    <ao:suffix>were increased by approximately 25%.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:588B27DA-246B-4806-9C1C-F6C04D43E761"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A47E5FC5-B36A-472F-9111-0543B5A932EE">
    <pav:lastSavedOn>2015-11-29 12:51:10 -0700</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:B78271A4-9E0E-4DA6-B268-8ECD0D6B20C5</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6674D773-F0E5-4992-BA73-5D71599D0C25"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-29 12:51:08 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N63096a48356f4f8b994e26c227d3415f"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:987B8B0E-2B2B-4B59-8315-9CDD3E52ED8E">
    <ao:exact>cisapride</ao:exact>
    <ao:suffix>, or </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:45:53 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:987B8B0E-2B2B-4B59-8315-9CDD3E52ED8E"/>
    <ao:prefix>to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine , astemizole , </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCD08072-2BA4-4B86-A00D-68E56D8C2980">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nefazodone </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>may be considered appropriate, only the lowest possible dose of triazolam should be used (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>with </ao:prefix>
    <pav:createdOn>2015-11-27 13:52:27 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCD08072-2BA4-4B86-A00D-68E56D8C2980"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4F6F024-4421-4E59-8E6E-4276436A62B4">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:7685bcaf-274a-44c1-9eb7-34cf3ee40830</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 16:36:20 -0700</pav:lastSavedOn>
    <ao:body rdf:nodeID="N5a6f29bbe5dd46249f4a2b5fd0ad201d"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-29 16:34:06 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E42CC82B-B62B-4329-994F-D7E63E8888EB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46ECE233-9F5E-4E9C-913F-02BE74E56C15">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>(1 mg BID) and </ao:prefix>
    <ao:suffix>(200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>nefazodone </ao:exact>
    <pav:createdOn>2015-11-27 13:52:35 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46ECE233-9F5E-4E9C-913F-02BE74E56C15"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/437442C7-5AC6-4F5F-A72A-054FD0209487">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>buspirone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>5</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4D29EC17-D765-4B47-B74D-DBC34F54F9F6">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A69FE3BA-005A-4475-8D84-0D338782B96E"/>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ED2C6388-FC38-4A19-98E4-C6ABFBC318C6"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E0C22CF-F9E2-4E78-9DF8-7D09A6A7ED9A">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>should be used cautiously in patients with a history of mania.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nefazodone </ao:exact>
    <pav:createdOn>2015-11-27 14:15:20 -0700</pav:createdOn>
    <ao:prefix>mbined tricyclic-treated groups, and 0% for placebo-treated patients. Activation of mania/hypomania is a known risk in a small proportion of patients with major affective disorder treated with other marketed antidepressants. As with all antidepressants, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E0C22CF-F9E2-4E78-9DF8-7D09A6A7ED9A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A0D9CAC-26FE-4761-BADE-3E001C7D5EDA">
    <domeo:uuid>8A0D9CAC-26FE-4761-BADE-3E001C7D5EDA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A0D9CAC-26FE-4761-BADE-3E001C7D5EDA"/>
    <pav:createdOn>2015-11-29 16:29:08 -0700</pav:createdOn>
    <ao:suffix>is not recommended.</ao:suffix>
    <ao:exact>lithium </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>) of lithium (n=13). Dose adjustment for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA9DE795-6121-45AB-9449-2F833405BCCB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BA9DE795-6121-45AB-9449-2F833405BCCB"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>). Rare occurrences of convulsions (including grand mal seizures) following nefazodone administration have been reported since market introduction. A causal relationship to </ao:prefix>
    <ao:suffix>has not been established (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>nefazodone </ao:exact>
    <pav:createdOn>2015-11-27 14:15:30 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A5AA7BFD-071A-4447-B1E7-6AAA9B76B757">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FFA5AE4B-BD31-4565-B4A1-21AAE6988CA6"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3E990F98-C4AB-4F6A-8C24-362FFCB05007"/>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63383907-5872-498C-8D64-787EDCABF2DB">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 14:15:44 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:411BA520-454B-4D9A-B1DE-3807D4BA809E"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4577F1B0-D5DD-4C41-A711-54E310F40FFC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 13:52:39 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:679B03FE-2E5B-4DEB-BC09-297F13FAE5CE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4CB53B1-DEAE-45A2-8AE0-7259A80F9DA5">
    <ao:suffix>, and </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:45:30 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   Terfenadine , astemizole , </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E4CB53B1-DEAE-45A2-8AE0-7259A80F9DA5"/>
    <ao:exact>cisapride</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FA1DBF78-82BE-4A68-8D0A-815CE4782B2F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CF2386BF-98B0-45F8-9D72-B8D67AF3FA04"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A69FE3BA-005A-4475-8D84-0D338782B96E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>5</dikbD2R:dose>
    <rdfs:label>Lorazepam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6D80E4F6-DF2F-492A-A075-BFC555F8321F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4D29EC17-D765-4B47-B74D-DBC34F54F9F6"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4FE66256-FA9F-40F0-BBC4-E8AC22487FDA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCB3B2E1-8478-425A-94F8-03758A62DB50">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B792182-9A40-4CC8-AE59-7F2FE0559A85"/>
    <pav:lastSavedOn>2015-11-27 13:05:05 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 12:58:54 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:F429F083-12DE-42FB-890B-4774DC586117</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F1D0F19A-7C85-40E3-B6E2-1BCB0E80BAE7">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A7D93C5A-A4E1-49B2-BD29-0CA6AD59BAC0"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:753A757B-7698-40A8-ACE1-691D171C6802">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>should be avoided for most patients, including the elderly.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>nefazodone </ao:exact>
    <ao:prefix>and </ao:prefix>
    <pav:createdOn>2015-11-27 12:59:04 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:753A757B-7698-40A8-ACE1-691D171C6802"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66BB73BD-A6E6-46F1-B487-603EC76686DD">
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4E55C71-12CF-4D43-8AE7-EBAFE0C2D7B7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-11-27 14:13:20 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E570E4D0-0CB6-4B1E-9820-60187D687316">
    <dikbD2R:dose>150</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>salicylic acid</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E28491B-65F8-4B63-9A96-CCE2CFF88C90">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-27 13:52:40 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E28491B-65F8-4B63-9A96-CCE2CFF88C90"/>
    <ao:prefix>sed by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefazodone</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ACA52ED-6885-4EB8-AC37-D77339B859E6">
    <pav:createdOn>2015-11-27 13:51:50 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC34F367-0167-447C-A81B-D8430B5CD93F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:573A616C-BF5A-493A-942F-CF264857AB94">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7A392041-33EF-4D12-8BF4-62EB95C30DEF"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:475F7B77-E061-4A6F-95B7-C36897DF559F">
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">50</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:45575562-5425-42B0-8236-C3A72EE08BCD</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 13:08:12 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 13:08:09 -0700</pav:createdOn>
    <ao:body rdf:nodeID="N85c237681f2645d29d33052bf25db3ba"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A434153-A2A6-4FC6-9D66-CB5ACB2E58C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C882DDF5-352F-46D1-93A8-982034BE5C30">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 15:29:11 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> metabolites </ao:prefix>
    <ao:exact>mCPP</ao:exact>
    <ao:suffix> and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C882DDF5-352F-46D1-93A8-982034BE5C30"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC629573-51D3-4FFB-9440-DF2AA2287864">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <pav:createdOn>2015-11-29 16:29:08 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:7685bcaf-274a-44c1-9eb7-34cf3ee40830</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A0D9CAC-26FE-4761-BADE-3E001C7D5EDA"/>
    <pav:lastSavedOn>2015-11-29 16:36:20 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D4D6DE49-6A19-44C3-AE29-4B5A7819802A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>3</dikbD2R:dose>
    <rdfs:label>iloperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D6697B00-B900-4593-8232-BFD5D2D55941">
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FE6CB980-8373-480F-9440-DFC8F41D4A3E"/>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptDuration>5</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/905AA69B-E22A-4630-B85E-D48866CCC483"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A6D4352-A705-4DB3-B216-30B7B670BF16">
    <ao:prefix>Terfenadine, astemizole, cisapride, and </ao:prefix>
    <pav:createdOn>2015-11-27 14:13:23 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>pimozide </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A6D4352-A705-4DB3-B216-30B7B670BF16"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36EA8083-445E-411E-8DBB-002ACED631D4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).</ao:exact>
    <domeo:uuid>36EA8083-445E-411E-8DBB-002ACED631D4</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 13:52:44 -0700</pav:createdOn>
    <ao:prefix> is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36EA8083-445E-411E-8DBB-002ACED631D4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96FDB1C0-D695-47D2-A45F-9D3FB620E026">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>96FDB1C0-D695-47D2-A45F-9D3FB620E026</domeo:uuid>
    <ao:prefix>    Immunosuppressive Agents   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96FDB1C0-D695-47D2-A45F-9D3FB620E026"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-29 13:21:18 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C98E3AD-5EBA-40B2-A31A-F464C6918864">
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4598B865-2B5B-4558-A503-0096D7533927"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:createdOn>2015-11-27 14:45:28 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C50FE61-4F0B-4249-A415-30D4C44EDA08">
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:216DABAE-4E29-4BD7-87F5-731C1468F641"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2CA0A178-DE20-47F5-B177-7B1D07667E8B</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-11-29 14:41:32 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 14:46:00 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="N92c4ea266cf54cf79c124c06645c3154"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:37611489-A0F7-485B-A33F-CB2770684409">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/43C3A7AA-6331-4E7E-B3B7-F85F8D52A484"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cl>UNKUNUNK</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E570E4D0-0CB6-4B1E-9820-60187D687316"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D92036A9-491B-4E9E-A724-A20467490C85">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B6AE9622-F852-4F0E-8192-892DC06D71D3"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N756c38cb7d6946b9b277347f0dd52eb2">
    <domeo:sets rdf:resource="urn:pddi:uuid:04A18420-679D-4661-9AC4-6044C7F2DE7D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:997A051C-D98A-46D5-BA19-A2359C7A14A1">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N32efa48fe35d4eefa02f2d796134911f"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6DC07C5B-EF00-49F9-A7FF-8F10DF49587F"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 12:05:41 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">38</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 12:05:38 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:989F01DA-4467-4D6E-B34D-1B4F28F0B2DB</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CFE2A317-E656-4F67-96CA-6F11F6840998">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F47F546B-6518-4B21-AC8B-302337C4A7B0"/>
    <dikbD2R:comment>eports of increased blood concentrations</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:651C4A9D-FD6C-4E9A-B29B-45A978F300BC">
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>4</dikbD2R:preciptDuration>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/54B33F62-B662-4CF7-93A0-ACDA0B5B0C32"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0E0AB83A-A859-4776-8F09-9D2BA268E2E0"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>35</dikbD2R:auc>
    <dikbD2R:numOfParticipants>19</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33BA3163-7132-44D6-8621-A686E664FD1F">
    <pav:lastSavedOn>2015-11-29 14:49:58 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C056EB53-AE10-4A6A-AD19-4A39136120BE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 14:46:35 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:61F0DE56-F005-4DD2-A033-E0C0FA936D0B"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB6BE9C9-6B1C-4A42-A0C7-E4294DC4A8C6">
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:createdOn>2015-11-27 13:52:41 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5AD91245-37B0-422A-A863-C949FC69D024"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A8FA6342-AE30-4A60-9DF2-2D38331CB23A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>600 to 1200</dikbD2R:dose>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1BFD0E33-C60D-4F25-AB63-31D35DC0B3BD">
    <rdfs:label>Desipramine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>75</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86888333-61F0-4045-9D83-5BD06A5658EC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:692B6F5F-B17E-4564-B8E1-791829862A6E"/>
    <pav:createdOn>2015-11-29 13:42:34 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:C2441E8C-5B5C-4F55-8CBF-27503BDC9E07</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-29 13:44:17 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0DEF03E-6F27-4EC3-AE06-F11EF6CCCD59">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E5784063-1E17-42C8-8F68-C35B051005F0"/>
    <pav:createdOn>2015-11-27 14:45:42 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64226B39-C96C-4FAB-87D6-62CE1560628B">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see </ao:suffix>
    <ao:prefix>should be avoided for most patients, including the elderly. In the exceptional case where coadministration of </ao:prefix>
    <pav:createdOn>2015-11-27 13:52:26 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64226B39-C96C-4FAB-87D6-62CE1560628B"/>
    <ao:exact>triazolam </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E38DC63F-30D7-4127-BC4B-E2CBBC433FEB">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-29 12:09:52 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E38DC63F-30D7-4127-BC4B-E2CBBC433FEB"/>
    <ao:exact>When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <ao:prefix>    Theophylline   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AF804F0C-F097-4171-B3B7-99C5FAB0CE4E">
    <rdfs:label>4-hydroxypropranolol</rdfs:label>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D9B0838-E163-4F3C-9EE0-11BA444876EB">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 14:45:43 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:52855BF6-0B46-4D03-BB11-691DB9AE86E7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6FD53334-CC40-4FC8-9034-8F9CF6A0400D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6503EA64-1BAE-4595-BB07-EE7A3AD7EBEC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DCC66E0-33AF-4335-B6DC-30738D4A7C1A">
    <pav:createdOn>2015-11-27 14:15:37 -0700</pav:createdOn>
    <ao:suffix>has not been established (see </ao:suffix>
    <ao:prefix>, rare reports of priapism have been received since market introduction. A causal relationship to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1DCC66E0-33AF-4335-B6DC-30738D4A7C1A"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>nefazodone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E18C1BE2-B602-4112-B7A7-3DDD62E07C5D">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D336AA33-2F87-448E-8CC3-5BE5D6212680"/>
    <dikbD2R:preciptDuration>6</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B957DF65-9B15-4E7C-9F17-5941A0E1977B"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2CAB70DC-64E8-4857-85DC-D99B49CF5BFD">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5FD0B3FA-2A79-45B0-96B2-BB0522ABB463"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D5926653-BAC0-4B5E-9BBD-04EA2D8729AF"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>QD</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2507ACFD-B2EA-4A26-A36A-ED36ED90FFD1">
    <pav:lineageUri>urn:domeoserver:annotation:8AD32DD8-F0B0-496E-B5F1-8A9618162596</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 15:07:38 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 15:06:16 -0700</pav:createdOn>
    <ao:body rdf:nodeID="Nf0f8eb7c9cdf4958a55a45fa34cfe179"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F7E3546-F959-4F93-BEDD-5AEC9A149B94"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F6D4C5D0-9A4A-44F7-86D3-FD38804A56A1">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>iloperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>up to 10</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3472857F-3CD4-4281-B61A-306505F32A94">
    <ao:exact>alprazolam </ao:exact>
    <ao:suffix>(1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coad</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 13:52:34 -0700</pav:createdOn>
    <ao:prefix>When </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3472857F-3CD4-4281-B61A-306505F32A94"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ED59BB5-AFB9-4A56-B36A-96423643B327">
    <pav:createdOn>2015-11-29 16:18:01 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4ED59BB5-AFB9-4A56-B36A-96423643B327"/>
    <ao:exact>Co-administration of INVEGA® 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>4ED59BB5-AFB9-4A56-B36A-96423643B327</domeo:uuid>
    <ao:suffix> On initiation of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8e95d883-bba5-4d9f-860b-5a4f00855ab5">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-11-17 07:06:31 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-17 07:06:31 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1c89215a-b43a-4651-8ab2-713205a2c758"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5157db18ad0e4f4bb7cce177884332c4">
    <domeo:sets rdf:resource="urn:pddi:uuid:147DD8EA-D504-4D39-9277-E8709104773F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3F43473-E023-4A0F-901B-4513286A37BD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 14:54:35 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>dose could then be increased to the previous level.   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3F43473-E023-4A0F-901B-4513286A37BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23E0AC7B-2AD6-4FC6-90D5-219E46CEF416">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">47</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4CBDA59-3E43-482A-A2FA-C01A3050549D"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N777d59439c094675a0c97294bdea6eb3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:681890F1-A444-44B4-8F87-F14218325B5E</pav:previousVersion>
    <pav:createdOn>2015-11-29 13:00:50 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 13:00:53 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2320B431-C8D9-4C7E-B2E9-2673D235C46E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>nefazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with </ao:prefix>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2015-11-27 13:51:55 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2320B431-C8D9-4C7E-B2E9-2673D235C46E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B9F853C-4776-489E-8666-77F967CF04F1">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-27 14:01:33 -0700</pav:createdOn>
    <ao:exact>When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. </ao:exact>
    <ao:suffix>Nefazodone</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4B9F853C-4776-489E-8666-77F967CF04F1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4876F066-5569-44B7-9CB0-2FED1CA3B2D3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BDB3DF29-D871-40F0-9690-C84209F70CF7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4B8A774-1126-4D3C-8273-B5F869ED1075">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 15:31:50 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:0FDAC113-5500-4D2C-A4A8-8851D9C7A92C</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-29 17:32:26 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B07978A-8308-4CF0-9A7D-9472FBB3045A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B61814CE-5644-4827-875F-97E5BF9D725C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4E57EC49-A8DC-41A3-8283-56ABF0D8E87A">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A5AA7BFD-071A-4447-B1E7-6AAA9B76B757"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1721C320-9792-47DC-A899-FDA7D84185FD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>250</dikbD2R:dose>
    <rdfs:label>hydroxynefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DF0A528C-40F9-465D-A2D8-6912FF96B34D">
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propranolol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63152761-0B27-4F80-B23F-9E0B64EDF988">
    <domeo:uuid></domeo:uuid>
    <ao:exact>mCPP</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> metabolites, </ao:prefix>
    <ao:suffix> and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63152761-0B27-4F80-B23F-9E0B64EDF988"/>
    <pav:createdOn>2015-11-29 11:47:55 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C5BBF77-91DF-409A-AE29-4E9A19C13FDD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:564DB284-021D-43B9-B1C5-06D253163E13</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:38693F8A-D66B-4B52-9D07-71D27A0A8BA2"/>
    <pav:createdOn>2015-11-29 15:26:27 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB848352-7DA0-4562-978F-4DC3B5FAE1BA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 14:45:51 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, astemizole, cisapride, or </ao:suffix>
    <ao:exact>terfenadine</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB848352-7DA0-4562-978F-4DC3B5FAE1BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51557084-C3B1-4B23-9BB1-3EA6299087BF">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3D5F6CB7-3E29-4CEA-903D-A13D1E9A24FF"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>5.5</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0D86F770-E184-4156-A0D3-0DF3712BDAE8"/>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>5.5</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C41444C-3C96-4FB5-81AF-EBD91491C396">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>and </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C41444C-3C96-4FB5-81AF-EBD91491C396"/>
    <ao:prefix>). Nefazodone hydrochloride tablets are also contraindicated in patients who have demonstrated hypersensitivity to nefazodone hydrochloride, its inactive ingredients, or other phenylpiperazine antidepressants.  The coadministration of </ao:prefix>
    <pav:createdOn>2015-11-27 12:58:48 -0700</pav:createdOn>
    <ao:exact>triazolam </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6D25492B-0310-45B3-B821-455ED079704E">
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>4</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BBE38590-3A0A-441D-B75D-368857FED92B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdfs:label>alprazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A916D10-B84F-4621-9F1E-090BC6494DAC">
    <ao:exact>triazolam </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-27 13:51:58 -0700</pav:createdOn>
    <ao:suffix>was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>When a single oral 0.25 mg dose of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A916D10-B84F-4621-9F1E-090BC6494DAC"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E35A43A-D2D9-46E9-A6D2-E61FD973908F">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:auc>4</dikbD2R:auc>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/620832B6-79D4-43B8-AB09-2652A2795BBD"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C9EED2C0-B5B1-4C38-B328-F3095EDCA93E"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmax>1.7</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12>4</dikbD2R:t12>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:version>2.0alpha</foafx:version>
    <foafx:homepage></foafx:homepage>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:build>040</foafx:build>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E67ED01D-77C2-4699-8D18-C97D690C4E83">
    <ao:exact>With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)</ao:exact>
    <ao:prefix>metabolite 1-pyrimidinylpiperazine.  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-27 15:07:30 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E67ED01D-77C2-4699-8D18-C97D690C4E83"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DBD2E063-6BE0-478A-BB85-A72491F80572">
    <rdfs:label>mCPP</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:45A51BCB-AE50-489B-82CA-9D7F71A1AE6F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9A16457C-AEBA-43B6-A5BD-6453D06F3550"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C8DEB36E-EA83-42F9-AE16-A84F81F4568C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72EF01A5-5210-4FE6-8A28-EEADBAB06B3E">
    <ao:exact>Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>dose could then be increased to the previous level.   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72EF01A5-5210-4FE6-8A28-EEADBAB06B3E"/>
    <pav:createdOn>2015-11-29 14:52:17 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68E8D8DE-2C22-46B8-87A7-D069AEDE2B2E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-29 11:37:17 -0700</pav:createdOn>
    <ao:exact>Phenytoin – Pretreatment for 7 days with 200 mg BID of nefazodone had no effect on the pharmacokinetics of a single 300 mg oral dose of phenytoin. However, due to the nonlinear pharmacokinetics of phenytoin, the failure to observe a significant effect on the single-dose pharmacokinetics of phenytoin does not preclude the possibility of a clinically significant interaction with nefazodone when phenytoin is dosed chronically. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>However, no change in the initial dosage of</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68E8D8DE-2C22-46B8-87A7-D069AEDE2B2E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:727A8BA0-3F81-4AB3-BC6C-D96DB9FEF1AE">
    <pav:previousVersion>urn:domeoserver:annotationset:7AC55B30-0153-4374-B888-9D1E54432921</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 13:42:04 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-11-29 13:42:03 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B99A2A53-02F3-4314-8A45-29FE68EECEDB"/>
    <ao:body rdf:nodeID="Nee94bbc5d27644958114d441d368dd3c"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7985F6B-21DA-4E6E-97F2-F0F3954B8AE5">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>and placebo patients having adverse events characterized as ‘syncope’ (nefazodone, 0.2%; placebo, 0.3%), the rates for adverse events characterized as ‘postural hypotension’ were as follows: nefazodone (2.8%), tricyclic antidepressants (10.9%), SSRI (1.1</ao:suffix>
    <ao:prefix>a change from baseline of ≥ 20 mmHg). While there was no difference in the proportion of </ao:prefix>
    <pav:createdOn>2015-11-27 14:14:38 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>nefazodone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7985F6B-21DA-4E6E-97F2-F0F3954B8AE5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6674D773-F0E5-4992-BA73-5D71599D0C25">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>are coadministered; plasma level monitoring for digoxin is recommended.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 12:51:08 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6674D773-F0E5-4992-BA73-5D71599D0C25"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF6FC2F3-8A44-4BD0-B1FE-A7B1A6AFE872">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <pav:createdOn>2015-11-29 15:23:58 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Midazolam (a sensitive CYP 3A4 substrate): A study in patients with schizophrenia showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax. Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.</ao:exact>
    <ao:prefix>fluoxetine (20 mg twice daily).   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF6FC2F3-8A44-4BD0-B1FE-A7B1A6AFE872"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71A61532-2D04-4324-8606-18596559220E">
    <pav:lineageUri>urn:domeoserver:annotation:49ABA59F-5BE9-4412-8201-82965FC1EF31</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4859033B-DE71-4BC4-B2B7-0DCAAECF7ACD"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-11-29 15:27:10 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C29CAAC8-B86B-4E07-9BFD-E3237ECEC5D6">
    <pav:createdOn>2015-11-29 14:49:56 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>When</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C29CAAC8-B86B-4E07-9BFD-E3237ECEC5D6"/>
    <ao:exact>Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7BF63951-B9D2-4094-B78E-FC18068E068C">
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC3ACA76-94BC-4A58-9097-A895F29B469B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C5CA1F88-1976-43FD-B462-F99B7752B8A1</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:72EF01A5-5210-4FE6-8A28-EEADBAB06B3E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nc83bd071bc5248e998f83b0fe391ef18"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 14:55:02 -0700</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-29 14:52:17 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4E55C71-12CF-4D43-8AE7-EBAFE0C2D7B7">
    <ao:suffix>, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4E55C71-12CF-4D43-8AE7-EBAFE0C2D7B7"/>
    <pav:createdOn>2015-11-27 14:13:20 -0700</pav:createdOn>
    <ao:prefix>Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that </ao:prefix>
    <ao:exact>ketoconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/43C3A7AA-6331-4E7E-B3B7-F85F8D52A484">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/528BC21C-A4D8-4312-AD83-83E6D9387EBB">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68C0A9F3-C764-45AC-B50A-0EEE75F16C59">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:14:38 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7985F6B-21DA-4E6E-97F2-F0F3954B8AE5"/>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:80BF077D-8A32-4E3B-B426-5FC6BA9AF123">
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>14</dikbD2R:cmax>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AF804F0C-F097-4171-B3B7-99C5FAB0CE4E"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>5.5</dikbD2R:objectDuration>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5BF20034-84BA-4A89-8D9E-66660691C724"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>5.5</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF3B6D5A-0359-4442-8B25-793A6BB3A014">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nbcfd0b43f8274cd7aa00ce3f514c2e50"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-27 13:56:37 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:98A10139-9236-4059-8660-0D76F5766654"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/96910636-0C9F-4EE8-8B13-24FBEEE5F9A4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Lorazepam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D4E3AC2-D21A-4E26-B388-CCF3A3111077">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, cisapride, and </ao:suffix>
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   Terfenadine , </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-27 14:45:29 -0700</pav:createdOn>
    <ao:exact>astemizole</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8D4E3AC2-D21A-4E26-B388-CCF3A3111077"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0B1784C1-B50E-4C0E-861A-7CD9AB89C48A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>4</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4D2DAB0-6E6E-4B66-A134-16AF90CB19EA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 15:12:19 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <ao:body rdf:nodeID="N8b275b5d23924d6e9b7074da1de35e44"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 15:12:17 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F08C8C2D-9065-4ED2-937B-2F57EE85829F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:EF3D50CD-E050-4140-A620-18FD6CD291AD</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14288A40-2D34-4A59-A608-C667DF61DAC4">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B09A4EF-4345-4E60-A0CC-F08B6357C035"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdOn>2015-11-29 15:32:00 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:1056975A-E62B-49C8-8214-8B32D93FB134</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 17:32:26 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61F0DE56-F005-4DD2-A033-E0C0FA936D0B">
    <ao:suffix>, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. </ao:suffix>
    <ao:exact>P88</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:61F0DE56-F005-4DD2-A033-E0C0FA936D0B"/>
    <ao:prefix> and its metabolite </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 14:46:35 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/568FFDF3-669F-43DF-8577-91E1FE29F73A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E68C3294-6CAC-4FB4-AF60-136E25A8C94B">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> The kinetics of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 12:37:33 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E68C3294-6CAC-4FB4-AF60-136E25A8C94B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EAEF1212-5720-4B9A-B0E1-5AE4B671EDD9">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:071B4042-31BD-4DB6-84DD-13AB240BDF31">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-29 11:50:12 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D874039-912B-45FA-9E2E-BF6AD01328D5"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N147f266d9958481da33d1df5cb412a85"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33B5B498-90EC-4A1B-988F-FB6761E80FEB">
    <domeo:uuid>33B5B498-90EC-4A1B-988F-FB6761E80FEB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>simvastatin acid </ao:exact>
    <pav:createdOn>2015-11-29 12:53:43 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33B5B498-90EC-4A1B-988F-FB6761E80FEB"/>
    <ao:suffix>and 3 to 4 fold increases in plasma concentrations of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6E7A70E-1E5A-4F2E-B5DC-2E630D29C99B">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 13:14:12 -0700</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">51</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2EEB6CB-CD25-4E3A-B21D-714A82928509"/>
    <ao:body rdf:nodeID="N4b4dd841faa843afac844884bd39ccea"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-29 11:57:15 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7D1FD71C-9A3B-43AC-9FA2-1A3EE43785C2</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67B0D6CC-D7D8-4C90-BE10-9A80D1CA4ADA">
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propranolol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0344BFF6-39FC-4D2D-9093-E650E5907A2A">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 14:45:41 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2CA0A178-DE20-47F5-B177-7B1D07667E8B</pav:previousVersion>
    <pav:lastSavedOn>2015-11-29 14:46:00 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N4e8fedfc32f449e79793d438caa24885"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DD4D886-51DE-473D-B43D-C634E023500A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7463F20A-89CE-4113-BB70-6AEAF246299D">
    <dikbD2R:dose>250</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BBDD7D3-7944-4527-A230-916714DFC640">
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdOn>2015-11-29 14:49:56 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C056EB53-AE10-4A6A-AD19-4A39136120BE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="Nc024eaed51d3421fa17bde0a541f83f5"/>
    <pav:lastSavedOn>2015-11-29 14:49:58 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C29CAAC8-B86B-4E07-9BFD-E3237ECEC5D6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1B3462E-12D2-4EEF-92D6-0B320A83DD37">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:15:24 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6E51206-8BFE-4851-8B13-CAD25CC39FE0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D874039-912B-45FA-9E2E-BF6AD01328D5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D874039-912B-45FA-9E2E-BF6AD01328D5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <ao:exact>Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-29 11:50:12 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:443A5DA9-9AD0-4DAE-8677-C9B482507B9F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FE8D2E0E-C1A2-4877-B915-E558A22472FE"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04C6CCB6-558D-4AB6-91B6-02DAB5A75576">
    <ao:prefix>may be necessary when coadministered with nefazodone .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04C6CCB6-558D-4AB6-91B6-02DAB5A75576"/>
    <ao:exact>Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:31:22 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4A8374B-E983-464E-B71D-B00BDF6788A0">
    <pav:createdOn>2015-11-29 11:47:40 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (200 mg BID) with </ao:prefix>
    <ao:suffix> (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>lithium</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4A8374B-E983-464E-B71D-B00BDF6788A0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E320105-D57B-40A4-8945-49913004210C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 11:47:49 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:69194F70-ED82-4288-827E-EFFB9FC5D936"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AF7624D5-4491-45F9-904C-72667DC92C38">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>omparable valproate average plasma concentrations</dikbD2R:comment>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8F539098-D81D-46D7-874E-E66FDA267171"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B688F9E-D542-479F-8A91-8A8FD6A4F743">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6B688F9E-D542-479F-8A91-8A8FD6A4F743"/>
    <ao:suffix>and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.</ao:suffix>
    <ao:prefix>with two triazolobenzodiazepines, i.e., </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:51:49 -0700</pav:createdOn>
    <ao:exact>triazolam </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CCE09D2-19D5-42EE-842B-42B5732FD010">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8CCE09D2-19D5-42EE-842B-42B5732FD010"/>
    <ao:prefix>permit sufficient dosage reduction, coadministration of </ao:prefix>
    <ao:suffix>with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>triazolam </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 13:52:21 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:977C7C15-6219-4D2B-A620-98EA85E22F8C">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="Nae73013afcff4b72919b6a00e2efa652"/>
    <pav:previousVersion>urn:domeoserver:annotationset:BA9CC25A-00A8-48BF-B5FF-EB9653A82632</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">18</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-27 14:57:09 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9ECE5E77-785E-438D-8726-64A0E9496202"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-27 14:57:02 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N950c3d1b466e4a179c65a222ea2e3202">
    <domeo:sets rdf:resource="urn:pddi:uuid:256318B4-8529-49FF-8231-F70ED9111A64"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C04EE2A-2410-449A-B9D9-C4AA64768FBA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C1AE698E-2B98-49FD-AF07-72694334CC92"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:createdOn>2015-11-27 13:52:12 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/36303156-C3AD-4C1D-887C-EF3E3BE504D1">
    <dikbD2R:dose>250</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6433215D-030F-458E-84EB-27FE5C702C88">
    <pav:createdOn>2015-11-29 13:53:49 -0700</pav:createdOn>
    <ao:exact>Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6433215D-030F-458E-84EB-27FE5C702C88</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6433215D-030F-458E-84EB-27FE5C702C88"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7F4E5F05-FC69-4996-B3E6-A6D8BBF5F29A">
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2B6F79C3-A90B-40B0-A414-E3F11AD062CE"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/008560B7-3003-4D7D-8678-9E5D49DF07FA"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20540CD8-D98D-43E5-8821-2996ABBA2593">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20540CD8-D98D-43E5-8821-2996ABBA2593"/>
    <ao:suffix>-</ao:suffix>
    <ao:prefix>In patients with cirrhosis of the liver, AUC values of nefazodone and </ao:prefix>
    <pav:createdOn>2015-11-27 14:16:07 -0700</pav:createdOn>
    <ao:exact>HO</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCE60582-EEF8-4903-A2CF-9A7A71EE4AFA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N856298b35489425caed32402d66ef94f"/>
    <pav:lastSavedOn>2015-11-29 14:46:00 -0700</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:096E7687-20C0-4169-98EF-462C12CAE3D3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:2CA0A178-DE20-47F5-B177-7B1D07667E8B</pav:previousVersion>
    <pav:createdOn>2015-11-29 14:44:02 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB2BC77B-643D-416D-A2D9-DE5D07159D6E">
    <ao:suffix>, or P95, but delayed T</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>P88</ao:exact>
    <ao:prefix>with a standard high-fat meal did not significantly affect the C max or AUC of iloperidone , </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB2BC77B-643D-416D-A2D9-DE5D07159D6E"/>
    <pav:createdOn>2015-11-29 15:26:33 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F9EE1B4-50A2-4FE6-980F-DE908E03BD71">
    <pav:createdOn>2015-11-29 14:46:46 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF3BF77C-DECB-4E19-A45E-7530D6C39947"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-29 14:49:58 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C056EB53-AE10-4A6A-AD19-4A39136120BE</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:312DCDDD-6A8D-4325-A858-41768533FD83">
    <pav:createdOn>2015-11-29 16:31:24 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
    <domeo:uuid>312DCDDD-6A8D-4325-A858-41768533FD83</domeo:uuid>
    <ao:exact>Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (n=13). Dose adjustment for lithium is not recommended.</ao:exact>
    <ao:prefix>Risperidone on other drugs    Lithium   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:312DCDDD-6A8D-4325-A858-41768533FD83"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9ACFE793-29DF-4CA6-9709-3C3107DBE6CD">
    <pav:lastSavedOn>2015-11-27 14:03:19 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:E351D5AE-A83A-49B1-AEF3-04554C2BA173</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:DA8F7667-C853-4A72-BB41-3B8D8C1474D9"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:03:13 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N6dfdc46c250b4269a507f83ef83c3cfa"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:312B5C01-D5D5-41FA-9D7A-314FF7E644F1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N6e76a96861ab45d4a747ba0f55005f19"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 15:19:40 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4D01D25A-181B-49A4-99C3-A1353CB53A50"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 15:18:44 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:CDB3B024-E033-41E5-A0CF-560711B0336C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:00F3F1FA-F661-41A6-BA0B-E84A054F53AC">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F94C0A01-5F75-4E9F-A12E-BF8BC89270DF"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D0B8D932-5F03-4E2B-A8BB-B5C513FAF339"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>35</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clType>Percent</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD628499-7A48-45E7-A5AD-9747726585FE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 13:52:02 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F7CC7534-1A8C-4535-8517-371CB9A40CCC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B09A4EF-4345-4E60-A0CC-F08B6357C035">
    <ao:exact>P95 </ao:exact>
    <ao:prefix>is generally equal or less than that of the parent compound. In contrast, the metabolite </ao:prefix>
    <pav:createdOn>2015-11-29 15:32:00 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <domeo:uuid>9B09A4EF-4345-4E60-A0CC-F08B6357C035</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>only shows affinity for 5-HT</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B09A4EF-4345-4E60-A0CC-F08B6357C035"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A615638A-6473-41F4-AEC2-59B4DC7846B8">
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EAF5A0BA-E0CA-4855-B381-65BE8CEFF681"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/96910636-0C9F-4EE8-8B13-24FBEEE5F9A4"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>UNKUNK</dikbD2R:auc>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC34F367-0167-447C-A81B-D8430B5CD93F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC34F367-0167-447C-A81B-D8430B5CD93F"/>
    <pav:createdOn>2015-11-27 13:51:50 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.</ao:suffix>
    <ao:prefix>and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>alprazolam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EAF5A0BA-E0CA-4855-B381-65BE8CEFF681">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8C8D787-1250-4EED-BAD2-DF784514C725">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 15:26:56 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE04E856-3A7E-44AC-91F8-571B7A656E33"/>
    <pav:lineageUri>urn:domeoserver:annotation:424020FC-CFC1-49B8-A82B-E9234955BB23</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13241C85-CB03-45BE-BB6E-F5F23CAEF107">
    <pav:createdOn>2015-11-27 15:29:11 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C882DDF5-352F-46D1-93A8-982034BE5C30"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 15:29:38 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:D7188365-B07E-42D3-A4B1-89DD9808BF1B</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:003D4AC4-0165-4256-B259-5CCB82BFE98F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>With 5 mg BID doses of</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-11-27 14:51:24 -0700</pav:createdOn>
    <ao:exact>Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:003D4AC4-0165-4256-B259-5CCB82BFE98F"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A7FA52CB-62CA-4127-B1FC-C38DA9AD69DB">
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/70733AD1-2EE6-469D-98E9-A3151B460028"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/610FF927-9DFC-47C2-8E0C-1A8DD134CD95"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52855BF6-0B46-4D03-BB11-691DB9AE86E7">
    <ao:suffix>, and </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:45:43 -0700</pav:createdOn>
    <ao:exact>cisapride</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine , astemi z ole , </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52855BF6-0B46-4D03-BB11-691DB9AE86E7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41125D0B-B211-4273-8318-2FBC61E9AAE0">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:13:23 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A6D4352-A705-4DB3-B216-30B7B670BF16"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29744B2E-45C4-468D-87FA-4CE4278A7188">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:068E23A7-91BA-46F8-8AA8-0BC4338961A3"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9359918F-57BB-46E0-A04F-8D6FC7A6CA01">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D6697B00-B900-4593-8232-BFD5D2D55941"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83247853-DEFC-4169-AB84-408FC75747DD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 13:04:31 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <domeo:uuid>83247853-DEFC-4169-AB84-408FC75747DD</domeo:uuid>
    <ao:prefix>were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83247853-DEFC-4169-AB84-408FC75747DD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C142D5C3-CBF1-4AED-B5BB-C6FE136BD4CC">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/57C27E72-C145-4435-B98C-35FCEEBD420B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>250</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>mCPP</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A3658EAB-8756-4D1A-B25F-34AAD48AFA0B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DD114721-812A-415C-837F-947D6A4AFE2F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D238B704-52E6-48AC-8DF4-362DADF1CF18"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02597B88-0CFA-45BA-BA3B-98FF8DD82C52">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02597B88-0CFA-45BA-BA3B-98FF8DD82C52"/>
    <ao:exact>9</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P</ao:prefix>
    <ao:suffix>5 by one-half. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 14:46:36 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5C52525A-B363-4F1D-8624-921F4140235B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>iloperidone</rdfs:label>
    <dikbD2R:dose>3</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D48B3D20-EBD4-4EF5-9EEF-A1034AB31107">
    <domeo:uuid>D48B3D20-EBD4-4EF5-9EEF-A1034AB31107</domeo:uuid>
    <pav:createdOn>2015-11-29 16:15:28 -0700</pav:createdOn>
    <ao:prefix>. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when INVEGA® 3–15 mg/day was added to their existing valproate treatment.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D48B3D20-EBD4-4EF5-9EEF-A1034AB31107"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75b981b1-74e6-4802-8fae-ca64180b375e">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-17 07:08:08 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75b981b1-74e6-4802-8fae-ca64180b375e"/>
    <ao:exact>INVEGA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <ao:prefix>he absolute oral bioavailability of paliperidone following </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EC6B81A5-22B5-40C8-80E2-8546831874E1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:28F1DBB9-C45D-4A78-9527-B93A8EF8991B"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>eports of increased blood concentrations</dikbD2R:comment>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0A2E871-78A7-4456-92EB-52F21BA18ED0">
    <ao:context rdf:resource="urn:domeoclient:uuid:B4A8374B-E983-464E-B71D-B00BDF6788A0"/>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-29 11:47:40 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/65A57778-0E8A-47BB-84C8-FDB9009067B0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A0D4EB95-9630-4A38-87A7-2ED34DE9BCB7">
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E6F6B010-B762-4725-8621-377C20EEC672"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0B87C805-657B-44E1-BA8B-DC30041700DC"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97DFBEEE-14F3-4028-B3E6-F6071E43FE3F">
    <ao:prefix>    Immunosuppressive Agents   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-29 13:20:52 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>97DFBEEE-14F3-4028-B3E6-F6071E43FE3F</domeo:uuid>
    <ao:exact>There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97DFBEEE-14F3-4028-B3E6-F6071E43FE3F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:074B9E92-F154-4ADC-860B-D18D27A7DA40">
    <ao:context rdf:resource="urn:domeoclient:uuid:46ECE233-9F5E-4E9C-913F-02BE74E56C15"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2015-11-27 13:52:35 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DC198BE2-4718-485E-B220-0325F0207DBE">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DE2E7A8-3EA3-4894-BD98-3884D1EA2A77">
    <pav:createdOn>2015-11-27 14:14:56 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:3C9C65E0-8BB9-4C88-A31B-A636A9CA4F56"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8EA8011-55E0-4390-BAA5-C227224B9F56">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:987B8B0E-2B2B-4B59-8315-9CDD3E52ED8E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:45:53 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FD603EBC-9FD4-4CEF-86E0-F8DCF2A7B86F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4BF2DDA9-5301-4F65-A3A3-46F56FCF2E06"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>entered plasma concentration as AUC</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CAED791-8BC7-4077-B358-AD64646EAB59">
    <ao:exact>Lorazepam </ao:exact>
    <pav:createdOn>2015-11-27 14:46:35 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>– When</ao:suffix>
    <ao:prefix>may be necessary when coadministered with nefazodone .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8CAED791-8BC7-4077-B358-AD64646EAB59"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE2C8D8A-01BD-4341-A339-CA41B9EB9A46">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:77E2CADC-AB7A-4C38-AA71-1135422EF5E4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-29 15:32:11 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:D765F05B-A800-4080-A05F-9EA3566D408C</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 17:32:26 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A1BD134-4AC0-4444-A720-169B060E6E66">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:13:41 -0700</pav:createdOn>
    <ao:exact>pimozide </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A1BD134-4AC0-4444-A720-169B060E6E66"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine, astemizole, cisapride, or </ao:prefix>
    <ao:suffix>(see</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA8C33F0-184B-4FE7-B56A-EB4C2B4E0EB2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7801A2A9-BE67-437A-8E47-743799319370"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 14:15:49 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BACA00A8-9EEE-4C95-AB22-7E57A47184F6">
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/52A722AB-F93B-490B-AFD6-51A6F2A3150C"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>55</dikbD2R:auc>
    <dikbD2R:numOfParticipants>19</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ADEF1686-9B2D-4122-9B86-705ECD19703B"/>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:preciptDuration>4</dikbD2R:preciptDuration>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>UNKUNUNK</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DD4D886-51DE-473D-B43D-C634E023500A">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:prefix>dose should be returned to the previous level.   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 14:45:41 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DD4D886-51DE-473D-B43D-C634E023500A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD6637B7-C3FE-45D0-8475-210B47AB50E8">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A47B065-DF4E-4861-A520-A5389C57DB72"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-29 12:28:45 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:04E00EBB-DAB5-4802-A8BB-7E38AE95CA57</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 12:37:36 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E141840D-0B7F-4C50-88A6-A8DB78AC8A14">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C056EB53-AE10-4A6A-AD19-4A39136120BE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:createdOn>2015-11-29 14:46:43 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABDC0958-CFFB-45EE-B1EE-0747B8656DC0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-29 14:49:58 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6503EA64-1BAE-4595-BB07-EE7A3AD7EBEC">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CBCCA656-7F10-4059-932E-C92BFF655E5C"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/73B10B9D-8C57-4A5C-B885-2451BB25CC97"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F487F5E1-C8E4-483F-97F9-488259318B02">
    <pav:createdOn>2015-11-29 11:37:17 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N3dc8fd10ee1a4c429ff4098a08dc4df3"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 11:37:19 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:A5B5B9C3-46B7-4C2D-8E46-951D400D2BCD</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:68E8D8DE-2C22-46B8-87A7-D069AEDE2B2E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">28</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81E7F1BA-1EF8-46DF-BB55-6BB90E0AD851">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <ao:body rdf:nodeID="N79781763125f40cfab5c34518330fc8d"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E68C3294-6CAC-4FB4-AF60-136E25A8C94B"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 12:37:36 -0700</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-29 12:37:33 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:04E00EBB-DAB5-4802-A8BB-7E38AE95CA57</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CC40722A-E2AC-4241-962B-D8CBA4DFAB09">
    <rdfs:label>cimetidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>300</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7E063E5E-6193-4E55-B6B5-A5D5D650879A">
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/64430F8F-C6AD-4E84-BEFA-7630E0D9E3AC"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9D5E70F2-0E95-4493-A611-D5501DEF27EF"/>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F08C8C2D-9065-4ED2-937B-2F57EE85829F">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (Cmax)of dextromethorphan. Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.</ao:exact>
    <pav:createdOn>2015-11-29 15:12:17 -0700</pav:createdOn>
    <ao:prefix>does not have enzyme inducing properties, specifically for the following cytochrome P450 isozymes: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F08C8C2D-9065-4ED2-937B-2F57EE85829F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2C3C70A-31A7-4682-8C0A-C17879CE7EE9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-29 16:36:18 -0700</pav:createdOn>
    <ao:prefix>is not recommended.   Valproate   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2C3C70A-31A7-4682-8C0A-C17879CE7EE9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D2C3C70A-31A7-4682-8C0A-C17879CE7EE9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f22dfcdf-2ba2-4ede-a1cc-3c8c9bdddc05">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-17 07:08:08 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f4bcdebf-db7b-4c95-b1b2-8bc46c7992e0</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E8FE416-EFE8-4F72-9F7D-D213DCF09D38</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:75b981b1-74e6-4802-8fae-ca64180b375e"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-17 07:08:08 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4859033B-DE71-4BC4-B2B7-0DCAAECF7ACD">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>P88 </ao:exact>
    <ao:suffix>are not substrates of P-gp and </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 15:27:10 -0700</pav:createdOn>
    <ao:prefix>Transporter Interaction: Iloperidone  and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4859033B-DE71-4BC4-B2B7-0DCAAECF7ACD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A111075-AE7E-477C-9ADA-490842585892">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>are coadministered; plasma level monitoring for digoxin is recommended.  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-29 12:44:05 -0700</pav:createdOn>
    <ao:exact>Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A111075-AE7E-477C-9ADA-490842585892"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9801D4E3-955C-4C3B-9440-75B0CFE38C53">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:67E962B2-BA92-4A9D-8B3F-ED7E10330F77"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04C214D6-1185-484E-885F-A1AFEF1A016C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0AF7509-C16D-44FE-8631-5B0BBD8621CA"/>
    <pav:createdOn>2015-11-27 14:14:05 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D01D25A-181B-49A4-99C3-A1353CB53A50">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>luoxetine: A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20 mg twice daily). </ao:exact>
    <ao:prefix>F</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4D01D25A-181B-49A4-99C3-A1353CB53A50"/>
    <pav:createdOn>2015-11-29 15:18:44 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81FACD58-5BE1-488B-900B-4BE4E0351527">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81FACD58-5BE1-488B-900B-4BE4E0351527"/>
    <pav:createdOn>2015-11-29 11:48:03 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>or </ao:suffix>
    <ao:exact>lithium </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CE94D821-2A6F-4B47-8C5D-A21979EE8BDC">
    <dikbD2R:auc>44</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>48</dikbD2R:cmax>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DF3F1FE6-6383-436B-AA73-246E1A36BD54"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/29B01A18-8768-499B-A905-33B352EFC3EF"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E6F6B010-B762-4725-8621-377C20EEC672">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desipramine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>75</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65AC8562-41F8-43FD-BD3F-A68C5954BF1E">
    <pav:lineageUri>urn:domeoserver:annotation:A38AA3E4-647D-43BE-ADD9-208D745E66E4</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 13:05:05 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8FD552F8-2891-4A9A-B659-BCE157930013"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-27 12:59:03 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd7b0fbaabcff402cbed4814e2b94ea76">
    <domeo:sets rdf:resource="urn:pddi:uuid:D2C6DFDC-B189-4A15-8CCF-CE82BF4FA736"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FDCCD847-5F18-485E-803B-690468AD1FCC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BF11ABBB-9E83-4224-86FD-EC3D62309994"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AEFCBDD-9999-40A7-84BC-AB85571CEA90">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of </ao:prefix>
    <ao:suffix>, astemizole, cisapride, and </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:45:39 -0700</pav:createdOn>
    <ao:exact>terfenadine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7AEFCBDD-9999-40A7-84BC-AB85571CEA90"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E1A61B2C-DD79-4787-A231-F8ADF9A5D1A2">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82CDE090-E6D4-4A1D-A232-DCE85D9B61A7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 14:15:30 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:BA9DE795-6121-45AB-9449-2F833405BCCB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08135AC9-72C6-4D42-90A8-CF119829E056">
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2015-11-27 13:52:18 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:575C52B3-A66C-4C65-8BB2-E3DB3445524C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1F9B1627-EB96-406D-BDAF-C3AA4101231B">
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B61814CE-5644-4827-875F-97E5BF9D725C"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/330E0151-A650-40AA-BC52-729A14DFD076"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CBCCA656-7F10-4059-932E-C92BFF655E5C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6CBF886-EB77-4871-9B92-E89575CC5C61">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:createdOn>2015-11-27 14:45:39 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7AEFCBDD-9999-40A7-84BC-AB85571CEA90"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:575C52B3-A66C-4C65-8BB2-E3DB3445524C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:52:18 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:575C52B3-A66C-4C65-8BB2-E3DB3445524C"/>
    <ao:exact>triazolam </ao:exact>
    <ao:prefix>dosage is recommended. Because not all commercially available dosage forms of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58D99026-B745-4FF7-A3A0-B2FACBA08309">
    <pav:createdOn>2015-11-27 13:52:21 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8CCE09D2-19D5-42EE-842B-42B5732FD010"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/77B2E7AD-59B1-4E2E-A0C9-38E25FC48AA0">
    <dikbD2R:dose>3</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>iloperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FFA5AE4B-BD31-4565-B4A1-21AAE6988CA6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0AF7509-C16D-44FE-8631-5B0BBD8621CA">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0AF7509-C16D-44FE-8631-5B0BBD8621CA"/>
    <ao:suffix> and hydroxynefazodone concentrations for achieving an antidepressant effect for nefazodone. Consequently, it is recommended that nefazodone not be used in combination with </ao:suffix>
    <pav:createdOn>2015-11-27 14:14:05 -0700</pav:createdOn>
    <ao:exact>nefazodone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F40AA5E-949C-4758-8E69-9A203FFBD851">
    <pav:createdOn>2015-11-29 15:26:38 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:prefix> in plasma is ~3% and of each metabolite (</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F40AA5E-949C-4758-8E69-9A203FFBD851"/>
    <ao:suffix>and P95) it is ~8%.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>P88 </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:411BA520-454B-4D9A-B1DE-3807D4BA809E">
    <ao:suffix>has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies during the product’s premarket</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:15:44 -0700</pav:createdOn>
    <ao:exact>Nefazodone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:411BA520-454B-4D9A-B1DE-3807D4BA809E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07F498A9-34E6-4620-9A6A-A2886D6E9236">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:51:53 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-27 14:52:01 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8F5D6204-4ADD-4EF3-99B1-9088E2DDCAAA</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:96D43F2F-23E0-474B-A1EE-2A64683D0859"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DE601BF-5AD9-4D33-AB58-050BE48C2BAD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-29 11:40:46 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 11:39:14 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:FCE35EA5-872E-4883-ADC4-0E05965DE708</pav:previousVersion>
    <ao:body rdf:nodeID="N0fb69e8dcf76419ca2b3724f383cc2bd"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1AE747D7-078B-417A-93E9-24BDFCF2213C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0B87C805-657B-44E1-BA8B-DC30041700DC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>150</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33F19646-4AFA-4867-A605-C09A6DD95562">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:createdOn>2015-11-29 11:47:55 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:63152761-0B27-4F80-B23F-9E0B64EDF988"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EBFDA249-D6E8-4CC2-9BEB-350D60F02189">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:preciptDuration>9</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0FD397D5-5535-4BD1-8D42-3B654A10CD9D"/>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:objectDuration>9</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EAEF1212-5720-4B9A-B0E1-5AE4B671EDD9"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E153D20-E1F7-4064-AAD5-9707020174CA">
    <pav:previousVersion>urn:domeoserver:annotationset:C5CA1F88-1976-43FD-B462-F99B7752B8A1</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-29 14:55:02 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdOn>2015-11-29 14:54:35 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N2e1992fe70024216af84670d32324655"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3F43473-E023-4A0F-901B-4513286A37BD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA4FA05E-AAA7-4B8D-BF3C-30C4573F837C">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 14:46:36 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C056EB53-AE10-4A6A-AD19-4A39136120BE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:02597B88-0CFA-45BA-BA3B-98FF8DD82C52"/>
    <pav:lastSavedOn>2015-11-29 14:49:58 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/abde6cc1-3f20-4db6-bfd3-7b337ada4a65">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-11-17 07:06:31 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:beb63e75-4aaf-41d3-9f38-3a3496c1d75e"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-17 07:06:31 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF3BF77C-DECB-4E19-A45E-7530D6C39947">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF3BF77C-DECB-4E19-A45E-7530D6C39947"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:suffix>and a 1.4-fold decrease in the </ao:suffix>
    <pav:createdOn>2015-11-29 14:46:46 -0700</pav:createdOn>
    <ao:prefix> and its metabolite </ao:prefix>
    <ao:exact>P88 </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6C22B5D-32E7-4D0F-9E6C-656D55C85BE2">
    <ao:exact>When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>    Theophylline   </ao:prefix>
    <pav:createdOn>2015-11-29 12:11:12 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6C22B5D-32E7-4D0F-9E6C-656D55C85BE2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D9F9167-BB9F-4316-89B9-E6836B470F29">
    <ao:context rdf:resource="urn:domeoclient:uuid:B5C1A788-DA8D-4A7A-8E4D-26B4ABD985CD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nf196bb915ca1464bbec45b9a233dd000"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-27 15:01:50 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-27 15:01:56 -0700</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:918DE8FE-A0E1-459E-8B0C-998A9D24B696</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">19</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc86695afb12c4af297022511189d2ff6">
    <domeo:sets rdf:resource="urn:pddi:uuid:DEB510C6-9058-4298-ADD7-06F703DA47B6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D70D5A4-70CD-48E9-B948-E08F0AEF8D76">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8D8A38D1-48DC-412E-AA3A-06B077AB96A7</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N4b15405162c944a99f3960ebfbd81bc2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:012D2011-9E95-44B8-B764-00D7FE59EB65"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 13:02:34 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">48</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 13:04:34 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09FB62C3-9235-4DAA-8A6C-92276BCB7074">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A2222541-AB12-4BE5-B2CC-348AD61D3190"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2015-11-27 13:52:08 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2214DB9E-4F05-43E2-B4B9-0AE1AE0EF56A">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:createdOn>2015-11-27 13:52:45 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B8F65635-1B59-4D68-831D-98C51B2BA1F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/008560B7-3003-4D7D-8678-9E5D49DF07FA">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>divalproex sodium</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:36284A10-D531-459C-9EEA-433957EFE6C1">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:17D83743-8B5B-46EE-8471-8E7B34339935"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:147DD8EA-D504-4D39-9277-E8709104773F">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:84EFB23F-8CEA-4AC6-9E0B-5794B485CFBC"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/23005184-A113-4DFD-BCFC-E9BEBEB8682F">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FE6CB980-8373-480F-9440-DFC8F41D4A3E">
    <rdfs:label>divalproex sodium</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>500 to 2000</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C181F797-C31B-483D-AFFA-8497935BDB0C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A241933B-4573-4A12-A430-14E450C510E4"/>
    <pav:createdOn>2015-11-27 14:14:12 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16430840-10CE-4EE0-8A15-4BD5C610B2F7">
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>triazole-dione</ao:exact>
    <ao:suffix> increased by 3 to 6 fold and 1.3 fold, respectively</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16430840-10CE-4EE0-8A15-4BD5C610B2F7"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 15:29:17 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0695463B-FC87-4370-88DA-456E999EA88E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>HO-NEF</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B1D81255-D16D-419E-BE81-0B4750F62110">
    <rdfs:label>haloperidol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>5</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7DC522EA-0A81-4830-B0EF-09FF5FAA9C04">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/70733AD1-2EE6-469D-98E9-A3151B460028">
    <dikbD2R:dose>300</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <rdfs:label>Phenytoin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C33A5FA2-1852-423F-B545-5E62A72CA176">
    <pav:createdOn>2015-11-27 15:33:19 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B10B8DAC-C047-4852-A9DF-77A1E80986E7"/>
    <ao:body rdf:nodeID="N2291f67b5f2a462783701243582badd0"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:C58C5536-A297-4D1B-8AD8-185B22AC095B</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 15:33:34 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:429BA634-0508-4EF4-B2CA-4E573CFD7834">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 11:40:44 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>dosage should be guided by usual clinical practices.  </ao:prefix>
    <ao:exact>Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:429BA634-0508-4EF4-B2CA-4E573CFD7834"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/610FF927-9DFC-47C2-8E0C-1A8DD134CD95">
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B10B8DAC-C047-4852-A9DF-77A1E80986E7">
    <ao:exact> When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B10B8DAC-C047-4852-A9DF-77A1E80986E7"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>in ‘Poor Metabolizers’ and Potential Interaction With Drugs That Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.   Fluoxetine – </ao:prefix>
    <pav:createdOn>2015-11-27 15:33:19 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE914B7B-F5CD-4D40-BE6B-2B95AA95022D">
    <ao:context rdf:resource="urn:domeoclient:uuid:8D4E3AC2-D21A-4E26-B388-CCF3A3111077"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 14:45:29 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7211DE65-1D7F-4967-9BD3-A2A431C2F43E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 14:33:25 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:suffix> and P95 by 57%, 55% and 35%, respectively. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and its metabolites</ao:prefix>
    <ao:exact> P88</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7211DE65-1D7F-4967-9BD3-A2A431C2F43E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D628FD1-D1C1-4432-A9FF-4420281EF24F">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 14:45:52 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B015734D-B0DC-4377-8093-DCC947A66F4D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EB95F59C-3400-49D0-BFB5-01B1FE8D88DA">
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/64430F8F-C6AD-4E84-BEFA-7630E0D9E3AC">
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>UNK</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A82CEC6D-892F-4BBE-890D-E8FB9AFA64D1">
    <pav:createdOn>2015-11-27 13:52:07 -0700</pav:createdOn>
    <ao:suffix>. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A82CEC6D-892F-4BBE-890D-E8FB9AFA64D1"/>
    <ao:prefix>plasma concentrations were unaffected by </ao:prefix>
    <ao:exact>triazolam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F96677C6-1C74-4FF9-A213-2E4759B0106A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated with QT prolo</ao:suffix>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>erythromycin</ao:exact>
    <pav:createdOn>2015-11-27 14:13:25 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F96677C6-1C74-4FF9-A213-2E4759B0106A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B">
    <permissions:permissions rdf:nodeID="Nf7788b977c4a4450bf1407b5b573192d"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2015-11-29 18:49:20 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC629573-51D3-4FFB-9440-DF2AA2287864"/>
    <pav:previousVersion>urn:domeoserver:annotationset:13D165CA-4AD0-429B-BF8F-0AB3CCABAD9D</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:982EBC66-3022-4CEC-AB8F-33FD1D92D401"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2BF69B5-7B29-4AFC-B095-D5DE3C3A5B62"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:1E56E467-D2E9-4FD0-906F-904EC26C2808"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4F6F024-4421-4E59-8E6E-4276436A62B4"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14305115b858015115cd5b5c0000"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/7400d882-47ff-4237-801a-927dbf080f1b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <pav:createdOn>2015-11-17 07:06:28 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:668F5F1A-8E9F-490A-B323-E2F7CC3086FA"/>
    <rdfs:label>NER Sets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/09B73A09-125E-448D-992D-C17E9E5803FC">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/857BBE20-9C66-4C69-99AA-7F6490B9925A">
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90C83758-E752-494B-815B-B550B4B2D07E">
    <pav:createdOn>2015-11-29 12:29:01 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 12:37:36 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:04E00EBB-DAB5-4802-A8BB-7E38AE95CA57</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:5EE23433-8EF2-40FB-B871-DEEDA02D7889"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/88EF6876-2009-4582-A53A-62889E0A1A28">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>300</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F8B34BDD-A209-463A-B8B6-624FEB4FD223">
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF558D38-AF1C-43FE-9304-D8FB65463A56">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A7FA52CB-62CA-4127-B1FC-C38DA9AD69DB"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96372F84-7A06-4AE7-8D78-4CDA367FF6DA">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N4b550cd9322d4010b1ec4f7e89c5f20a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:8A7E09B5-7C04-47CC-9ABE-F84454602776</pav:previousVersion>
    <pav:createdOn>2015-11-27 15:22:40 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <pav:lastSavedOn>2015-11-27 15:24:30 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:739BD25D-E4E1-4CCD-BE8D-4356360E904D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/54B33F62-B662-4CF7-93A0-ACDA0B5B0C32">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>ketoconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0576B398-81B8-4A8F-9F54-F85CFC881F7C">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD3EFC85-5FA0-4DAE-BD52-248DCE9DAEC7">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-29 11:42:39 -0700</pav:createdOn>
    <ao:exact>There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.</ao:exact>
    <ao:prefix>or its metabolite, 2-hydroxy desipramine .  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD3EFC85-5FA0-4DAE-BD52-248DCE9DAEC7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A03880A5-ADD9-410F-A58C-19C4CCED885C">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B8C300A8-3898-4B01-B923-32150E90FA5A"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8F41F658-0ADE-4E4A-9252-9AC8D20226F4"/>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:auc>UNK</dikbD2R:auc>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:28F1DBB9-C45D-4A78-9527-B93A8EF8991B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/528BC21C-A4D8-4312-AD83-83E6D9387EBB"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4B6EEFF9-747E-492B-9223-624F0F824166"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndf95894c96614900841170cbb1d9472e">
    <domeo:sets rdf:resource="urn:pddi:uuid:B30B563B-4A7D-44AE-AD42-A9AC8B51E1FC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1AE698E-2B98-49FD-AF07-72694334CC92">
    <ao:exact>triazolam </ao:exact>
    <pav:createdOn>2015-11-27 13:52:12 -0700</pav:createdOn>
    <ao:suffix>is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should b</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>If </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C1AE698E-2B98-49FD-AF07-72694334CC92"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04E60AFE-2853-4C84-9C0F-031D4E56A4B7">
    <ao:exact>HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>04E60AFE-2853-4C84-9C0F-031D4E56A4B7</domeo:uuid>
    <pav:createdOn>2015-11-29 13:06:04 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04E60AFE-2853-4C84-9C0F-031D4E56A4B7"/>
    <ao:prefix>were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5C1A788-DA8D-4A7A-8E4D-26B4ABD985CD">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B5C1A788-DA8D-4A7A-8E4D-26B4ABD985CD"/>
    <ao:suffix> Subjects receiving</ao:suffix>
    <pav:createdOn>2015-11-27 15:01:50 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2260640B-B516-4CFE-B20A-E869B24B0887">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>-demethylation (mediated by CYP3A4). There are 2 predominant iloperidone  metabolites, </ao:prefix>
    <ao:suffix>and P88. The </ao:suffix>
    <pav:createdOn>2015-11-29 15:26:46 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>P95 </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2260640B-B516-4CFE-B20A-E869B24B0887"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AE96EFD3-AD7D-495C-8A97-23CB1568B909">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:41241210-B2F3-4462-A957-B7BFD185ABAD"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F06B6FD-6E00-42FD-B366-E3E782E6C08D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively</ao:exact>
    <pav:createdOn>2015-11-27 15:35:28 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>in ‘Poor Metabolizers’ and Potential Interaction With Drugs That Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.   Fluoxetine –  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F06B6FD-6E00-42FD-B366-E3E782E6C08D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DD1A843-1C70-4B7A-8D88-C88ACBFD7200">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-29 11:51:35 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DD1A843-1C70-4B7A-8D88-C88ACBFD7200"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAFE5868-DB88-40F0-8060-90A49501BE3A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>2-hydroxy desipramine.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> or its metabolite, </ao:prefix>
    <pav:createdOn>2015-11-29 11:39:37 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CAFE5868-DB88-40F0-8060-90A49501BE3A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7400d882-47ff-4237-801a-927dbf080f1b">
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-17 07:06:28 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:b2b22f48-8306-48e1-a4c3-550c7918331f"/>
    <pav:createdOn>2015-11-17 07:06:28 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6E51206-8BFE-4851-8B13-CAD25CC39FE0">
    <domeo:uuid></domeo:uuid>
    <ao:exact>nefazodone </ao:exact>
    <ao:prefix>During premarketing testing, a recurrence of a petit mal seizure was observed in a patient receiving </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:15:24 -0700</pav:createdOn>
    <ao:suffix>who had a history of such seizures. In addition, one nonstudy participant reportedly experienced a convulsion (type not documented) following a multiple-drug overdose (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6E51206-8BFE-4851-8B13-CAD25CC39FE0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28744B2C-4D66-48C7-A127-44A7969798E7">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-27 13:52:42 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>nefazodone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28744B2C-4D66-48C7-A127-44A7969798E7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4A3FF706-7E4B-4542-8C52-57BB688BC187">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AF4DEBC5-9BB5-4E67-9233-EA6CF63CDDD1"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B47B0B5-D658-4672-99AA-89C615EC69A8">
    <pav:createdOn>2015-11-29 11:48:00 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:356A0201-5302-4E1F-BF6B-B3266CAF28E7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:957CB6EB-1223-4840-B725-8918855B9F6A">
    <ao:exact>Nefazodone plasma concentrations were unaffected by alprazolam. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:957CB6EB-1223-4840-B725-8918855B9F6A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 14:12:40 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>If</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F47F546B-6518-4B21-AC8B-302337C4A7B0">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C51775D9-7505-43A1-9619-E7B832F77F21"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/51926A58-0CD1-4D65-9EB7-9ACE7EA3022D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C16A4386-E817-47EE-BB17-CFB546704691">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <ao:body rdf:nodeID="N6502093a139a462ea97351843360407d"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:559472FC-CFF2-4DE2-B68C-00DB95B54C02"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:185ce6a5-62ff-4f7d-9697-a128d9bfc171</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-29 13:36:22 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 13:36:22 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DF3F1FE6-6383-436B-AA73-246E1A36BD54">
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>75</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6AFD35D6-426E-411A-980B-61F7308B57FB">
    <pav:previousVersion>urn:domeoserver:annotationset:681890F1-A444-44B4-8F87-F14218325B5E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-29 12:53:35 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 13:00:53 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">47</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C336D483-AD79-4A10-9DE7-AB384EF16E7C"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CBA39573-1C14-4F68-A99F-C2DFE3C435F5">
    <dikbD2R:dose>80</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>dextromethorphan</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5FD0B3FA-2A79-45B0-96B2-BB0522ABB463">
    <rdfs:label>2-hydroxy desipramine.</rdfs:label>
    <dikbD2R:dose>75</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BFFC0AC-72FC-4E80-85FF-37492628DB14">
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A82CEC6D-892F-4BBE-890D-E8FB9AFA64D1"/>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdOn>2015-11-27 13:52:07 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D9EC5242-3B85-4C10-B091-55CD228BA988">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>norfluoxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1544A574-F608-456A-A725-943C69DFDA8B">
    <ao:exact> When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively</ao:exact>
    <ao:prefix>in ‘Poor Metabolizers’ and Potential Interaction With Drugs That Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.   Fluoxetine – </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1544A574-F608-456A-A725-943C69DFDA8B"/>
    <pav:createdOn>2015-11-27 15:28:55 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8FD552F8-2891-4A9A-B659-BCE157930013">
    <ao:suffix>and nefazodone should be avoided for most patients, including the elderly.</ao:suffix>
    <pav:createdOn>2015-11-27 12:59:03 -0700</pav:createdOn>
    <ao:prefix>dosage is recommended if the two drugs are to be given together. Because not all commercially available dosage forms of triazolam permit a sufficient dosage reduction, the coadministration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8FD552F8-2891-4A9A-B659-BCE157930013"/>
    <ao:exact>triazolam </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:homepage></foafx:homepage>
    <foafx:build>050</foafx:build>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:version>2.1alpha</foafx:version>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B015734D-B0DC-4377-8093-DCC947A66F4D">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine , </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>astemizole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 14:45:52 -0700</pav:createdOn>
    <ao:suffix>, cisapride, or </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B015734D-B0DC-4377-8093-DCC947A66F4D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/93C01C02-AC29-476C-9710-886515E4BB20">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>simvastatin acid</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36567</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:469D9F68-7273-4C34-81EF-DD3D61DBBCB3">
    <ao:prefix>Repeated oral doses of </ao:prefix>
    <pav:createdOn>2015-11-29 16:29:13 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:469D9F68-7273-4C34-81EF-DD3D61DBBCB3"/>
    <ao:exact>risperidone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
    <domeo:uuid>469D9F68-7273-4C34-81EF-DD3D61DBBCB3</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2372A928-BD15-42B9-8687-3034567BE4FB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2372A928-BD15-42B9-8687-3034567BE4FB"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact> HO-NEF</ao:exact>
    <ao:suffix>; however, the mean AUC levels of the </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 15:24:42 -0700</pav:createdOn>
    <ao:prefix>Similarly, there were no changes in the pharmacokinetic parameters of nefazodone  or</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93573759-2565-4DCB-A5AF-E79501572BD5">
    <pav:previousVersion>urn:domeoserver:annotationset:2E416E6E-3B50-4259-ABDF-A1008E7DD3CF</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2015-11-29 14:37:58 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 14:38:11 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F19C4849-57EB-46B1-AACC-CBE5EE8D0228"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D238B704-52E6-48AC-8DF4-362DADF1CF18">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <rdfs:label>triazolam</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B8C300A8-3898-4B01-B923-32150E90FA5A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1A910D8-A39E-4044-8FF4-DFBD6BEE3166">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:156CA5B3-F6BF-40D9-99AA-5F874D48C169"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:15:34 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83D6CEA6-6E31-4CB7-AC57-0377FA37BDF1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-29 12:11:14 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6C22B5D-32E7-4D0F-9E6C-656D55C85BE2"/>
    <ao:body rdf:nodeID="N83b658c846ef459e87b609362f24844f"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:02B0B865-4699-49D9-A091-C1B40D2CE573</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 12:11:12 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7CC7534-1A8C-4535-8517-371CB9A40CCC">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:52:02 -0700</pav:createdOn>
    <ao:exact>triazolam </ao:exact>
    <ao:suffix>half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. </ao:suffix>
    <ao:prefix>(200 mg BID) at steady state, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F7CC7534-1A8C-4535-8517-371CB9A40CCC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:012D2011-9E95-44B8-B764-00D7FE59EB65">
    <pav:createdOn>2015-11-29 13:02:34 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>012D2011-9E95-44B8-B764-00D7FE59EB65</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:012D2011-9E95-44B8-B764-00D7FE59EB65"/>
    <ao:exact>HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent</ao:exact>
    <ao:prefix>were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE04E856-3A7E-44AC-91F8-571B7A656E33">
    <domeo:uuid></domeo:uuid>
    <ao:prefix> and its metabolites in plasma at steady-state for extensive metabolizers (EM) and 25% for poor metabolizers (PM). The active metabolite </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE04E856-3A7E-44AC-91F8-571B7A656E33"/>
    <ao:suffix>accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively.</ao:suffix>
    <pav:createdOn>2015-11-29 15:26:56 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>P88 </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6152FDD-70FC-4215-9F3E-F24C433EF15D">
    <pav:createdOn>2015-11-27 13:52:22 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6152FDD-70FC-4215-9F3E-F24C433EF15D"/>
    <ao:prefix>with </ao:prefix>
    <ao:exact>nefazodone </ao:exact>
    <ao:suffix>should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:724B14F4-6D2F-42DF-942A-A6FFC1282B68">
    <ao:exact>astemizole</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>,</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 14:45:54 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine , </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:724B14F4-6D2F-42DF-942A-A6FFC1282B68"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A83638F6-F9F8-4ED0-95A7-9FB860F8D0DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>alprazolam </ao:exact>
    <ao:suffix>is coadministered with </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-27 13:52:46 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A83638F6-F9F8-4ED0-95A7-9FB860F8D0DB"/>
    <ao:prefix>plasma concentrations were unaffected by alprazolam. If </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87737B8C-62BC-40FB-87DD-A6EA94A5DA88">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <ao:prefix>may be necessary when coadministered with nefazodone .  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87737B8C-62BC-40FB-87DD-A6EA94A5DA88"/>
    <pav:createdOn>2015-11-27 14:29:31 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A92CBBE-B7B0-497D-B206-F8C4234E12EC">
    <pav:createdOn>2015-11-29 11:45:58 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.</ao:exact>
    <ao:prefix>or its metabolite, 2-hydroxy desipramine .  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A92CBBE-B7B0-497D-B206-F8C4234E12EC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/73B10B9D-8C57-4A5C-B885-2451BB25CC97">
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6B30CCA2-3CEC-40E0-94C6-4E933221FAFD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5CEDFFC9-712F-4814-B6B2-CBE93DBB409C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC5B9E57-4081-43F0-A67C-5EBABB88972A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 12:58:56 -0700</pav:createdOn>
    <ao:exact>triazolam </ao:exact>
    <ao:prefix>), and a 75% reduction in the initial </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>dosage is recommended if the two drugs are to be given together. Because not all commercially available dosage forms of triazolam permit a sufficient dosage reduction, the coadministration of triazolam and nefazodone should be avoided for most patients, </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC5B9E57-4081-43F0-A67C-5EBABB88972A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:344272B9-FC48-4C52-9382-8CB229B86151">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 14:16:13 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B0DB2B3-1E3F-4F34-BF73-8C1AC6EA6F08"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/52A722AB-F93B-490B-AFD6-51A6F2A3150C">
    <rdfs:label>P88</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>3</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:17A332F2-ED26-461B-B83A-C8FC5BBE44ED">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F92632C7-44F1-4AFC-80AE-0C4922C62A0A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/49D30C46-2051-4B34-BB22-9ED56951BD81"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4479E5E3-3FE8-44E9-8B48-B203349BAC6A">
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/40254</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>valproate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54B8C0D1-B5E4-40A2-8AAA-72247E9E6B09">
    <ao:context rdf:resource="urn:domeoclient:uuid:D95B1124-4116-4693-BC27-750D9B3C32EB"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <pav:createdOn>2015-11-27 14:45:40 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67DF62D5-C811-414F-98EE-B90C1A865DD7">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E0C22CF-F9E2-4E78-9DF8-7D09A6A7ED9A"/>
    <pav:createdOn>2015-11-27 14:15:20 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9C41DDE-3F6D-4606-B417-57AB4D40FA7D">
    <ao:suffix> were seen. These effects appear to be due to the inhibition of CYP3A4 by</ao:suffix>
    <pav:createdOn>2015-11-29 12:54:01 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>atorvastatin lactone</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>F9C41DDE-3F6D-4606-B417-57AB4D40FA7D</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F9C41DDE-3F6D-4606-B417-57AB4D40FA7D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na3d95202e09945e1954fe5850326dbea">
    <domeo:sets rdf:resource="urn:pddi:uuid:6FD53334-CC40-4FC8-9034-8F9CF6A0400D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ED2C6388-FC38-4A19-98E4-C6ABFBC318C6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N179fef97738f431892eb0503cc85fa5b">
    <domeo:sets rdf:resource="urn:pddi:uuid:6B30CCA2-3CEC-40E0-94C6-4E933221FAFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD63DE1C-43CB-4089-924D-0B86E2FF0C4F">
    <pav:createdOn>2015-11-29 12:23:31 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> Cardiovascular-Active Drugs   </ao:prefix>
    <ao:exact>Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD63DE1C-43CB-4089-924D-0B86E2FF0C4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/21EB9187-B2EE-4FBA-8A9F-50DC725B6F05">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/40254</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>valproate</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4b550cd9322d4010b1ec4f7e89c5f20a">
    <domeo:sets rdf:resource="urn:pddi:uuid:573A616C-BF5A-493A-942F-CF264857AB94"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6809831-35EE-4FF0-BBF6-A1445A3F2796">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 11:52:45 -0700</pav:createdOn>
    <ao:prefix>are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A6809831-35EE-4FF0-BBF6-A1445A3F2796"/>
    <ao:exact>Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6AA7E7BB-591C-444B-8624-E3164CD7E995">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:681890F1-A444-44B4-8F87-F14218325B5E</pav:previousVersion>
    <pav:createdOn>2015-11-29 12:54:01 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F9C41DDE-3F6D-4606-B417-57AB4D40FA7D"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">47</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 13:00:53 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8F539098-D81D-46D7-874E-E66FDA267171">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/21EB9187-B2EE-4FBA-8A9F-50DC725B6F05"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C538CB02-22BE-4286-82B2-2EE80CC5B6CF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3E990F98-C4AB-4F6A-8C24-362FFCB05007">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>warfarin</rdfs:label>
    <dikbD2R:dose>1 to 10</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33EA5337-D252-4182-9DB8-587566E439DA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>pimozide </ao:exact>
    <ao:prefix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsade de pointes type. Nefazodone has been shown </ao:suffix>
    <pav:createdOn>2015-11-27 14:13:31 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33EA5337-D252-4182-9DB8-587566E439DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80E1AEE9-40DF-434F-81D4-046998DE0B9D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:14:34 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:70C656BD-BA26-4F74-AE2F-121ADEEFC233"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7B981729-1102-4DCF-B836-64C4FC862D6A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A3658EAB-8756-4D1A-B25F-34AAD48AFA0B"/>
    <dikbD2R:comment>increase in the plasma level of triazolam</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N25f45236cd7d42fcad34217c08ee9c6d">
    <domeo:sets rdf:resource="urn:pddi:uuid:3A808FED-FC76-4DD7-A423-5A4EF610D9CE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CC9400B2-6234-42D1-BF9A-62833F467AAE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>HO-NEF</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A34E444D-9FFD-4D2B-B51C-143C85D22CAC">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D8ACAFB7-FEA4-485B-BAE1-FA78D203E02D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0E24E1CD-CB5A-4E16-B21E-4F4B8E9BCBB2">
    <rdfs:label>BRINTELLIX</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36342C92-85CE-4C41-921A-E7DD3B99659B">
    <ao:context rdf:resource="urn:domeoclient:uuid:CBEA875C-AFB9-4EA6-B530-661CD4AF59CF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-11-27 14:14:44 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5E2860B-5E68-4789-B133-52ECBA940C11">
    <pav:createdOn>2015-11-27 14:45:41 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A5E2860B-5E68-4789-B133-52ECBA940C11"/>
    <ao:prefix>, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine , </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>astemizole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>, cisapride, and</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15365EF7-6E42-430A-BE5A-2DA60F8E0317">
    <pav:createdOn>2015-11-29 13:33:21 -0700</pav:createdOn>
    <ao:exact>lithium </ao:exact>
    <domeo:uuid>15365EF7-6E42-430A-BE5A-2DA60F8E0317</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>No clinically relevant effect was observed on steady state </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15365EF7-6E42-430A-BE5A-2DA60F8E0317"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>exposure following coadministration with multiple daily doses of </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F19C4849-57EB-46B1-AACC-CBE5EE8D0228">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> by one-half. </ao:suffix>
    <ao:prefix>, by about 2- to 3-fold, and decreased the AUC of its metabolite </ao:prefix>
    <pav:createdOn>2015-11-29 14:37:58 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F19C4849-57EB-46B1-AACC-CBE5EE8D0228"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>P95</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:04A18420-679D-4661-9AC4-6044C7F2DE7D">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:51557084-C3B1-4B23-9BB1-3EA6299087BF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:668F5F1A-8E9F-490A-B323-E2F7CC3086FA">
    <pav:createdOn>2015-11-29 16:29:13 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:7685bcaf-274a-44c1-9eb7-34cf3ee40830</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 16:36:20 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:7b83a0d2-d4e5-45b7-80ff-8b2875e504b4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:469D9F68-7273-4C34-81EF-DD3D61DBBCB3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/65094F27-7584-4279-88E4-44C277B96B36">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25F48C6A-0C09-4752-BCC2-A60CEB930637">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:17A332F2-ED26-461B-B83A-C8FC5BBE44ED"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>small decreases in the steady-state plasma concentrations</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ADA95F0-9E4F-48C0-AECF-8A3311B99135">
    <ao:suffix>plasma concentrations were unaffected by triazolam. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:52:04 -0700</pav:createdOn>
    <ao:prefix>half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Nefazodone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0ADA95F0-9E4F-48C0-AECF-8A3311B99135"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F41C1936-689B-4577-B03B-777A68399AC8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-29 15:26:39 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B2AFDFE-F0AC-4165-A5F5-3C333B1497E3"/>
    <pav:lineageUri>urn:domeoserver:annotation:37A56C83-4D7B-4955-8CFE-40BBF24752FA</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2222541-AB12-4BE5-B2CC-348AD61D3190">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>Coadministration of </ao:prefix>
    <ao:suffix>potentiated the effects of triazolam on psychomotor performance tests. </ao:suffix>
    <ao:exact>nefazodone </ao:exact>
    <pav:createdOn>2015-11-27 13:52:08 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A2222541-AB12-4BE5-B2CC-348AD61D3190"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5703BD03-8DCC-4337-A01D-50171BFCC1AB">
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:39281CC9-DF0A-4F89-8DD6-1F0090BAA8B5"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-27 14:46:01 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/330E0151-A650-40AA-BC52-729A14DFD076">
    <rdfs:label>theophylline</rdfs:label>
    <dikbD2R:dose>600 to 1200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A96D8D9E-6636-429C-8548-0DECAE6C9056">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:34F1F10A-984B-413E-86E0-20388197DE2F"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B0DB2B3-1E3F-4F34-BF73-8C1AC6EA6F08">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>In patients with cirrhosis of the liver, AUC values of nefazodone and </ao:prefix>
    <ao:exact>HO-NEF</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B0DB2B3-1E3F-4F34-BF73-8C1AC6EA6F08"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:16:13 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84A05B74-066D-4648-87E1-73D6B43E3B58">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-29 11:52:45 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A6809831-35EE-4FF0-BBF6-A1445A3F2796"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">36</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:A7345FBF-08B2-47B8-A4A7-0CC26DEBB6DA</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-29 11:52:47 -0700</pav:lastSavedOn>
    <ao:body rdf:nodeID="N59bc49fd301f4c059ef06d7278fbe324"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/170BED1E-0308-4D70-A22C-296D933E6822">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E08E393A-F69F-4986-9750-C4292A3A1CAB">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E08E393A-F69F-4986-9750-C4292A3A1CAB"/>
    <ao:prefix> (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-29 11:47:46 -0700</pav:createdOn>
    <ao:exact>lithium</ao:exact>
    <ao:suffix>, </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22D3DA0E-4B6B-4D98-A518-21851A279008">
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdOn>2015-11-27 14:14:00 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C9E33A2A-7BD9-4822-9008-1B0A9340EAFB"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B31D86F8-979F-491C-ACB5-52CAFCC76E01">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>The coadministration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:13:45 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>200 mg BID with nefazodone 200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving a</ao:suffix>
    <ao:exact>carbamazepine </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B31D86F8-979F-491C-ACB5-52CAFCC76E01"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C336D483-AD79-4A10-9DE7-AB384EF16E7C">
    <domeo:uuid>C336D483-AD79-4A10-9DE7-AB384EF16E7C</domeo:uuid>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2015-11-29 12:53:35 -0700</pav:createdOn>
    <ao:suffix>acid and 3 to 4 fold increases in plasma concentrations of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>simvastatin </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C336D483-AD79-4A10-9DE7-AB384EF16E7C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C784173E-ACF0-41C2-BFCD-7D3C2721638A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C3595456-0C41-4682-BBCB-C8A0ADDEE583"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ACCD478-5329-40B1-B5E2-2C12525A80F7">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 14:46:13 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:375A9CC7-95E2-412A-ADE8-FEB080F0EF23</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 14:45:30 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E4CB53B1-DEAE-45A2-8AE0-7259A80F9DA5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4C0B0F5-8154-4C4B-AB5D-E0020CB44B39">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Haloperidol – When a single oral 5 mg dose of haloperidol was coadministered with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance decreased by 35% with no significant increase in peak haloperidol plasma concentrations or time of peak.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-11-27 14:24:05 -0700</pav:createdOn>
    <ao:suffix> This change is of unknown clinical significance. Pharmacodynamic effects of</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4C0B0F5-8154-4C4B-AB5D-E0020CB44B39"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/47B72996-9818-4E71-8012-F051F26EC31B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>500</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Lithium</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nee94bbc5d27644958114d441d368dd3c">
    <domeo:sets rdf:resource="urn:pddi:uuid:4E57EC49-A8DC-41A3-8283-56ABF0D8E87A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F84C2E30-58FA-40DA-956B-0EA7D04827C3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-27 14:16:08 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F51E7E06-E0E7-4E54-A47C-30B4702B7021"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9590A493-CDA3-4742-85A0-7175CC26C03B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BC65EE1C-3EDA-4DA8-B82D-D39939681594"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf0f8eb7c9cdf4958a55a45fa34cfe179">
    <domeo:sets rdf:resource="urn:pddi:uuid:069B52FD-41F4-4B6C-97AF-5E746376D00B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59CF9A2D-CDE1-4B21-811F-F66588AAB846">
    <pav:createdOn>2015-11-29 11:48:03 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-29 11:50:15 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:BEFE1EDE-6A13-481D-A1F8-62DC9C8A1FC1</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:81FACD58-5BE1-488B-900B-4BE4E0351527"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:867FA548-AB1D-4E98-A667-D66F5E87B146">
    <ao:suffix>on psychomotor performance tests. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:52:10 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:867FA548-AB1D-4E98-A667-D66F5E87B146"/>
    <ao:exact>triazolam </ao:exact>
    <ao:prefix>potentiated the effects of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD30BB22-1CA0-48D7-A3E3-CAA83997648E">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact> When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.</ao:exact>
    <pav:createdOn>2015-11-27 15:24:14 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD30BB22-1CA0-48D7-A3E3-CAA83997648E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> –</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE2CE7EA-E303-4246-B06F-5986E6406A5E">
    <ao:prefix>are coadministered; plasma level monitoring for digoxin is recommended.  </ao:prefix>
    <ao:exact>Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.</ao:exact>
    <pav:createdOn>2015-11-29 12:41:51 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE2CE7EA-E303-4246-B06F-5986E6406A5E"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC1092C9-5217-4C0E-BFC9-4FFAD5C9B30B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-27 13:52:15 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:0917477B-68F0-44F6-A47F-9FFFCACAFC47"/>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23513472-8961-48CA-B8A4-C77322C0E2CF">
    <ao:body rdf:nodeID="Nc86695afb12c4af297022511189d2ff6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:3A4ACCB8-C5C3-41C0-9840-63C809DC53B1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-27 15:35:28 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 15:35:40 -0700</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F06B6FD-6E00-42FD-B366-E3E782E6C08D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B957DF65-9B15-4E7C-9F17-5941A0E1977B">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E8DA484-C2D9-420A-AED5-3F50F80F061E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 15:04:22 -0700</pav:createdOn>
    <ao:prefix>metabolite 1-pyrimidinylpiperazine.  </ao:prefix>
    <ao:exact>With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E8DA484-C2D9-420A-AED5-3F50F80F061E"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:478CF235-C243-45F5-9098-9713BA1DA1E0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:C53022DB-44D7-4605-AFC3-3C5070751F00</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N1d10699fa00f46aeaa4c9b7ee925d296"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">45</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 12:47:05 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A111075-AE7E-477C-9ADA-490842585892"/>
    <pav:createdOn>2015-11-29 12:44:05 -0700</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDAD52D0-9CC6-4371-BACC-491A985D5815">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>elimination and cause increased blood levels.   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 14:35:14 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDAD52D0-9CC6-4371-BACC-491A985D5815"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCD3D309-6C84-42A8-85F3-867FDC2E4317">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DCD3D309-6C84-42A8-85F3-867FDC2E4317"/>
    <ao:suffix>. If </ao:suffix>
    <pav:createdOn>2015-11-27 13:52:47 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>plasma concentrations were unaffected by </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>alprazolam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:131535CD-04B3-4FFC-8AFA-59E77B73EACA">
    <pav:createdOn>2015-11-29 14:46:37 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EAC61939-5337-460D-8BF8-EB2ECC54257D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 14:49:58 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:C056EB53-AE10-4A6A-AD19-4A39136120BE</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0792ae05f1e34e97b30569518ac49a12">
    <domeo:sets rdf:resource="urn:pddi:uuid:4AC4B5BF-D4AE-4AB7-97CF-6F2D00F94527"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C59A29B3-C3AA-4D0A-BD93-1AB34E0ED1CE">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:268B86ED-00B7-4A33-9D2E-6D537E9DBD1A"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67481C74-371C-4862-A91B-2EF001CD2459">
    <ao:suffix>, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, incl</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>is coadministered with </ao:prefix>
    <pav:createdOn>2015-11-27 13:52:13 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:67481C74-371C-4862-A91B-2EF001CD2459"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nefazodone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/56648156-2C2B-4EAE-95D6-2147A90F399A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>triazole-dione</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0917477B-68F0-44F6-A47F-9FFFCACAFC47">
    <ao:prefix>, a 75% reduction in the initial </ao:prefix>
    <pav:createdOn>2015-11-27 13:52:15 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0917477B-68F0-44F6-A47F-9FFFCACAFC47"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case </ao:suffix>
    <ao:exact>triazolam </ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C7674D1F-ED6E-408E-AD48-415C955E2497">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7E063E5E-6193-4E55-B6B5-A5D5D650879A"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3B7EBBC-118C-4A78-931A-EC3760A0E444">
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-29 15:59:31 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:body rdf:nodeID="Nd79a2e53179b4040a8901cfcfbb43d30"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0B7E0E7C-F4ED-4E26-8500-017A82645502"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:435AC482-B550-4896-9D37-AB23CBE6AB19</pav:lineageUri>
    <pav:createdOn>2015-11-29 13:59:30 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD512468-772D-4AE1-8975-3FADDF6E2E04">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-29 12:45:33 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>are coadministered; plasma level monitoring for digoxin is recommended.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD512468-772D-4AE1-8975-3FADDF6E2E04"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E9B9271-8DC8-4D37-99B4-BE38177BEAF3">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0763E981-403C-4677-A372-37B630B60197"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 14:15:55 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N56b312e5e84f474aa1e3cfa5af7e18ad">
    <domeo:sets rdf:resource="urn:pddi:uuid:56FF991F-01CD-4B10-BA03-63EC3C881C68"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7C7584DA-CC8A-4325-BC44-F99B15A42393">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>2.5 or 5</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>buspirone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6EF929C7-38C5-4509-B375-2683C3B0201F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D3707F84-929A-45B8-B833-790099CE9F32"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7ECB32D8-479A-4CEF-8299-8F2F7A860947">
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67B0D6CC-D7D8-4C90-BE10-9A80D1CA4ADA"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>14</dikbD2R:auc>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/088FA3C3-2B58-47C7-86F2-57858619916E"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:cmax>30</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>5.5</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>5.5</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77be304281174bb1a15a7a687b7d9e25">
    <domeo:sets rdf:resource="urn:pddi:uuid:EA02908E-FA9B-4765-A77C-B830A8B20DED"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5087328A-6B7E-45AB-AA35-A9864D92E659">
    <rdfs:label>Risperidone</rdfs:label>
    <dikbD2R:dose>.25</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0C8CDB5-88C4-48D8-AA9A-519896EE0B7B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3472857F-3CD4-4281-B61A-306505F32A94"/>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:createdOn>2015-11-27 13:52:34 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0fb69e8dcf76419ca2b3724f383cc2bd">
    <domeo:sets rdf:resource="urn:pddi:uuid:232E072B-2D05-4F39-8029-2BE099A7FF54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5234AC97-29F8-4BF6-94F3-1D0DAB147BDB">
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DCD3D309-6C84-42A8-85F3-867FDC2E4317"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 13:52:47 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86A1A8FE-C01D-4C84-839E-7CF9C2E972D5">
    <pav:lastSavedOn>2015-11-29 13:57:37 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1806CB91-1ED9-469A-A95D-EFBD45BE7F9B</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <pav:createdOn>2015-11-29 13:57:35 -0700</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <ao:body rdf:nodeID="N903a9593f3aa40ff979720b766a06dfc"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:42AC4CE0-AB6A-4478-A4F8-4C3C2FC6DF78"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0C2DC2BC-E67A-425C-84AB-E10836C88580">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9EF2D22D-6C98-45DB-819E-ED5CDF2D662C">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:96B7DE32-6FEA-4443-8BCF-EF92853D8652"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3D66B71A-4333-4A35-8DB0-890966E9C179">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:59184FDB-08F9-4704-B62C-A542084105F2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FCEB0F6A-9394-474A-B008-98BEEE9273F7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F23FD930-9B00-45B9-BCB8-4727885A2F3A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B30B563B-4A7D-44AE-AD42-A9AC8B51E1FC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A8A292EA-FED9-44CC-9255-2525F7C85520"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F7099DDF-67D9-406A-A830-65A9D8C03CEA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/56648156-2C2B-4EAE-95D6-2147A90F399A"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>UNK</dikbD2R:t12>
    <dikbD2R:cmin>UNK</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>UNK</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cl>UNK</dikbD2R:cl>
    <dikbD2R:auc>1.3</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>UNK</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FAB224A5-5C96-486B-AFBB-80CF9FE0ED5B"/>
    <dikbD2R:numOfParticipants>UNK</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70C656BD-BA26-4F74-AE2F-121ADEEFC233">
    <pav:createdOn>2015-11-27 14:14:34 -0700</pav:createdOn>
    <ao:suffix>patients compared to 2.5% of placebo patients (p ≤ 0.01) met criteria for a potentially important decrease in blood pressure at some time during treatment (systolic blood pressure ≤ 90 mmHg </ao:suffix>
    <ao:prefix>A pooled analysis of the vital signs monitored during placebo-controlled premarketing studies revealed that 5.1% of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70C656BD-BA26-4F74-AE2F-121ADEEFC233"/>
    <ao:exact>nefazodone </ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55BA3168-311F-4107-98C7-2DF9DA05D254">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D065F2DD-5CFB-4FD7-8670-C2609A7AF841"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DD114721-812A-415C-837F-947D6A4AFE2F">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/710EDE66-0C1A-45F5-93EC-1FA51222A7E7">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BF42D0A2-4BC9-4E65-B819-CB0664F47B40">
    <rdfs:label>nefazodone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7801A2A9-BE67-437A-8E47-743799319370">
    <ao:suffix>in 6 to 8 week, double-blind, placebo-controlled trials did not indicate that nefazodone is associated with the development of clinically important ECG abnormalities. However, sinus bradycardia, defined as heart rate ≤ 50 bpm and a decrease of at least 1</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies during the product’s premarketing testing. Evaluation of electrocardiograms of 1153 patients who received </ao:prefix>
    <ao:exact>nefazodone </ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:15:49 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7801A2A9-BE67-437A-8E47-743799319370"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DEB510C6-9058-4298-ADD7-06F703DA47B6">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F7099DDF-67D9-406A-A830-65A9D8C03CEA"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F9737EE-2E26-497A-A104-45CCDED3729E">
    <pav:lastSavedOn>2015-11-27 14:16:57 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-27 14:13:45 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B31D86F8-979F-491C-ACB5-52CAFCC76E01"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:D0B1FF3E-4581-49E0-BBCE-DDC253EF1D23</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A0DF2F4-47BC-466E-B9FF-1B8DB8E12EF7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A0DF2F4-47BC-466E-B9FF-1B8DB8E12EF7"/>
    <ao:exact>nefazodone </ao:exact>
    <ao:suffix>(200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>was coadministered with </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 13:51:59 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98A10139-9236-4059-8660-0D76F5766654">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 13:56:37 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>Interaction With Triazolobenzodiazepines  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98A10139-9236-4059-8660-0D76F5766654"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/727D32F2-D4B1-4ED5-A97B-EC20F66BCDDE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>triazole-dione</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>150</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8860D4F1-061C-4487-846C-3A90F231BB2F">
    <pav:createdOn>2015-11-29 13:14:10 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <ao:exact>Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.</ao:exact>
    <domeo:uuid>8860D4F1-061C-4487-846C-3A90F231BB2F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8860D4F1-061C-4487-846C-3A90F231BB2F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3476269B-9BD1-48F7-AF3D-4E5F488D761B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3476269B-9BD1-48F7-AF3D-4E5F488D761B"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Cimetidine   </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:exact>When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <pav:createdOn>2015-11-29 12:07:09 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DFD46492-1AC8-4E48-A884-19A1E574CB6D">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9F69369B-851D-46BA-9757-58771CAC6045"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4AAD4CA7-7462-46F4-9045-95F2DCA449F7">
    <dikbD2R:dose>75</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3AD95BDA-9AB8-4242-867A-D6901708F40D">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>INVEGA</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:53A9625B-7A0A-47D2-A09F-148873E554B1">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:651C4A9D-FD6C-4E9A-B29B-45A978F300BC"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EA02908E-FA9B-4765-A77C-B830A8B20DED">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FB0E10E8-73E3-46E8-96FC-06F9CF61641C"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0CF0B1F-3057-41D9-821F-12154CF94FE0">
    <pav:createdOn>2015-11-29 12:47:03 -0700</pav:createdOn>
    <ao:exact>Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0CF0B1F-3057-41D9-821F-12154CF94FE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>are coadministered; plasma level monitoring for digoxin is recommended.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA8F7667-C853-4A72-BB41-3B8D8C1474D9">
    <ao:exact>Nefazodone plasma concentrations were unaffected by triazolam.</ao:exact>
    <pav:createdOn>2015-11-27 14:03:13 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DA8F7667-C853-4A72-BB41-3B8D8C1474D9"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30F89F72-D818-4D92-8E13-B51DAEC88BA1">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>3</dikbD2R:dose>
    <rdfs:label>iloperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D2C6DFDC-B189-4A15-8CCF-CE82BF4FA736">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:58FA4C9E-EFE5-451B-BDB2-2A0E16D15FE7"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4A8D7449-0CF6-4125-9DAB-EEC4C0334A69">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>150</dikbD2R:dose>
    <rdfs:label>HO-NEF</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87824097-8AE4-4BE2-B08E-EE8B1E80C84C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:1806CB91-1ED9-469A-A95D-EFBD45BE7F9B</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:099a48d5-5ead-4e8a-a473-8d35bba3c307</pav:lineageUri>
    <ao:body rdf:nodeID="N67856a4144884a0daaeb831a5c8538f5"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-29 13:57:37 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 13:53:49 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6433215D-030F-458E-84EB-27FE5C702C88"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2987E7CF-BAFF-4E83-95BE-7A9116FA7410</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/29B01A18-8768-499B-A905-33B352EFC3EF">
    <dikbD2R:dose>150</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>mCPP</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32ED9CF2-3B2D-49DE-A5FB-3BF6BBE03DF3">
    <pav:createdOn>2015-11-29 15:32:10 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, or P95, but delayed T max by 1 hour for iloperidone , 2 hours for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>P88 </ao:exact>
    <domeo:uuid>32ED9CF2-3B2D-49DE-A5FB-3BF6BBE03DF3</domeo:uuid>
    <ao:suffix>and 6 hours for P95. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:32ED9CF2-3B2D-49DE-A5FB-3BF6BBE03DF3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A7F8466-E6AE-4795-B31C-ACB51FC05039">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0888B2A8-E583-46EB-A6E9-E57BAACEAC21"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D2E2348-A23F-4EA3-A871-CE3E46E25FA6">
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:04E00EBB-DAB5-4802-A8BB-7E38AE95CA57</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 12:28:55 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFECA5A9-DBC3-4CA2-8043-D4ECB305BB03"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-29 12:37:36 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/905AA69B-E22A-4630-B85E-D48866CCC483">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>12</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>INVEGA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EC37481F-0E3F-4A67-8255-9B40021D038C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9F3F11D3-C7A1-420F-B53D-7DDD99F26149">
    <dikbD2R:dose>5</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>buspirone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39281CC9-DF0A-4F89-8DD6-1F0090BAA8B5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-27 14:46:01 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>not be used in combination with either </ao:suffix>
    <ao:exact>nefazodone </ao:exact>
    <ao:prefix> to be an inhibitor of CYP3A4. Consequently, it is recommended that </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:39281CC9-DF0A-4F89-8DD6-1F0090BAA8B5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ADA22F9B-C4CA-4FE9-829F-163EA37F8475">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7ECB32D8-479A-4CEF-8299-8F2F7A860947"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9E33A2A-7BD9-4822-9008-1B0A9340EAFB">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving an antidepressant effect for</ao:suffix>
    <ao:prefix>200 mg BID with </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>nefazodone </ao:exact>
    <pav:createdOn>2015-11-27 14:14:00 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C9E33A2A-7BD9-4822-9008-1B0A9340EAFB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:156CA5B3-F6BF-40D9-99AA-5F874D48C169">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 14:15:34 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:156CA5B3-F6BF-40D9-99AA-5F874D48C169"/>
    <ao:exact>nefazodone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>While priapism did not occur during premarketing experience with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, rare reports of priapism have been received since market introduction. A causal relationship to nefazodone has not been established (see </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9381913D-7524-48AF-8838-3B6C1D9FE98E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>digoxin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>.2</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:beb63e75-4aaf-41d3-9f38-3a3496c1d75e">
    <ao:suffix> and placebo was not statistically significant. This result </ao:suffix>
    <ao:exact>nefazodone</ao:exact>
    <pav:createdOn>2015-11-17 07:06:31 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>other study, the differentiation in response rates between </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:beb63e75-4aaf-41d3-9f38-3a3496c1d75e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6656620-1F85-48FD-B0C5-BAFBDD4C41DF">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:createdOn>2015-11-29 15:26:54 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:76CD61D3-8390-45D3-8DA0-4AFDD6B5EE80</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-29 15:27:14 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:80427DD1-9946-4A18-B0CC-52160F5D6046"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:692B6F5F-B17E-4564-B8E1-791829862A6E">
    <ao:exact>salicylic acid</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2015-11-29 13:42:34 -0700</pav:createdOn>
    <domeo:uuid>692B6F5F-B17E-4564-B8E1-791829862A6E</domeo:uuid>
    <ao:prefix>had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin  and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:692B6F5F-B17E-4564-B8E1-791829862A6E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5BF20034-84BA-4A89-8D9E-66660691C724">
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5B669579-A81E-4650-A229-9EBB75064E12">
    <rdfs:label>atorvastatin lactone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9ECE5E77-785E-438D-8726-64A0E9496202">
    <ao:exact>Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine.</ao:exact>
    <pav:createdOn>2015-11-27 14:57:02 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>and alcohol in depressed patients is not advised.  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9ECE5E77-785E-438D-8726-64A0E9496202"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/421E96B0-CAC4-4E68-A79F-6C0DF2560E58">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Lithium</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3F5CE9D1-9BE0-4896-90DD-9982AA914CB7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E55E5C30-F484-4AC6-8BEC-AEFBB5F6DB49">
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-27 13:56:43 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-27 13:51:58 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:362FA7D6-33DC-4877-9C31-5CB120EFB193</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A916D10-B84F-4621-9F1E-090BC6494DAC"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N80385adc78eb46e691a76a920169b26b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e14305115b858015115cd5b5c0000</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F94C0A01-5F75-4E9F-A12E-BF8BC89270DF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N79781763125f40cfab5c34518330fc8d">
    <domeo:sets rdf:resource="urn:pddi:uuid:ADA22F9B-C4CA-4FE9-829F-163EA37F8475"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ED7BCDDA-9007-4379-9C77-72B89D443978">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6CC24C09-171B-4BD4-B94A-C325790CA1C2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4AC4B5BF-D4AE-4AB7-97CF-6F2D00F94527">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A0D4EB95-9630-4A38-87A7-2ED34DE9BCB7"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D5926653-BAC0-4B5E-9BBD-04EA2D8729AF">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <dikbD2R:dose>150</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77105346d2394659ba3c71f38add78fa">
    <domeo:sets rdf:resource="urn:pddi:uuid:29744B2E-45C4-468D-87FA-4CE4278A7188"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACD60A5C-AAC2-45EB-B79C-40CB7139B22B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Interaction With Triazolobenzodiazepines  </ao:prefix>
    <pav:createdOn>2015-11-27 13:58:50 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ACD60A5C-AAC2-45EB-B79C-40CB7139B22B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4CBDA59-3E43-482A-A2FA-C01A3050549D">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 13:00:50 -0700</pav:createdOn>
    <ao:prefix>were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  </ao:prefix>
    <domeo:uuid>A4CBDA59-3E43-482A-A2FA-C01A3050549D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4CBDA59-3E43-482A-A2FA-C01A3050549D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6D6115CF-616C-4D9D-96F2-D0737F234FD0">
    <rdfs:label>simvastatin</rdfs:label>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36567</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:232E072B-2D05-4F39-8029-2BE099A7FF54">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:66A72D72-C10C-4A3D-B807-16C7C3FF656E"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/29EC21B1-34CA-45AA-8A52-909FC2BBD0D2">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A060D451-18E0-40D1-8530-AC514DC29D11">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>buspirone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>5</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C51775D9-7505-43A1-9619-E7B832F77F21">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454F492B-D0E0-4A76-BDD3-E5E5352E985A">
    <ao:exact>When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-27 15:26:53 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:454F492B-D0E0-4A76-BDD3-E5E5352E985A"/>
    <ao:suffix> When a 200 mg dose of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/24489CCC-A5C7-44A7-8C17-85AB593AE745">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DC07C5B-EF00-49F9-A7FF-8F10DF49587F">
    <ao:exact>When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <pav:createdOn>2015-11-29 12:05:38 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>    Cimetidine   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6DC07C5B-EF00-49F9-A7FF-8F10DF49587F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D0B8D932-5F03-4E2B-A8BB-B5C513FAF339">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>haloperidol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>5</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E42CC82B-B62B-4329-994F-D7E63E8888EB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>is not recommended.   Valproate   </ao:prefix>
    <domeo:uuid>E42CC82B-B62B-4329-994F-D7E63E8888EB</domeo:uuid>
    <pav:createdOn>2015-11-29 16:34:06 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E42CC82B-B62B-4329-994F-D7E63E8888EB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1760788-5433-46AC-BD9D-E7C6CAFBA554">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-27 14:14:41 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>and placebo patients having adverse events characterized as ‘syncope’ (</ao:prefix>
    <ao:suffix>, 0.2%; placebo, 0.3%), the rates for adverse events characterized as ‘postural hypotension’ were as follows: nefazodone (2.8%), tricyclic antidepressants (10.9%), SSRI (1.1%), and placebo (0.8%). Thus, the prescriber should be aware that there is some r</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1760788-5433-46AC-BD9D-E7C6CAFBA554"/>
    <ao:exact>nefazodone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1FD5F1C6-1085-4817-A546-75285BE357C4">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B6F3917C-0C4F-4A59-A88E-BE65DF876BE3"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77E2CADC-AB7A-4C38-AA71-1135422EF5E4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>77E2CADC-AB7A-4C38-AA71-1135422EF5E4</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77E2CADC-AB7A-4C38-AA71-1135422EF5E4"/>
    <ao:exact>P95</ao:exact>
    <pav:createdOn>2015-11-29 15:32:11 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, but delayed T</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:prefix>max or AUC of iloperidone , P88 , or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2BF69B5-7B29-4AFC-B095-D5DE3C3A5B62">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C53015A7-51FD-4284-8372-FDC146EE4D6B</domeo:belongsToSet>
    <ao:body rdf:nodeID="N77105346d2394659ba3c71f38add78fa"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-29 18:49:20 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-29 16:49:19 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:747C6EE8-52EC-4F95-9A35-C976901B6DFF</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3FD2065B-F0FB-4033-8DD9-432A069E81E1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C538CB02-22BE-4286-82B2-2EE80CC5B6CF">
    <rdfs:label>INVEGA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N777d59439c094675a0c97294bdea6eb3">
    <domeo:sets rdf:resource="urn:pddi:uuid:43F463C7-C891-4889-BC65-A3073882E738"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBDD2F62-38ED-408D-BC5D-77DD22BFAEE8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:D7188365-B07E-42D3-A4B1-89DD9808BF1B</pav:previousVersion>
    <ao:body rdf:nodeID="Ndad8aef3f3ec4636924296402627580e"/>
    <pav:lastSavedOn>2015-11-27 15:29:38 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:1544A574-F608-456A-A725-943C69DFDA8B"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-27 15:28:55 -0700</pav:createdOn>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N04e98ca531a14745a4bb6fb7f48e541e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e14305115b858015115cd5b5c0000</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C8EAD2D-AAFB-4337-8707-BCEDEA93ED13">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <ao:body rdf:nodeID="Nd876c7b33c704ff7bca6c3e2444f61f4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:41E7D41D-DD1E-419C-A65D-6623180CADD9</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD63DE1C-43CB-4089-924D-0B86E2FF0C4F"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-29 12:23:31 -0700</pav:createdOn>
    <pav:lastSavedOn>2015-11-29 12:23:33 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">42</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAC61939-5337-460D-8BF8-EB2ECC54257D">
    <ao:exact>P95 </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>by one-half.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 14:46:37 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EAC61939-5337-460D-8BF8-EB2ECC54257D"/>
    <ao:prefix>, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8C03D9A3-3740-4537-A617-9284F9AA7380">
    <dikbD2R:dose>75</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:46BC3399-7A1A-47C2-9D35-416DF2D546B0">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EBFDA249-D6E8-4CC2-9BEB-350D60F02189"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C9EED2C0-B5B1-4C38-B328-F3095EDCA93E">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N632063493ca04019a30267209db39a4e">
    <domeo:sets rdf:resource="urn:pddi:uuid:95870830-AF59-4DFB-971A-73777FABF0DC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne7e6d36b15d546138a25434be95b7135">
    <domeo:sets rdf:resource="urn:pddi:uuid:10673974-435F-4B70-9255-F2BE9DA4F9AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8E66C442-6C2C-41FE-905E-FF91B89F26BF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:45A51BCB-AE50-489B-82CA-9D7F71A1AE6F"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AE2D4040-4391-4FCC-8C6F-0E0963CE0DF0">
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F7E3546-F959-4F93-BEDD-5AEC9A149B94">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F7E3546-F959-4F93-BEDD-5AEC9A149B94"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-27 15:06:16 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)</ao:exact>
    <ao:prefix>metabolite 1-pyrimidinylpiperazine.  </ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75EB1BA8-B7AD-4FB9-8C24-8B944CCAC185">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26, and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37, and 31 hours, respectively. Steady-state concentrations are attained within 3 to 4 days of dosing. </ao:suffix>
    <ao:exact>P88 </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 15:26:24 -0700</pav:createdOn>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75EB1BA8-B7AD-4FB9-8C24-8B944CCAC185"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/005E8EC2-F0C0-482F-9B71-4663FC89EDA3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Lithium</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>500</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ED288664-24FB-4FF6-A270-47DDF85B1512">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:87509163-41CC-484B-913D-AE9FB357321D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D5222288-15F4-495D-88A8-9021F107F313">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lithium</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F92632C7-44F1-4AFC-80AE-0C4922C62A0A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>triazole-dione</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FAB224A5-5C96-486B-AFBB-80CF9FE0ED5B">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:015ED94F-F9DD-4BBD-8D22-659C85DDFB5C">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F4E8CAF6-6B7D-41AE-893B-AB50CD112F4B"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:935D5DAF-6E42-4B32-88C8-482DA69D4417">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E18C1BE2-B602-4112-B7A7-3DDD62E07C5D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2e638e00fd5f454f9305682697464f75">
    <domeo:sets rdf:resource="urn:pddi:uuid:5FFA28EC-26F7-4105-B4D0-174459E8B00D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FE2E97A-E5A9-4650-95C4-7A69F34113EA">
    <pav:previousVersion>urn:domeoserver:annotationset:681890F1-A444-44B4-8F87-F14218325B5E</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:33B5B498-90EC-4A1B-988F-FB6761E80FEB"/>
    <pav:createdOn>2015-11-29 12:53:43 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">47</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 13:00:53 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3f792f7a-5613-41a1-8bc5-95d8ba5cc59e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne743ee0d2e8343f58c4d64e212adb3e0">
    <domeo:sets rdf:resource="urn:pddi:uuid:7B981729-1102-4DCF-B836-64C4FC862D6A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A7FE19B5-26AF-40CF-96FD-36C7B69F7FB6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:00F3F1FA-F661-41A6-BA0B-E84A054F53AC"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4cba0044424f4783a55a841fabaa9238">
    <domeo:sets rdf:resource="urn:pddi:uuid:015ED94F-F9DD-4BBD-8D22-659C85DDFB5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C9EDA675-ED26-43E4-8061-1C047319A799">
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B227973-2B53-41B9-8774-F63BFDF81B04">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7211DE65-1D7F-4967-9BD3-A2A431C2F43E"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:73bc681a-ded2-47ba-af75-402a32218891</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 14:35:23 -0700</pav:lastSavedOn>
    <pav:createdOn>2015-11-29 14:33:25 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:6dd98b92-a077-48a1-b8bc-dadebf926c34</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:81ED9ADA-54C6-447D-9EB5-7167D07F33E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ADEF1686-9B2D-4122-9B86-705ECD19703B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <rdfs:label>ketoconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:642DB230-AAAA-4CB7-B2CE-D3AA1F7CFAF7">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/421E96B0-CAC4-4E68-A79F-6C0DF2560E58"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DBD2E063-6BE0-478A-BB85-A72491F80572"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2e1992fe70024216af84670d32324655">
    <domeo:sets rdf:resource="urn:pddi:uuid:41A7ABF1-B4B7-4925-A8CD-598B99C5448A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4b4dd841faa843afac844884bd39ccea">
    <domeo:sets rdf:resource="urn:pddi:uuid:961C7CE6-D7CE-4C28-AD91-DDB7E75792F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:83CB534A-E955-40B1-BB34-C5140E714F66">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BACA00A8-9EEE-4C95-AB22-7E57A47184F6"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EB8F485-7B2D-4E91-8290-E04362E785A0">
    <pav:previousVersion>urn:domeoclient:uuid:1d92f51b-f93a-492d-9865-cf9ec1e317e7</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:f4bcdebf-db7b-4c95-b1b2-8bc46c7992e0</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Ne2a200c2453e482a845278d40be608b8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A09359D-D57C-4AE2-ACF4-939491BA5632"/>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E8FE416-EFE8-4F72-9F7D-D213DCF09D38</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-29 16:14:39 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-29 16:14:23 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D8602CEF-7247-436E-AD67-D4E7BC3EAF20">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6A91F928-56CF-47B5-BF20-792888E25196"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D2DFAF53-20A2-4BFF-B083-E22F1F812283">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9D5E70F2-0E95-4493-A611-D5501DEF27EF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <rdfs:label>diazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EE23433-8EF2-40FB-B871-DEEDA02D7889">
    <ao:prefix>, and AUC of </ao:prefix>
    <pav:createdOn>2015-11-29 12:29:01 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5EE23433-8EF2-40FB-B871-DEEDA02D7889"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>m-chlorophenylpiperazine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix> were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6dfdc46c250b4269a507f83ef83c3cfa">
    <domeo:sets rdf:resource="urn:pddi:uuid:9801D4E3-955C-4C3B-9440-75B0CFE38C53"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e76a96861ab45d4a747ba0f55005f19">
    <domeo:sets rdf:resource="urn:pddi:uuid:DFD46492-1AC8-4E48-A884-19A1E574CB6D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB17E6F4-D252-45F1-99C2-453CD278FBEE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-27 13:05:05 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6641D6BF-1442-4D56-90E3-6F3B8E679BBA</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89E146BE-FB7F-45FE-A878-2705FAA8519B</domeo:belongsToSet>
    <pav:createdOn>2015-11-27 12:58:56 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC5B9E57-4081-43F0-A67C-5EBABB88972A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14305115b858015115cd5b5c0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8F41F658-0ADE-4E4A-9252-9AC8D20226F4">
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C8DEB36E-EA83-42F9-AE16-A84F81F4568C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>1 to 10</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naebc4acaafd542228a5ea16cbeed86f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:A8E22455-896F-4D87-A8C3-0FB8329B5D18"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5d9213528b5341f5b63e872e6df9a648">
    <domeo:sets rdf:resource="urn:pddi:uuid:4A3FF706-7E4B-4542-8C52-57BB688BC187"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D096C9B6-B7B2-4148-86EF-7CC085891A03">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:172456A8-6419-405D-BEE0-97CBA06A001E"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N856298b35489425caed32402d66ef94f">
    <domeo:sets rdf:resource="urn:pddi:uuid:9A7F8466-E6AE-4795-B31C-ACB51FC05039"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N83b658c846ef459e87b609362f24844f">
    <domeo:sets rdf:resource="urn:pddi:uuid:D096C9B6-B7B2-4148-86EF-7CC085891A03"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9FAFA165-1231-44D3-B913-4A4F118D53A9">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>lithium</rdfs:label>
    <dikbD2R:dose>UNK</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndde46d6c9edb4e6a969529714d2dee1b">
    <domeo:sets rdf:resource="urn:pddi:uuid:29F80390-619A-4D4E-85DF-9F91BBC93E1F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3D5F6CB7-3E29-4CEA-903D-A13D1E9A24FF">
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>propranolol</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41A7ABF1-B4B7-4925-A8CD-598B99C5448A">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5ECC8EDB-2666-470D-B355-05C9ACBBBDBB"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:66B7898A-49A1-4BD6-AEB5-844694BF5551">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A03880A5-ADD9-410F-A58C-19C4CCED885C"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1043149b1a734d098e35b9cdf88fb831">
    <domeo:sets rdf:resource="urn:pddi:uuid:53A9625B-7A0A-47D2-A09F-148873E554B1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N922c1f28b08e4e2bb190039bc837bcc5">
    <domeo:sets rdf:resource="urn:pddi:uuid:EC6B81A5-22B5-40C8-80E2-8546831874E1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5ea60460902a406e89d16c5b3dad3b65">
    <domeo:sets rdf:resource="urn:pddi:uuid:7B5F6CD6-A6B7-475C-82D1-F3BEA147402C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndbf6fe0552424d979ec1b5125b51a7ed">
    <permissions:accessType>urn:person:uuid:080e14305115b858015115cd5b5c0000</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F2980295-2A51-40F5-AA37-45335104B965">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>UNK</dikbD2R:dose>
    <rdfs:label>digoxin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3A808FED-FC76-4DD7-A423-5A4EF610D9CE">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1F9B1627-EB96-406D-BDAF-C3AA4101231B"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/99261751-D59D-463D-908B-2C86EF9FBEA1">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5A4BDF91-021A-4D7D-B7E5-68DE542CE18C">
    <rdfs:label>alprazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>1</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABDC0958-CFFB-45EE-B1EE-0747B8656DC0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABDC0958-CFFB-45EE-B1EE-0747B8656DC0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-29 14:46:43 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html </ao:hasSource>
    <ao:exact>P95 </ao:exact>
    <ao:suffix>in the presence of </ao:suffix>
    <ao:prefix> and its metabolite P88 and a 1.4-fold decrease in the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne8d158f41d1c48fabba9d45b9183b042">
    <domeo:sets rdf:resource="urn:pddi:uuid:D8602CEF-7247-436E-AD67-D4E7BC3EAF20"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1d10699fa00f46aeaa4c9b7ee925d296">
    <domeo:sets rdf:resource="urn:pddi:uuid:43CD3C9E-13E0-4527-A496-E582926D0C6C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9FE5B89F-F4FE-4B5E-B025-7F456FC828D6">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:480F8392-D266-442E-A27E-89378F9ADE68"/>
    <dikbD2R:comment>entered plasma concentration as AUC</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf7788b977c4a4450bf1407b5b573192d">
    <permissions:accessType>urn:person:uuid:080e14305115b858015115cd5b5c0000</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/94B3F018-11E2-4832-8B5E-0A7A8E4C14A4">
    <rdfs:label>buspirone</rdfs:label>
    <dikbD2R:dose>5</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6502093a139a462ea97351843360407d">
    <domeo:sets rdf:resource="urn:pddi:uuid:FDCCD847-5F18-485E-803B-690468AD1FCC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N14831740d60b45699222461d20275537">
    <domeo:sets rdf:resource="urn:pddi:uuid:9C0943F7-6177-4002-9661-4C1DDC40D3C3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4b15405162c944a99f3960ebfbd81bc2">
    <domeo:sets rdf:resource="urn:pddi:uuid:FD603EBC-9FD4-4CEF-86E0-F8DCF2A7B86F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N903a9593f3aa40ff979720b766a06dfc">
    <domeo:sets rdf:resource="urn:pddi:uuid:C7674D1F-ED6E-408E-AD48-415C955E2497"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3168CEF7-B7F3-41EE-ACBD-19FB41053065">
    <rdfs:label>nefazodone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc024eaed51d3421fa17bde0a541f83f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:F1D0F19A-7C85-40E3-B6E2-1BCB0E80BAE7"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/273D8417-392D-492E-97C8-B512585685DA">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>P88</rdfs:label>
    <dikbD2R:dose>8 or 12</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbcfd0b43f8274cd7aa00ce3f514c2e50">
    <domeo:sets rdf:resource="urn:pddi:uuid:BB2A5668-ED51-4F1C-8504-94D32FB63543"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/51926A58-0CD1-4D65-9EB7-9ACE7EA3022D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cyclosporine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3008</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/088FA3C3-2B58-47C7-86F2-57858619916E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9815A9B0-2D1B-42F7-83FF-5F58C2163BA9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>iloperidone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>8 or 12</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4e8fedfc32f449e79793d438caa24885">
    <domeo:sets rdf:resource="urn:pddi:uuid:C784173E-ACF0-41C2-BFCD-7D3C2721638A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N92c4ea266cf54cf79c124c06645c3154">
    <domeo:sets rdf:resource="urn:pddi:uuid:AE96EFD3-AD7D-495C-8A97-23CB1568B909"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd9c40516134d463aaad39dc42dc86fe2">
    <domeo:sets rdf:resource="urn:pddi:uuid:FCEB0F6A-9394-474A-B008-98BEEE9273F7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N71267490521a4f4c9703b13b39d9218d">
    <domeo:sets rdf:resource="urn:pddi:uuid:ED288664-24FB-4FF6-A270-47DDF85B1512"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N147f266d9958481da33d1df5cb412a85">
    <domeo:sets rdf:resource="urn:pddi:uuid:36284A10-D531-459C-9EEA-433957EFE6C1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N684948a7d5e74782989590c90de07c15">
    <domeo:sets rdf:resource="urn:pddi:uuid:E2DEC3D4-2592-4FA7-92C1-9771F986D7B6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe253546b3704f74be69a602b0524595">
    <domeo:sets rdf:resource="urn:pddi:uuid:C59A29B3-C3AA-4D0A-BD93-1AB34E0ED1CE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8009a3549d324212add59536328733a8">
    <domeo:sets rdf:resource="urn:pddi:uuid:F63985B6-6C0C-4191-AF0A-5278649B8768"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd5c8428f7c2c4e10ba4e3df40545824b">
    <domeo:sets rdf:resource="urn:pddi:uuid:9FE5B89F-F4FE-4B5E-B025-7F456FC828D6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne1eca61a60be4c78b490a250513af48e">
    <domeo:sets rdf:resource="urn:pddi:uuid:8F1EAF47-5BC2-44C1-A73B-5D8A7B6F27A1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nae73013afcff4b72919b6a00e2efa652">
    <domeo:sets rdf:resource="urn:pddi:uuid:1FD5F1C6-1085-4817-A546-75285BE357C4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N25a38dd81ac44ac4af75ab450445e725">
    <domeo:sets rdf:resource="urn:pddi:uuid:FA1DBF78-82BE-4A68-8D0A-815CE4782B2F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3dc8fd10ee1a4c429ff4098a08dc4df3">
    <domeo:sets rdf:resource="urn:pddi:uuid:CF558D38-AF1C-43FE-9304-D8FB65463A56"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2717e2ed8ba742e384f2fffa7354a237">
    <domeo:sets rdf:resource="urn:pddi:uuid:A7FE19B5-26AF-40CF-96FD-36C7B69F7FB6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N805d473eb3e54362a0ec00c8bfad6bd8">
    <domeo:sets rdf:resource="urn:pddi:uuid:CFE2A317-E656-4F67-96CA-6F11F6840998"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N63096a48356f4f8b994e26c227d3415f">
    <domeo:sets rdf:resource="urn:pddi:uuid:ED7BCDDA-9007-4379-9C77-72B89D443978"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N59bc49fd301f4c059ef06d7278fbe324">
    <domeo:sets rdf:resource="urn:pddi:uuid:55BA3168-311F-4107-98C7-2DF9DA05D254"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N825c86de9e1c46dfa95b22bb8666f74d">
    <domeo:sets rdf:resource="urn:pddi:uuid:46BC3399-7A1A-47C2-9D35-416DF2D546B0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N32efa48fe35d4eefa02f2d796134911f">
    <domeo:sets rdf:resource="urn:pddi:uuid:6EF929C7-38C5-4509-B375-2683C3B0201F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7d8a126f4902488a82db1b8e5896e119">
    <domeo:sets rdf:resource="urn:pddi:uuid:AF7624D5-4491-45F9-904C-72667DC92C38"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0aa7035b2b3c49689cf061333bf8ae08">
    <domeo:sets rdf:resource="urn:pddi:uuid:9EF2D22D-6C98-45DB-819E-ED5CDF2D662C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne2a200c2453e482a845278d40be608b8">
    <domeo:sets rdf:resource="urn:pddi:uuid:9359918F-57BB-46E0-A04F-8D6FC7A6CA01"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7d0efe0871974046a0fc4cce68de5f35">
    <domeo:sets rdf:resource="urn:pddi:uuid:464BCBC3-CECA-4BBE-A5E8-BF79FC6A24FF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na26011b93ebf4cfcaf067b9bf24a5ccf">
    <domeo:sets rdf:resource="urn:pddi:uuid:D92036A9-491B-4E9E-A724-A20467490C85"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndad8aef3f3ec4636924296402627580e">
    <domeo:sets rdf:resource="urn:pddi:uuid:0FE3AFEE-397E-4C79-87D5-6E537C6CFB8D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc83bd071bc5248e998f83b0fe391ef18">
    <domeo:sets rdf:resource="urn:pddi:uuid:3D66B71A-4333-4A35-8DB0-890966E9C179"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb4c017d1815746f6b10561216b467a6a">
    <domeo:sets rdf:resource="urn:pddi:uuid:83CB534A-E955-40B1-BB34-C5140E714F66"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd79a2e53179b4040a8901cfcfbb43d30">
    <domeo:sets rdf:resource="urn:pddi:uuid:8E66C442-6C2C-41FE-905E-FF91B89F26BF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N67856a4144884a0daaeb831a5c8538f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:66B7898A-49A1-4BD6-AEB5-844694BF5551"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N85c237681f2645d29d33052bf25db3ba">
    <domeo:sets rdf:resource="urn:pddi:uuid:935D5DAF-6E42-4B32-88C8-482DA69D4417"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N864f94d73a2b48fd989b4f3e23c6e899">
    <domeo:sets rdf:resource="urn:pddi:uuid:443A5DA9-9AD0-4DAE-8677-C9B482507B9F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2cfb4948fd12491d8f48191275338fe6">
    <domeo:sets rdf:resource="urn:pddi:uuid:6D80E4F6-DF2F-492A-A075-BFC555F8321F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8b275b5d23924d6e9b7074da1de35e44">
    <domeo:sets rdf:resource="urn:pddi:uuid:A96D8D9E-6636-429C-8548-0DECAE6C9056"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Neca71e7e24584a75863c94e3ccef07ae">
    <domeo:sets rdf:resource="urn:pddi:uuid:25F48C6A-0C09-4752-BCC2-A60CEB930637"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf196bb915ca1464bbec45b9a233dd000">
    <domeo:sets rdf:resource="urn:pddi:uuid:29F288B3-A31F-4DEB-8BDB-5FE8B771E151"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2291f67b5f2a462783701243582badd0">
    <domeo:sets rdf:resource="urn:pddi:uuid:9590A493-CDA3-4742-85A0-7175CC26C03B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5a6f29bbe5dd46249f4a2b5fd0ad201d">
    <domeo:sets rdf:resource="urn:pddi:uuid:4876F066-5569-44B7-9CB0-2FED1CA3B2D3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd876c7b33c704ff7bca6c3e2444f61f4">
    <domeo:sets rdf:resource="urn:pddi:uuid:88AC51BB-6A81-45C3-AFD2-0FD7512E36BE"/>
  </rdf:Description>
</rdf:RDF>
